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Welcome to Cochrane
Methods
Cochrane is a global independent network of researchers, professionals, patients, carers, and people interested in health. This not-for-
proﬁt organization has more than 37,000 contributors from over 130 countries, dedicated to making accessible, up-to-date, and credible
information about the effects of health care free from commercial sponsorship and other conﬂicts of interest.
Welcome to the 2016 issue of Cochrane Methods, the ofﬁcial annual publication that reports on methodological developments and
related issues within Cochrane. We propose to make this the last issue of Cochrane Methods, as we move to developing a section for
methods articles in the Cochrane Database of Systematic Reviews (p 7). Sally Hopewell a previous Cochrane Methods editor records
the journey of Cochrane Methods since 1997 (pp 2–3).
Our reviews help providers, practitioners, patients and the public make informed decisions about health care. Underpinning the
credibility of these reviews is the vital contribution that methodologists make. We have 17 Cochrane Methods Groups, with potential
new Groups waiting in the wings. These Groups have a variety of responsibilities including: providing methodological policy advice to
Cochrane; conducting methods research; providing methods support through training; and providing peer review and consultancy,
particularly in the case of specialized reviews. You can read more on the current activities of our individual Methods Groups and their
achievements on pages 46–69.
Cochrane continues to transform in order to safeguard the organization as we move towards 2020; see pages 4–8 for an update. This
includes conclusions from the recent Methods Structure and Function Review that identify the priorities ahead; as well as updates on
methods work, and, in particular, summaries of Cochrane’s small grants for developments of various methods.
We continue our series of published article abstracts with commentaries covering a broad range of methodological topics including:
searching for theory and qualitative studies; selecting social theories for complex interventions; dealing with missing participant
data; automation techniques; reporting review results at medical conferences; selective reporting; and disease-speciﬁc guidance in
economic evaluations. In addition, we include statistical topics such as an evaluation of the Hartung-Knapp method; a review of the
use of subgroup analysis and meta-regression in Cochrane Reviews; use of multivariate analysis to examine the impact of outcome
reporting bias; and a review of network meta-analysis methodology. Finally, we look at a taxonomy for rapid reviews.
We have a series of short articles providing updates, information on new developments and viewpoints. These articles include: search
methods to identify methods articles; data sharing; addressing complex interventions in reviews; ‘Risk of bias’ 2.0; preparing GRADE
and ‘Summary of ﬁndings’ tables; iterative systematic reviews; and ﬁnally, an introduction to a database of systematic review tools.
Sadly, after a full life much dedicated to Cochrane, pursing consumer interests and the assessment of harmful effects of treatments
AndrewHerxheimerdied. TheAdverseEffectsMGrememberhiswork. (seepages46–47). SeveralexperiencedCochranemethodologists
received awards this year. Julian Higgins and Tianjing Li from the Society for Research Synthesis Methodology, and Julie Glanville and
Jill Hayden from the Medical Library Association. Congratulations to all.
We are, as ever, very grateful to themany people who have contributed to this publication. In particular, Jane Burch, editor (Cochrane
Editorial Unit) for completing the structured abstracts and Louisa Dunn, Methods Support worker, for her work on content layout, and
ﬁnally Elizabeth Royle for her copy-editing.
We thank all our contributors over the last 20 years for providing ideas, time, and effort to support this publication so willingly. There
are so many, that we cannot thank people individually. We will ensure that reporting of Methods Groups activities continues. We look
forward to the exciting opportunity to show-case Cochrane Methods in a formal journal environment.
Jackie Chandler, Jo McKenzie, Isabelle Boutron, and Vivian Welch (Editors of Cochrane Methods)
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Editorial
Cochrane Methods has come of age!
Sally Hopewell
sally.hopewell@csm.ox.ac.uk
Oxford Clinical Trials Research Unit, University of Oxford, UK
Cochrane Methods 2015
Cochrane Methods has come of age and this is its last issue as we see it moving towards
becominganopenaccesspeer-reviewedCochraneMethods section in theCochraneDatabase
of Systematic Reviews (CDSR) (see page 7). As a section of the CDSR, it will gain, and
contribute to, the CDSR impact factor and allow publication of high quality research on
methods applicable to the production and dissemination of systematic reviews and research
synthesis.
The methodology of Cochrane Reviews has come a long way since the formal launch of The
Cochrane Collaboration in 1993. The need for high quality research evidence has always
been central to themission statement of Cochrane, i.e. ‘‘to promote evidence-informedhealth
decision-making by producing high-quality, relevant, accessible systematic reviews and other
synthesized research evidence’’. However, we cannot have high quality systematic reviews
without the development of high quality systematic reviewmethodology. Thus the method-
ology of systematic reviews has evolved, and will continue to evolve over time; from the ﬁrst
Cochrane Handbook entitled ‘Preparing and Maintaining Systematic Reviews’, published in
1994 and led by Andy Oxman, via version 5, the ‘Cochrane Handbook for Systematic Reviews
of Interventions’—published as a textbook byWiley Blackwell in 2008—to an updated version
of the Cochrane Handbook that is currently in preparation.
Cochrane Methods 1997
First published in 1997 the ‘Cochrane Methods Working Groups Newsletter’ (as it was then called),
was produced by the Norwegian Branch of the Nordic Cochrane Centre in Oslo with Mike Clarke
and Cheryl Carling as editors. The aim was to provide a mechanism for sharing information
among Cochrane Methods Groups and to inform others within The Cochrane Collaboration about
methodological research of relevance to systematic reviews.
I became editor of the ‘Cochrane Methods Groups Newsletter’ alongside Mike when responsibility
moved from Oslo to Oxford in 2000.
In 2010 we redesigned and renamed the Newsletter ‘Cochrane Methods’—which is the glossy
format published by Wiley Blackwell that you are reading now—and Julian Higgins joined Mike
andmyself as editors. The aim was to give greater prominence to the work of
Methods Groupswithin Cochrane and to raise their proﬁlemorewidely. Jackie Chandler took over
the reins when I moved on to pastures new in 2012, and she, along with current editors, Joanne
McKenzie, Isabelle Boutron and Vivian Welch (who commenced in 2013), has been instrumental
in the move towards the new Cochrane Methods section of the CDSR.
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Cochrane Methods 2000
From a very early stage Methods Groups were inﬂuential in the development of systematic
review methods within Cochrane. There are currently 17 Methods Groups: the ﬁrst were the
StatisticsMethods Group and the Individual Patient (now ‘Participant’) DataMethods Group,
which were registered in 1994. Groups such as Agenda and Priority Setting, Comparing
Multiple Interventions, and Rapid Reviews have registered more recently, reﬂecting the fact
that themethodology for conducting Cochrane Reviews continues to evolve. One prominent
example of statistical methods development is the I2statistic, which is used to help assess
and quantify the consistency of the results of studies in a meta-analysis; this statistic is
now seen routinely at the bottom of a forest plot in Review Manager. ‘Summary of ﬁndings’
tables are also seen routinely in Cochrane Reviews and provide a clear and simple format for
readers to access key information about review ﬁndings quickly andmore easily.
Cochrane Methods 2010
Although the methodology of Cochrane Reviews has come a long way, it is important that
methods continue to evolve and develop to meet the needs of our end users. Much of this is
happeningalreadyandwill continueover thecomingyears. Cochrane isbeginning toaddress
different types of systematic review questions, for example, Cochrane Reviews of diagnostic
test accuracy and Overviews of Cochrane Reviews, with several exemplar Cochrane Reviews
of prognosis currently in preparation. Increasingly, our reviews include different types of
data, for examplenon-randomized studies, economicdata andqualitative studies. Cochrane
needs to continue to progress and invest as new methodology evolves, for example, for
conductingnewtypesofmeta-analyses, suchas indirectcomparisonsandmultiple treatment
meta-analyses. As technology advances, Cochrane also needs to think aboutmodernising its
existing methods, possibly by streamlining the process of systematic review production –an
aspect that is being tested by Project Transform (community.cochrane.org/tools/project-
coordination-and-support/transform). As Cochrane Methods comes of age and is included
as a new section in the CDSR it will provide a unique vehicle for show-casing changes and
advancing methods in systematic reviews and evidence synthesis in the years to come!
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News
Jackie Chandler
Correspondence to: jchandler@cochrane.org
Cochrane Editorial Unit, Cochrane, UK
methods.cochrane.org
Introduction
During 2015 and 2016 Cochrane undertook a review of our or-
ganization, its key functions and governance. This resulted in
proposals forgovernancereformwithanewCochraneBoard (pre-
viously Steering Group), and a restructure of Cochrane Groups.
We will also set up a Scientiﬁc Committee. In her editorial Sally
Hopewell reﬂects on the contribution of this publication (page
xx) as we plan to develop the CDSR to incorporate other article
types that include methods articles. In the 1997 issue early
thoughts from Mike Clarke, Andy Oxman and Lesley Stewart,
who all remain involved in some way with Cochrane, indicated
the original motivation and need for Methods Groups, previously
known asMethodsWorking Groups. The abridged extract, below,
indicates the ﬁne balance between meeting Cochrane’s needs
and maintaining the enthusiasm of volunteers. We need to
keep this in mind as the organization reorganizes to meet future
objectives.
Abridged extract from the June 1997 ﬁrst Methods Working
Group newsletter
Methods Working Groups: Are they working?
Mike Clarke, Andy Oxman, Lesley Stewart
Methods Working Groups (MWGs) have evolved as a means
of meeting the Collaboration’s need for methodological ad-
vice. . . . . . .groups of people with common methodological
interests came together in various ways and expressed a
desire to contribute to the Collaboration on an ongoing ba-
sis. . . . . . ... The role of MWGs . . . . . ...is to provide guidance
to those responsible for decisions, not to take decisions for
them. . . . . .In general, MWGs must be viewed as a scarce
resource . . . . . . . . .So far as possible, the advice that MWGsPhotograph courtesy of the Cochrane’s Anniversary Archive
provide should be based on good evidence. [And ﬁnally] . . . . . .for MWGs to survive it is essential that wemaintain the enthusiasm
and sense of fun that has brought people together. The trick that we must try to master is to ﬁnd the right balance between the
need for effectiveness and efﬁciency on the one side, and enthusiasm and fun on the other.
Updates on a number of major projects and initiatives underway
in Cochrane follow.
Changes at Cochrane
Governance reform
The current Cochrane Steering Group (CSG) have reviewed the
function and membership of the Steering Group and agreed to
a new Board structure, now referred to as the Cochrane Board.
This represents a signiﬁcant shift in previous arrangements, key
points are:
• The Board structure will comprise six internal members
elected from thewhole Cochranemembership, and up to
ﬁve new positions on the Board for externally appointed
members.
• Under the new membership scheme individual mem-
bers will vote directly for Board members standing for
election.
• The Cochrane Boardwill no longer represent the Groups.
Skillsets of Board members rather than Group represen-
tation is the focus. However, the Board propose setting
upaCochraneCouncil basedatﬁrst on theexistingGroup
Executives to provide a collective forum for Group repre-
sentation. This Council will advise the Board to ensure
Cochrane’s major constituencies’ voices are heard. The
Group Executives will lead the structural development of
the Council.
• Board membership speciﬁes experience with systematic
reviewmethodology. MethodsGroup representatives are
seeking to strengthen this particular criterion.
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Cochrane Groups will vote on these proposals at this year’s An-
nual General Meeting at the 2016 Seoul Colloquium to agree any
amendments to Cochrane’s Articles of Association. Following a
previousconsultation, theMethodsExecutive responded, stating,
in their view, skills in methods research was an important Board
skill when considering membership.
Membership scheme
Cochrane will bring in a formal membership scheme. This will
involve setting criteria for different forms of membership based
ondifferent forms of contribution to Cochrane. Onebeneﬁt of the
scheme is themembership database, whichwill allow centraliza-
tion of Methods Groups email discussion lists helping with data
management. Please look out for communications with further
details on scheme developments.
Scientiﬁc Committee
Setting up a Scientiﬁc Committee is an important new devel-
opment in Cochrane. This ‘Scientiﬁc Committee’ will give inde-
pendent authoritative advice on the systematic review methods
Cochrane should employ in its reviews. Support for clearer de-
cision making on methods for Cochrane Reviews emerged from
the Methods Structure and Function Review and is supported by
the Cochrane Board. A selection panel (see Box 1) will run the
nominations and selection. We expect the Committee will be in
place by the end of 2016.
Box 1
Panel members are:
Lisa Bero - Co-chair Cochrane Board (CSG)
David Tovey - Editor in Chief, Cochrane Library
Holger Schu¨nemann - Current CSG Methods
representative and co-convenor of the Methods
Executive, Centre Director Cochrane Canada and
convenor of Cochrane GRADEing
Tianjing Li - Co-convenor of the Comparing Multiple
Interventions MG and Priority Setting MG, Eyes and
Vision CRG and Cochrane US
Rene Spijker - Dutch Cochrane Center, Co-convenor
Information Specialists’ Executive.
Graziella Filippini - Co-ordinating Editor, Multiple
Sclerosis and Rare Diseases of the Central Nervous
System Group, Co-ordinating Editors’ Executive
Jill Hayden - Co-convenor Prognosis Methods Group
Agustin Ciapponi - Director, Argentine Cochrane Centre
David Crosby - ProgrammeManager for Methodology and
Experimental Medicine
Medical Research Council, UK
Methods Structure and Function Review
A sustainable and effective organization is a key strategic objec-
tive. Therefore, Cochrane undertook several organizational re-
views across all Cochrane’s Group structures including Methods.
The Methods Reviewmade the following key recommendations:
Scientific 
Restructure
Recruitment
Support
Strategy Develop an integrated strategy for methods developments
A recruitment plan to engage methods people 
to support Cochrane’s methodological needs  
Suggest support for clustering arrangements and 
promote closer working between Methods Groups 
Funded methods support unit(s) to provide 
an advice service directly to CRGs  
Propose a scientific committee to guide and 
oversee the methods Cochrane should employ  
TheCochraneBoard (SteeringGroup) agreed to set upaScientiﬁc
Committeeandacall fornominations forcommitteemembership
will go out in the last quarter of 2016. Also, there is widespread
support for a managed methods support structure and this will
develop further through the Group restructuring exercise.
Following Group reviews the Cochrane Board decided Cochrane
should consolidate the current 120 separate Group structures,
as they continue to increase. The proposed structural changes
foster greater integration by using thematic (clinical ﬁeld, meth-
ods, knowledge translation) and geographical (regional Groups,
Centres, branches, networks formations) to organize structures.
We are consulting and negotiating with Groups on the suitability
of these structural arrangements.
Cochrane’s core areas of work are methods research and devel-
opment (which methods we should use), review development
and production (supporting review authors and editorial man-
agement of the review to publication) and ﬁnally knowledge
translation (evidence communication and dissemination). The
key roles ofmethods research andmethods support are separate
tasks, each needing a different approach to their management
addressing the capacity of people to contribute. In the con-
sultation we are exploring the notion of a single structure for
all Methods Groups – a hub. Potential beneﬁts include closer
working relationships and sharing of resources (support struc-
tures), stronger visible leadership for methodology in Cochrane,
greater global presence for review methodology, and possibly,
as a single entity, potential for the hub to apply for external
funding streams. Most Methods Groups receive no funding to
support their activities. Internal organization of the hub is open
for discussion with some early ideas suggested (Figure 1).
Figure 1.
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Cochrane Grant Awards
Cochrane supports academic researchers and others with funds
to conduct work for multiple research and development pur-
poses across all areas of Cochrane activity. Within the speciﬁc
area of supporting methods development and implementation
Cochrane funds allocated will total over 1.3million GBP between
2011-20. These funds are enhanced by the support of unfunded
methods experts and their Universities.
Methods Innovation Fund 1
Theﬁrst grant scheme forMethods Innovation (MIF) fundedmeth-
ods development, evaluation and research for 329,378 GBP. This
programme of six projects is now complete. Following previous
reports, we now feedback on the ﬁnal outputs and reﬂections
from project leads’ ﬁnal reports. The following provides a sum-
mary of the programme’s success and impact. Funds mostly
covered researcher, and research support time, travel to Collo-
quia and project meetings (expert development and consensus).
These grants were welcome as methodological work struggles
for success in more typical funding streams. Particularly valued
were funds for face to facemeetings of international experts. The
tablebelowsummarizes researchproducts, outputsand impacts,
programme limitations and additional resources drawn on to en-
sure project completion. Projects need continuing development,
dissemination and training in varying levels. Managing this mo-
mentum is a challenge post funding. Programme management
received positive feedbackwith the one concern that Universities
need to receive payments on time.
METHODS INNOVATION FUND 1
Research products Other research outputs Programme impacts
-Development of a bibliography for
methodological papers for network
meta-analysis, Cochrane Overviews, and
Reviews that use network meta-analysis.
-Cochrane Handbook chapter for indirect
comparisons and network meta-analysis.
-Development of recommendations and an
editorial decision tree on whether to conduct
an overview or an intervention review to
manage indirect comparisons.
-Online list of tools and software for network
meta-analysis.
-Guidance on how to report, deal with, and
judge risk of bias associated with missing
participants in systematic reviews.
-Development of a tool to assess intervention
complexity (iCAT SR) and extract
intervention data.
-Resources for conceptual frameworks and
theories to facilitate assessment of complex
interventions.
-Publication of an exemplar of an integrated
qualitative evidence synthesis with an
intervention review.
-Guidance and tools to support a Handbook
chapter on complex interventions.
-Annotated bibliography of published studies
addressing searching for unpublished studies.
-Information on the value of obtaining
unpublished data on drugs.
-New formats for ‘Summary of ﬁndings’ tables
for both intervention and diagnostic
accuracy reviews.
-A new ‘comprehensive’ tool for the risk of bias
for non-randomized studies and guidance for
its use (ROBINS-I).
-Numerous peer reviewed
publications in excess of 35
papers and editorials.
-Numerous training
events/workshops and
conference presentations
(2 projects totalled 22 and
25 separate events
respectively).
-Developments to support
Cochrane Handbook
for Systematic Reviews of
Interventions chapters.
-Qualitative and Quantitative
studies obtaining views and
experiences of those using
the method or tool.
-Conducted user testing
through a randomized trial.
-Conducted pilots of tools.
-Project leads engaging a vast network of ‘world
class’ experts in all projects.
-Project leading to additional funds from a key
UK funding agency for further development.
-Working closely with CRGs on development
and piloting of products.
-Responding to rapidly evolving ﬁelds e.g.
using network meta-analysis.
-Plugging methodological gaps e.g. missing
participant data.
-Spin off projects: GRADE CERQual tool to
assess the conﬁdence in the ﬁndings of
qualitative research. Some further
development supported in MIF 2.
-Working with other organizations such as the
World Health Organization.
-Providing funding for projects unlikely to
receive funds elsewhere.
Future developments (proposed or
underway):
-Developments will need further improvement
e.g. lack of user-friendly software for network
meta-analysis.
-Missing participant data for continuous
variables and individual participant data and
reporting guidance for handling missing
participant data.
-Cochrane to continue to support advocacy
efforts for obtaining drug trial data.
-Identiﬁcation of suitable methods to obtain
data fromwebsites such as the European
Medicines Agency and the Food and Drug
Administration.
-Additional development work on the current
‘Risk of bias’ tool (inclusion of signalling
questions) which will include cluster and
cross-over designs.
-Software development for tools.
-ROBINS-I extension to cover public health and
organization of care studies.
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Limitations Additional resources obtained Learning outcomes
-MIF funds not reﬂective of level of work
required.
-Timeliness of scheduled payments needs
improvement.
-Expert time: Leads, expert
collaborators (nearly 40–50
each in several projects), with
most unfunded, ‘‘1000s’ of
hours of highly qualiﬁed
expert time’’.
-Funding Colloquium
attendance and travel, face
to face meetings.
-Use of other monies available
to researchers to plug MIF
gaps.
-Researchers supported by
other grant funds enabled
their contribution to the
project.
-Project collaboration works well.
-The wider Cochrane community needs better
preparation to respond to project
development needs (piloting/participation).
-Volunteer activity inevitably leads to delays,
most projects over-ran.
-Value of funding research staff to co-ordinate
projects.
-Large collaborations beneﬁt from strong
structured leadership.
-Projects require ongoing development,
dissemination and training in varying levels
across projects
Methods Innovation Fund 2: 2015-2018
Seven projects funded (total programme fund 375,000 GBP) are
underway to:
• identify when to search for unpublished data;
• produce guidance on assessing harms in reviews,
• develop Plain language summaries for diagnostic test
accuracy Cochrane Reviews;
• develop guidance and methods for prognostic Cochrane
Reviews;
• identify critical appraisal tools to assess methodolog-
ical limitations of qualitative research as part of the
GRADE CERQual tool that assesses the level of conﬁ-
dence in qualitative evidence syntheses;
• provide guidance onwhen to include, assess and present
non-randomized evidence in systematic reviews using
GRADE and ‘Summary of ﬁndings’ tables; and ﬁnally
• identify all statistical methods proposed for updating or
repeating meta-analyses and compare their properties
by applying them to existing Cochrane Reviews using
simulated meta-analyses.
Strategic Methods Fund: 2017-2020
Fund allocation 600,000 GBP over 3 years
A new Cochrane grant – the Strategic Methods Fund (SMF) – tar-
gets improving the implementation and use of both established
and strategically important methods for Cochrane Reviews to
meet the needs of healthcare policy makers, professionals and
consumers by the 2020s. Cochrane needs to encourage greater
uptake of all methods across both Cochrane Handbooks (sys-
tematic reviews for interventions and diagnostic test accuracy
studies), as demand increases for these methods. Similarly, as
we embark on broadening question types and their associated
methods we need to invest up front in their introduction and
roll out. ‘Implementation’, for our purpose here, is a planned
process that translates recommended methods into the active
application of methods in Cochrane Reviews. This addresses the
combinedhurdlesofchanginghabitualproceduresandpractices,
the complexity and difﬁculty of the methods or methods-related
process, and ﬁnally their organization into current systems. We
will notify successful applicants before the end of this year with
an expected start date in early 2017.
CDSR ‘Methods Section’
Cochrane Methods is a supplement to the Cochrane Database of
Systematic Reviews (CDSR). Editors review contributions but do
not conduct formal peer review. On reading, you will note that it
mixes an annual report format and newsletter with an academic
focus, such as reviewing published article types. An opportunity
has arisen to extend the CDSR to include a methods section. This
will include other article types and, in particular, articles present-
ing empirical research studies onmethods, reviews of simulation
studies and other evaluations of methods. Wiley Blackwell, our
publishers, are building a new platform to accommodate for-
mats beyond systematic review article types. We expect the
launch of this platform early 2017, with a preliminary plan for the
Methods Section to follow towards the end of 2017, into early
2018.
Methodological Expectations of Cochrane Intervention Re-
views (Cochrane standards)
In 2013, after early work conducted in 2011, we launched con-
duct and reporting standards for Cochrane Intervention Reviews
(MECIR) followed by several audits which showed an overall im-
provement in review quality (see page 35). More recently we
revised these standards adding new standards for the reporting
of protocols, and theplanning, conduct and reportingof updates.
We are grateful for several strands of support for this ﬁnal set of
standards from:
• members of Review Groups and Methods Groups;
• recommendations provided by the Panel for Updating
Guidance for systematic reviews that met in Hamilton,
Canada in June 2014, and ﬁnally;
• the MECIR Co-ordinating team Julian Higgins and Rachel
Churchill along with Cochrane Editorial Unit members
Toby Lasserson, David Tovey (Editor in Chief), and Jackie
Chandler.
We will disseminate these standards in a booklet format down-
loadable as a PDF. Also an online version will provide links to
resources. In this version standards are downloadable section
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by section. We are also planning a purchasable hard copy
version.
Cochrane Handbook for Systematic Reviews of Interventions
(Cochrane Handbook)
Cochrane Methods Groups with other contributing authors are
key to the success of the Cochrane Handbook, a key reference
guide for Cochrane policy on methods. This expanding vol-
ume needs greater sources of support than current editors and
contributors can afford. A Cochrane Handbook summit in early
September 2016 discussed an expansion of the scientiﬁc editor-
ship and future editorial management.
New developments
Several major projects underway will address creating greater
efﬁciencies in systematic review processes. See links for further
information
1. Living Systematic Reviews
Living systematic reviews are the focus of this year’s Methods
Symposium. These are online summaries of healthcare research
that are updated as new research becomes available. Momen-
tum is building around the living systematic review concept, with
Cochrane at the forefront of piloting new approaches. Living
systematic reviews differ from traditional systematic reviews in
several ways and have important implications for review meth-
ods and processes that affect authors, editors and publishers.
Please visit both the Colloquium site and the Methods website
methods.cochrane.org for further information and availability of
symposium slides.
2. Linked data
The use of new data technologies will allow Cochrane’s data
stores (e.g. systematic reviews) to be linked. The PICO (Partic-
ipants, Intervention, Comparison, Outcome) will structure data
to enable the accumulation of data to address speciﬁc user
needs. Please see the website for further information, linked-
data.cochrane.org.
3. Project Transform
This project has several key components:
Evidence pipeline: to improve the efﬁciency of study identiﬁca-
tion for reviews.
Cochrane crowd: to enable greater contribution to Cochrane
work.
Task exchange: an online platform that matches task requests
with those available and skilled within Cochrane.
Production models: to explore new approaches to review pro-
duction.
For further information: community.cochrane.org/tools/project-
coordination-and-support/transform/components#EP
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Published methodological
research: structured
abstracts and commentaries
Systematic searching for theory to
inform systematic reviews: is it
feasible? Is it desirable?
Booth A, Carroll C. Health Informatics Library Journal
2015;32(3):220-35.
Background: A theory is ‘‘a set of inter-related concepts, deﬁni-
tions andpropositions that present a systematic viewof events or
situationsby specifying relations among variables, to explain and
predict the events or situations’’.1 Inability to identify relevant
theory may prevent reviewers from explaining how an effective
intervention is understood to work.
Objective: To explore the feasibility of systematic identiﬁcation
of theory.
Design and analysis: PubMed and MEDLINE (1998 to 2012) were
searched for reports of systematic review searches that featured
theory in the context of health behaviour change and a list of
search terms was compiled to develop a template for use in
identifying theory. This template was tested in two systematic
reviews.
Main results: Twelve systematic reviews reported a search strat-
egythat includedtheory-relatedterms. Reviewsused: speciﬁcally
namedtheories(threereviews); singlesearchtermssuchasmodel
or framework with – or without – searching a specialist database
(two reviews each); multiple search terms (two reviews); com-
pound termssuchas ‘cultural competencemodels’ (two reviews);
or a master-list of widely used theories and models and search
of a specialist database (one review). As a minimum, a list of
search terms should include ‘framework*’, ‘model*’, ‘theor* and
‘concept*.
The individual elements of the BeHEMoTh template for the spec-
iﬁcation and identiﬁcation of models/theories for systematic
reviews were:
Be – Behaviour of interest: the way a population or pa-
tient interactswithinahealthcontext, for exampleaccess
for a service, compliance, attitude to policy.
H – Health context: i.e. the service, policy, programme or
intervention.
E – Exclusions: the exclusion of non-theoretical/technical
models (depends on volume).
MoTh – Models or Theories: operationalized as a generic
‘model* or theor* or concept* or framework*’ strategy
together with namedmodels or theories if required.
Following question formulation using the BeHEMoTh Frame-
work, and preliminary standard searches to ﬁnd opportunistic
occurrences of frameworks, conceptual models or theories, the
following steps are recommended.
Step 1: Compile a list of the theories identiﬁed from the
preliminary search, then search external databases using
the BeHEMoTh Formulation search strategy.
Step 2: Merge the list of opportunistic theories with
standard lists of most common theories.
Step 3: Search external databases for each candidate
theory identiﬁed (known item).
Step 4: Identify key cited references for each known item
and search citation databases for each reference COM-
BINED WITH (narrowed to) Behaviour AND/OR Health
Context.
Finally, select appropriate models/theories/frameworks. The
case study indicated the utility of the template, however, a law of
diminishing returns suggested that researchers need to discern a
stopping point.
Conclusions: The BeHEMoTh template and procedure offers a
feasible and useful approach for the identiﬁcation of theory.
Applications include realist synthesis, framework synthesis or
reviews of complex interventions.
Reference
1. Glanz K, Rimer BK. Theory at a Glance: A Guide for Health
Promotion Practice. Bethesda, MD: National Cancer Institute,
1995.
Commentary
Prepared by Jessie McGowan
Correspondence to: jmcgowan@uottowa.ca
School of Epidemiology, Public Health and Preventive Medicine,
University of Ottawa, Ottawa, ON, Canada
In the introduction, Booth and Carroll present an overview of
the challenges systematic review (SR) authors face in their re-
viewswhendealingwithcomplex interventionsandhowtheories,
frameworks, concepts and models have been applied in primary
studies. They identify a problem: there are no published search
methods to identify theory. They decided to explore the issue
and designed a study to look at SRs of ‘health behaviour change
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interventions’ to investigate the feasibility of searching this lit-
erature for theory. The methods in their study included a brief
cross-sectional literature survey of published reviews of theory
in SRs and development of search template, which was tested
using two case studies. In their survey results, they conﬁrmed
the current methods in the literature were inadequate for iden-
tifying theory within SRs. Their search template ‘BeHEMoTh’
was created using three elements that they felt were systematic:
forming a structured question, use of methodological ﬁlters and
speciﬁcationof aprocess for search reproduction. Their template
was proposed as a structured way of specifying and identifying
theories for an SR search strategy. The elements of ‘BeHEMoTh’
include:
• Be – Behaviour of interest
• H – Health context
• E – Exclusions
• MoTh – Models or Theories
Similar to using PICO (Population, Intervention, Comparator,
Outcome) or PICOT (Population, Intervention, Comparator, Out-
come,Time) forclinicalquestions, BeHEMoTh isusedtopredeﬁne
criteria for retrieval of behavioural change theories. The full pro-
cedure for using BeHEMoTh is described. In their two test cases,
they found that the procedure improved the search strategy
development.
Like the biblical creature of mythical proportions, the behemoth,
thenewBeHEMoThmaybequitedaunting. In the title theauthors
ask two questions: ﬁrstly, whether it is feasible, and secondly
whether it is desirable?
I feel the answer to the ﬁrst question is ‘yes’. The factors that will
contribute to the success of using this process, inmy opinion, are
the skills and time of an expert librarian/information specialist
and the time and input from other members of the review team.
The skill level of the librarian/information specialist should be
advanced. Someone who is very familiar with searching as well
as research would need to undertake this process. Learning
and implementing the process would add additional time for
the librarian/information specialist. This process also requires
additional time from the review team. However, because SRs
are very resource intensive, it may be difﬁcult to convince teams
to use this process as it adds time and costs due to requiring
additional resources. I feel that the answer to the second ques-
tion of whether it is desirable is also ‘yes’ for the searching of
interventions that are based on models, or using theory to syn-
thesize results of health behaviour change interventions. The
next step is now for librarians and information specialists to test
and evaluate this research!
What value is the CINAHL database
when searching for systematic reviews
of qualitative studies?
Wright K, Golder S, Lewis-Light K. Systematic Reviews
2015;4:104.
Background: Some databases are thought to be more useful
than others for speciﬁc types of review. The Cumulative Index to
Nursing andAlliedHealth Literature (CINAHL) is understood to be
a good source of qualitative evidence, as the thesaurus includes a
rangeof terms relating to qualitative researchmethods, essential
for such reviews in nursing. It is unclear whether CINAHL is a
valuable source of qualitative studies for other topic areas.
Objective: To investigate CINAHL’s potential contribution to sys-
tematic reviewsofqualitativestudies, particularly thepercentage
of included studies available in, and unique to, CINAHL.
Design and analysis: A convenience sample of 10 systematic
reviews of qualitative studies, identiﬁed from the Database of
Abstracts of Reviews of Effects (DARE), were used to develop in-
clusion criteria: qualitative studies only, published from 2007 to
2012, databases listed, CINAHL included, list of included studies,
≥ 50% databases freely available or accessible via University
subscription, and published in English. A further 33 systematic
reviews thatmet these inclusion criteria were added to the initial
convenience sample of 10. To identify whether or not records
wereunique toCINAHL, availability inCINAHLwaschecked, along
with a check to establish whether the records were available in
anyof theother databasesused in theoriginal review. Therewere
14 subscription-only databases for which there was no access,
anda further six thatwere either no longer available or not clearly
deﬁned.
Main results: Forty-three systematic reviews of qualitative stud-
ies were included. All reviews had some included studies avail-
able in CINAHL; nine had all included studies available in CINAHL,
whilst 21 reviews (49%) had 80% or more of included studies
available in CINAHL. Eighteen of the 43 reviews (42%) had at least
one unique study from CINAHL. However, since examination of
these 18 reviews showed that all databases used in the original
search were accessible for 11 reviews, CINAHL’s contribution of
unique studies can only be based on these 11. The median
proportion of unique studies in this sample of 11 reviews was 9%
(range 5% to 33%).
Conclusions: Assuming a rigorous search strategy was used and
the records sought were accurately indexed, CINAHL is a good
source of primary studies for qualitative evidence syntheses. The
authors found some indication that CINAHL had the potential to
provide unique studies for systematic reviews, but caution is re-
quired in interpreting this ﬁnding because of the limited number
of reviews evaluated.
Commentary
Prepared by Andrew Booth
Correspondence to: A.Booth@shefﬁeld.ac.uk
Information Resources, School of Health and Related Research,
University of Shefﬁeld, Shefﬁeld, UK
Anecdotally, the qualitative review community has good reason
to recommend the Cumulative Index of Nursing and Allied Health
Literature (CINAHL) when searching for qualitative studies, par-
ticularly in topics related tonursing andallied health professions.
CINAHL offers a more granular approach to qualitative research
thanMEDLINE, indexing speciﬁc study types in contrast to the sin-
gle MEDLINE term ‘Qualitative Research’, and contains a higher
proportion of qualitative research. Fewempirical studies support
this ‘library lore’. Two previous case studies date from 2005 and
2007. Now information specialists from the University of York
have attempted to quantify the contribution of CINAHL database
to qualitative evidence synthesis (QES).
Characteristically, for database coverage research, the team
conducted a retrospective analysis of a relatively small set of
qualitative systematic reviews. They examined coverage and
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unique coverage to offer an informed assessment of the database
contribution. They conducted known item searches to establish
whether included studies were in databases at the time of their
study, acknowledging that it was not possible, practically, to es-
tablish coverage contemporaneously with the original searches.
As experienced information specialists, the authors acknowledge
the methodological limitations of their study. They could not
establish whether review authors had selected valid groupings
of databases. Neither could they access all cited databases
when seeking to establish unique hits from CINAHL. Neverthe-
less, they were able to document the contribution of CINAHL
for unique studies (in 11 of the 43 reviews) and for uniquely
populating a review (in ﬁve of the included reviews). Eighty-six
per cent of included reviews used methods other than biblio-
graphic databases to identify studies for potential inclusion. This
accords with Cochrane Qualitative and Implementation Group
guidance, which encourages use of citation searching and follow
up of reference lists to supplement deﬁciencies in topic-based
searching.
How does this study enhance our evidence base? CINAHL offers
potential beyond its ‘nursing and allied health’ label. However,
as the authors caution ‘‘using this information to prospectively
select which databases to use in future reviews has limitations’’.1
Past performance does not necessarily predict future perfor-
mance. While it would be helpful to analyse reviews against
shared characteristics to enhance prediction, we do not know
what these characteristics should be – nor whether they op-
erate at a discipline, specialty, or intervention-type level. For
the foreseeable future, effective information retrieval of qualita-
tive research or other literature, will rely on team knowledge of
the topic, information specialist experience of database cover-
age, rigorous search strategy development, extensive piloting of
candidate strategies and, dare I say it, a liberal dose of alchemy!
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Current use was established and
Cochrane guidance on selection of
social theories for systematic reviews
of complex interventions was
developed
Noyes J, Hendry M, Booth A, Chandler J, Lewin S,
Glenton C, et al. Journal of Clinical Epidemiology
2016;75:78-92.
Background: ‘Theory-led’ evidence synthesis (e.g. Realist Re-
view) uses different types of evidence to understand multiple
potential realities and outcomes. Increasing production of non-
standard Cochrane Reviews has stimulated interest in the role of
social theory in reviews of complex interventions. Despite such
interest, there seems to be an absence of reference to, or guid-
ance on, the use of theory in reviews beyond low-level theories
to systematize the review process.
Objective: To identify examplesofhowsocial theoriesareused in
systematic reviewsofcomplex interventionsto informproduction
of Cochrane guidance.
Design and analysis: The authors produced a ‘snap shot’ of
examples of social theories, rather than a description of all
theories available. Systematic reviews of complex interven-
tions incorporating social theories were sought through scoping
searches and expert consultation. Approximately 100 Method-
ological Investigation of Cochrane Complex Intervention (MICCI)
project co-applicants and collaborators, Montebello meeting
attendees, and systematic reviewers interested in developing
methods for reviews of complex interventions, were contacted.
Review protocols, reports, or articles that incorporated a theory,
and methodological articles describing or evaluating methods
for using theory in systematic reviews were identiﬁed. Each
theorywasnamedandbrieﬂydescribed, and its theoretical back-
ground, examples of systematic reviews in which it had been
used, and authors’ comments about its usefulness in complex
intervention reviews, recorded. Theories were classiﬁed as low-
level (no inter-relationships between concepts), mid-range (in-
terconnected relationships between concepts), or grand (highly
abstracted theories; organized and integrated concepts).
Main results:Over 100 theorieswere identiﬁed and classiﬁed; no
reviewsusedgrand theories. Several low-level theorieswerewell-
known and considered standard practice (e.g. Participants, In-
tervention, Comparison, Outcome (PICO), Critical Appraisal Skills
Programme (CASP), PRISMA). New low-level theories included
GRADE (determines conﬁdence in ﬁndings for effect reviews) and
CERQual (Conﬁdence in the Evidence from Reviews of Qualita-
tive Research). Three newly developed tools are yet to be fully
tested: the Template for Intervention Description and Replica-
tion (TIDieR), the Intervention complexity Assessment (iCAT SR)
tools for reporting or classifying complex interventions, and a
tool to measure complexity in public health interventions. Nu-
merous mid-range theories commonly used in primary studies
were transferred for use in systematic reviews (e.g. Health Belief
Model (a conceptual framework for qualitative evidence synthe-
sis) and Normalization Process Theory (a conceptual framework
for complex interventions)). Review-speciﬁc logic models were
increasingly used and were noted as challenging to develop.
Conclusions: Use of appropriate theory can enhance and
strengthen systematic review methods and interpretation of
complex evidence. Low-level theories are common and evolving;
incorporationofmid-rangetheory isstill theexceptionratherthan
the norm. Choice of social theory reﬂects personal preference.
Commentary
Prepared by Hilary Thompson
Correspondence to: Hilary.Thomson@glasgow.ac.uk
MRC/CSO SPHSU, University of Glasgow, Glasgow, UK
Background: For many systematic review authors, whose inter-
est is usually in the empirical, there is a lack of familiarity and
conﬁdence in the use and value of theory. The authors of this
paper suggest that all reviews use theory, either knowingly or
unknowingly, for example through use of the PICO to develop a
review question, critical appraisal, reporting tools etc. Despite
its incomprehensible title, this paper presents a valuable and
timely overview of the use and value of theory in the conduct of
systematic reviews.
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Whatdid theauthors say? Awideselectionof systematic reviews
were used to illustrate the different types of theories used, how
they were used and the value of incorporating theory to support
the conduct of a review and interpretation of the data (note:
this work does not comment on how reviews can contribute
to developing new theories). Using an existing classiﬁcation of
theory, the theories were grouped into three levels (low, mid-
range, and grand). The authors use example reviews to illustrate
how the use of additional low and mid-range level theory has
helped in managing complexity and high levels of heterogene-
ity, and consequently improve the utility and relevance of these
resource-intensive endeavours.
Importance of the research for practice
• This work developed guidance for Cochrane authors on
the use of theory in systematic reviews, as well as a
searchable Wiki and methodology register on Mendeley.
These valuable resources should help demystify the use
of theory for review authors, and consequently improve
the conduct of complex reviews, andultimately theutility
of complex reviews.
• The use of theory in systematic reviews will need moni-
toring to assess which theories are regularly used and to
assess how theory adds value to reviews.
Reporting, handling and assessing the
risk of bias associated with missing
participant data in systematic reviews:
a methodological survey
Akl EA, Carrasco-Labra A, Brignardello-Petersen R,
Neumann I, Johnston BC, Sun X, et al. BMJ Open
2015;5(9):e009368.
Background: Clinical trial investigators often fail to achieve
follow-up of all randomized participants; 87% of trials published
in general medical journals were found to have missing data
for the primary outcome, with a median of 6% of participants
(interquartile range 2% to 14%) havingmissing data. Various sys-
tematic review guidelines recommend that authors of systematic
reviews should report a description of incomplete data in the
included trials, and furthermore, how themissing data have been
incorporated into the review ﬁndings.
Objective: To describe how systematic reviewers report miss-
ing data for dichotomous outcomes, handle missing data in the
analysis, and judge the risk of bias associated with missing data.
Designandanalysis:MEDLINEand theCochraneDatabaseofSys-
tematic Reviewswere searched for systematic reviews published
in 2010. Reviews were eligible for inclusion if they included ran-
domized trials and reported estimates of intervention effect for a
dichotomous outcome from either a single trial ormeta-analysis.
Ninety-eight Cochraneand104non-Cochrane systematic reviews
were included. From each review, a pairwise comparison and the
most patient-important outcome were selected using prespeci-
ﬁed criteria. Multivariable regression was used to explore factors
associated with whether review authors used: 1) complete case
analysis, or 2) reported risk of bias judgements for missing data.
Main results:Of the 98 Cochrane Reviews and 104 non-Cochrane
reviews, 34% and 17%, respectively, planned to collect the num-
berand reasons formissingdata,with26%and19%, respectively,
actually doing so. Where plans for handling missing data were
reported, the most common approaches were complete-case
analysis (8.5% of all 202 reviews) and assuming no participants
with missing data had the event (4% of all 202 reviews); 11% of
reviews used a variety of other methods, with 2% providing justi-
ﬁcation. The use of complete-case analysis was more commonly
associated with Cochrane Reviews (relative to non-Cochrane:
odds ratio (OR) 7.25, 95% conﬁdence interval (CI) 1.58 to 33.3; P
= 0.01).
Of the 202 reviews, 65% reported assessing the risk of bias associ-
ated withmissing data; 42% used the Cochrane ‘Risk of bias’ tool
and 23% used an alternative tool. Only 11% of reviews discussed
the implications of missing data in the results and 10% in the
discussion. The ‘Risk of bias’ assessment was more commonly
associatedwith Cochrane Reviews (OR 6.63, 95%CI 2.50 to 17.57;
P = 0.0001) as was the use of GRADE (OR 5.02, 95% CI 1.02 to
24.75; P= 0.047).
Conclusions: Most Cochrane and non-Cochrane systematic re-
views fail to report and handle missing data adequately, po-
tentially resulting in misleading judgements regarding risk of
bias.
Commentary
Prepared by Nikolaos Pandis
Correspondence to: npandis@yahoo.com
DepartmentofOrthodonticsandDentofacialOrthopedics, Dental
School andMedical Faculty, University of Bern, Bern, Switzerland
Missing data from trials included in a systematic review can
introduce bias. The authors of this publication conducted a
methodological survey in order to describe how systematic re-
view authors report, handle and judge the risk of bias associated
with missing data for dichotomous outcomes only in Cochrane
and non-Cochrane systematic reviews.
This is an appropriately conducted review. The authors randomly
selected 98 Cochrane and 104 non-Cochrane systematic reviews
with meta-analyses. The Cochrane Reviews were more likely to
report on the number of participants with missing data and on
how they planned to handle missing categorical data compared
to non-Cochrane reviews. Although Cochrane Reviews seem to
do a better job of handling missing data from included studies
than non-Cochrane reviews, the process is still problematic and
leaves the question open to potential attrition bias and its effect
on the estimated pooled results. A relevant review published in
2015 also concluded that reporting and handling of missing data
in Cochrane Reviews was suboptimal.1
In this review, Akl and colleagues indicated that although
CochraneReviewshandlemissingdatabetter thannon-Cochrane
reviews, their treatment is still suboptimal and requires further
attention fromboth systematic review authors and editors. How-
ever, it is also important that trialists reportmissingdataproperly
in order to improve transparency and facilitate the work done at
the systematic review level.
The review included systematic reviews published in 2010. An
update using more recent Cochrane Reviews would be reason-
able. In addition, assessing whether the reporting and handling
of missing data varies across Review Groups would be useful.
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RobotReviewer: evaluation of a system
for automatically assessing bias in
clinical trials
Marshall IJ, Kuiper J, Wallace BC. Journal of the American
Medical Informatics Association 2016;23(1):193-201.
Background: Risk of bias (RoB) assessment is time-consuming;
an automated system that could assess each of the RoB do-
mains could reduceworkload and improve reliability. Supervised
machine learning (ML) requires humanannotation,which is time-
consuming and expensive. Distant supervision uses existing
sources (e.g. string matching). It has a higher error rate than
manual annotation, but can exploit larger training datasets.
Objective: Todevelop and evaluate RobotReviewer, aML system
that automatically assesses bias in clinical trials. From a (PDF-
formatted) trial report, the system should determine risks of bias
for the domains deﬁned by the Cochrane ‘Risk of Bias’ (RoB) tool,
and extract supporting text for these judgments.
Methods: Algorithmically, we annotated 12,808 trial PDFs using
data from the Cochrane Database of Systematic Reviews (CDSR).
Trials were labelled as being at lowor high/unclear risk of bias for
each domain, and sentences were labelled as being informative
or not. This dataset was used to train a multi-task ML model.
We estimated the accuracy of ML judgments versus humans by
comparing trialswith twoormore independent RoBassessments
in the CDSR. Twenty blinded experienced reviewers rated the rel-
evance of supporting text, comparing ML output with equivalent
(human extracted) text from the CDSR.
Results: By retrieving the top three candidate sentences per
document (top 3 recall), the best ML text was rated more rel-
evant than text from the CDSR, but not signiﬁcantly (60.4% ML
text rated ‘highly relevant’ versus 56.5% of text from reviews;
difference +3.9%, (-3.2% to +10.9%)). Model RoB judgments
were less accurate than those from published reviews, though
the difference was< 10% (overall accuracy 71.0%with ML versus
78.3% with CDSR).
Conclusion: RoB assessment may be automated with reason-
able accuracy. Automatically identiﬁed text supporting bias
assessment is of equal quality to the manually identiﬁed text in
the CDSR. This technology could substantially reduce reviewer
workload and expedite evidence syntheses.
Commentary
Prepared by Julian Elliott
Correspondence to: julian.elliott@monash.edu
Australasian Cochrane Centre, School of Public Health and Pre-
ventive Medicine, Monash University, Melbourne, Australia
Background: The median time to produce a Cochrane Review
is two and a half years.1 There is increasing interest in methods
and processes that improve the efﬁciency of review production
and the feasibility of keeping reviews up to date. Research in this
area has focussed on the use of text mining (deriving high quality
information from text), machine learning (models that learn from
data tomakepredictionsordecisions, rather than followingstatic
program instructions),2−4 crowdsourcing,5 betterworkﬂow tools
and improving workﬂow processes.
Whatdid theauthors say? Theauthorsdevelopedandevaluated
a text mining and machine learning program that automatically
makes judgements about a study’s risk of bias and selects text
from the full-text article to support these judgements.6 They
trained their program using a sample of Cochrane Reviews with
available full-text articles. Using studies that had been assessed
in more than one Cochrane Review as a reference standard, they
demonstrated that the program was inferior to human judge-
ment, but the numeric difference in accuracy was usually less
than 10%. The program was also able to identify text that was
highly relevant to the judgements at a similar level of accuracy.
Importance of the research for practice: The long-term objec-
tiveof thiswork is full automationof someof the tasks required to
produce a systematic review, but in the short-term the value pro-
vided by this and other systems is likely to be ‘semi-automation’
where the machine assists humans in the conduct of systematic
reviews.
The performance achieved by the machine in this study is im-
pressive given this is early work and there were some limitations
in the training data. Two key steps are now required. First,
evaluation of the effect this system has on accuracy, efﬁciency
and reviewer experience when used in conjunction with humans
producingsystematic reviews. Second, improving theaccuracyof
themachine learningmodels, assisted by access to large training
data sets.
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Machine learning to assist risk-of-bias
assessments in systematic reviews
Millard LA, Flach PA, Higgins JP. International Journal of
Epidemiology 2016;45(1):266-77.
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Background: One study estimated that 80% of ‘Risk of bias’
assessments took between 10 to 60 minutes to perform. Further
studies have shown that reviewers often report different levels of
risk of bias for the same trials, possibly due to a reviewer missing
key sentences. Text mining methods may potentially be used to
automate ‘Risk of bias’ assessments through identiﬁcation of rel-
evant sentences and prediction of ‘Risk of bias’ assignment from
text in the articles. If successful, text mining has the potential to
reduce the time required to perform a review and reduce human
error and subjectivity in the reviewing process.
Objective: To investigate the use of text mining methods to
automate ‘Risk of bias’ assessments in systematic reviews.
Designandanalysis: Adatasetconsistingof1467 full-textarticles
was constructed from data collected from Cochrane Database of
Systematic Reviews. Each article had a value assigned for at
least one of three ‘Risk of bias’ properties (sequence generation,
allocation concealment, blinding), where the values were cate-
gorized as either low risk or not low risk of bias. Sentences within
the articles were labelled as relevant or not relevant (or were
unlabelled) with respect to a ‘Risk of bias’ property. The ‘Risk
of bias’ values, and labelling of sentences, was determined from
‘Risk of bias’ judgements along with their supporting quotations
in the associatedCochraneReviews. Twomachine-learningmod-
elswere trained for each of the three ‘Risk of bias’ properties; one
predicted whether a sentence contained relevant information
and the other predicted a ‘Risk of bias’ value for each article.
Logistic regression was used to compare the performance of dif-
ferent models at predicting the relevance of each sentence and
the ‘Risk of bias’ value.
Mainresults:Theprobability thatarelevantsentencewasranked
more highly than a not-relevant sentence was over 98.5%. The
ranking of articles by risk of bias (correctly distinguishing low risk
from not low risk of bias) was 72% when full text articles were
used, 67% when only PubMed titles were used, and 68% when
PubMed titles and abstracts were used. It was estimated that
more than 33%of articles could be assessed by a single reviewer,
as these were considered to have been labelled as low risk or not
low risk with higher certainty than a human reviewer.
Conclusions: Text mining can be used to assist ‘Risk of bias’
assessments.
Commentary
Prepared by Asbjørn Hro´bjartsson, Isabelle Boutron, Doug
Altman, David Moher on behalf of the Cochrane Bias Methods
Group.
Correspondence to: Asbjorn.Hrobjartsson@rsyd.dk
Center for Evidence-BasedMedicine, University of Southern Den-
mark & Odense University Hospital, 5000 Odense C, Denmark
Background: The assessment of risk of bias of a randomized trial
is an essential part of conducting a systematic review to evaluate
the beneﬁts and harms of a healthcare intervention. However,
‘Risk of bias’ assessments are sometimes time consuming. Text
mining offers a possible strategy to reduce this workload.
What did the authors say? The authors used supervised ma-
chine learning to train two types of models for three ‘Risk of
bias’ domains: sequence generation, allocation concealment
and blinding. They found that sentences in PDF of scientiﬁc
articles could be successfully ranked by relevance to ‘Risk of
bias’ assessments, with area under the receiver operating char-
acteristic curve (AUC) greater than 0.98, and that articles could
be ranked by risk of bias with AUC ranging from 0.72 to 0.77
depending on bias domain. The authors suggested that more
than 33% of articles could be assessed by just one reviewer and
concluded that text mining can be used to assist ‘Risk of bias’
assessments.
Importance of the research for practice: This study ﬁnds that
text mining of journal articles may assist in identifying informa-
tion relevant for ‘Risk of bias’ assessments. However, ranking
trials according to risk of bias generated by machine learning
was not accurate. Automatised procedures may assist the initial
phase of a standard ‘Risk of bias’ assessment, but it is important
to emphasize that ‘Risk of bias’ assessments frequently involve
complex evaluations requiring methodological knowledge. Text
mining andmachine learning should therefore not be considered
as an alternative to standard human assessment of risk of bias,
but a supplement. The workload-reducing potential of text min-
ing may be greater for texts that are not journal articles such as
trial protocols, company study reports or drug regulary authority
documents. Follow-up studies addressing such alternative text
formats would be interesting.
Automating data extraction in
systematic reviews: a systematic
review
Jonnalagadda SR, Goyal P, Huffman MD. Systematic
Reviews 2015;4:78.
Background: Systematic reviews, speciﬁcally data extraction,
are time-consuming. Natural language processing (NLP), includ-
ing text mining, involves information extraction; discovery by
computer of new, previously unfound information by automat-
ically extracting information from different written resources.
Automation of data extraction may reduce the time to complete
a systematic review.
Objective: To describe methods of automating data extraction
for systematic reviews.
Design and analysis: A systematic review was undertaken to
identify studies that described and provided some evaluation of
automation tools for data extraction from systematic reviews.
Three databases were searched (PubMed, IEEExplore, and ACM
digital library) to identify studies published between January
2000 and January 2015. Information was abstracted on the
data element extracted from the systematic review (e.g. details
of methods, participants, setting, context, interventions, out-
comes, results), the algorithm or technique used, and the results
of the evaluation. Results were summarized narratively.
Main results: Twenty-six studiesmet the inclusion criteria. Stud-
ies exploredmethods for automaticdataextractionofparticipant
characteristics (n = 16) (e.g. number of participants, age); inter-
vention groups and details (n= 13); outcomes and comparisons
(n = 14); results (n = 2); interpretation (n = 3); objectives (n
= 2); and, methods (n = 12) (e.g. randomization method, ‘Risk
of bias’ assessment). Of the potential 52 data elements used
in systematic reviews, the largest number of elements extracted
automatically by a single study was seven.
Conclusions: The authors found no uniﬁed information extrac-
tion framework tailored to the systematic review process, and
published reports focused on a limited number of data elements.
Biomedical natural language processing techniques have not
been fully utilized to fully or even partially automate the data
extraction step of systematic reviews.
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Commentary
Prepared by Tari Turner and James Thomas
Correspondence to: tari.turner@monash.edu
School of Public Health and Preventive Medicine, Monash Uni-
versity, Melbourne, Australia
Background: As technology continues to improve in its abil-
ity to process natural language, there is increasing interest in
the development and evaluation of automation tools, based on
machine learning and text mining, for application in systematic
review production.1 After all, every systematic reviewer has at
somepointwished that the tedious, time-consuming elements of
the process could be given to someone who could do themmore
quickly; whether a helpful postgraduate student or, in this case,
a computer.
This systematic review included 26 studies that reported on tools
for automating data extraction in systematic reviews, published
between 2000 and 2015. While the results reported were cer-
tainly encouraging – in terms of demonstrating potentially useful
machine performance – the authors found that there was little
consistency between the studies in the data elements extracted,
or methods used to judge accuracy, so they could not compare
the approaches presented in the included papers meaningfully.
Importance of the research for practice: Anumber of initiatives
within Cochrane, such as Project Transform in which we are
both involved,2 are currently exploring how automation, or semi-
automation, can be used to help authors and support production
of Cochrane Reviews. While the exact forms of technology that
will be used are still being reﬁned, what is clear is that in the
very near future technology will be increasingly used to make
Cochrane Review production quicker – and more fun – for the
humans involved.
As the authors note, we need to have much better data on the
reliability of automated approaches. It is vital that automation
techniques are rigorously evaluated to ensure that the applica-
tion of technology to review production results in high quality
reviews. Reviewers need to be able to trust the results of auto-
mated systems as they produce reviews, and, ultimately, review
users need to be conﬁdent that the reviews produced using au-
tomation or semi-automation are reliable. Then we also need
to evaluate the utility of these new technologies in the review
process; are there potential downsides to reducing reviewers’ en-
gagementwith the text of the papers in systematic reviews? Time
will tell, but with ever-increasing numbers of studies published
every year, it is clear that we need to look to automation to assist
wherever it is feasible and appropriate to do so.
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Hartung-Knappmethod is not always
conservative compared to ﬁxed-effect
meta-analysis
Wiksten A, Ru¨cker G, Schwarzer G. Statistics in Medicine
2016;35:2503–15.
Background: A widely used method in classic random-effects
meta-analysis is the DerSimonian-Laird method. An alterna-
tive meta-analytical approach is the Hartung-Knapp method. In
recent publications, the use of the classic DerSimonian-Laird
method has been condemned, and the Hartung-Knapp method
has been suggested as a possible alternative.
Objective: To compare the Hartung-Knapp method with the
DerSimonian-Laird method.
Design and analysis: Three approaches were used to compare
the Hartung-Knapp and DerSimonian-Laird methods: an empiri-
cal comparison, a statistical simulation study, and an analytical
comparison. The empirical comparison involved reanalysing 157
meta-analyses of binary outcomes using bothmethods and com-
paring the resulting treatment estimates, standard errors, and
associated P values. Simulation scenarios were generated by
varying the number studies in the meta-analysis, the between-
study variance, and the average probability of an event in the
treatment and control group. The simulation meta-analyses
were analysed using both methods and coverage probabilities
and conﬁdence interval widths were compared.
Main results: Results from the empirical evaluation and simu-
lation study revealed that, generally, results were more conser-
vative with the Hartung–Knappmethod, giving wider conﬁdence
intervals and larger P values for the overall treatment effect.
However, in some meta-analyses with very homogeneous in-
dividual treatment results, the Hartung–Knapp method yielded
narrower conﬁdence intervals and smaller P values than the
classic random-effects method, which in this situation, reduces
to a ﬁxed-effect meta-analysis.
Conclusions: Results from the current study were consistent
with previous evaluations that have shown the Hartung-Knapp
method to be superior to the DerSimonian-Laird method. There-
fore, theHartung-Knappmethodshouldbe theprimary statistical
approach, but it is recommended that a sensitivity analysis based
on the ﬁxed-effect model is also conducted.
Commentary
Prepared by Dean Langan
Correspondence to: d.langan@ucl.ac.uk
Institute of Child Health, University College London, UK
Study results are often combined in a meta-analysis assum-
ing a random-effects model, which accounts for any observed
heterogeneity between study effects. The DerSimonian-Laird
method1 is commonly used in this model, primarily to estimate
the heterogeneity variance parameter. The DerSimonian-Laird
method is also often associated with the approach to estimate
the summary effect parameter and its Wald-type conﬁdence in-
terval. Alternatively, the Hartung-Knapp method2−4 can be used
to calculate this conﬁdence interval, and a growing body of ev-
idence suggests that this method is usually more conservative,
with coverage closer to the nominal level.5−7 In this article, these
twomethods are compared empirically, analytically and through
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simulated meta-analysis data. Results show that the Hartung-
Knapp conﬁdence interval can be less conservative when study
effects are homogeneous. Although the article is well written
and provides an important clear message, the authors confuse
methods for estimating the heterogeneity variance with conﬁ-
dence interval methods for the summary effect parameter, and
suggest there is an inherent link between them. The authors
should have clariﬁed that their article is a comparison of two
conﬁdence interval methods for random-effects meta-analysis.
Otherwise, the article is well written and provides an impor-
tant and clear message going forward; conﬁdence intervals for
the meta-analytic pooled effect should be calculated using the
Hartung-Knapp method, but sensitivity analysis is required to
check whether a ﬁxed-effect Wald-type conﬁdence interval leads
to more conservative results. Further simulation-based research
should investigate the impact on coverage of using results from
the ﬁxed-effect analysis in these cases.
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Exploring treatment by covariate
interactions using subgroup analysis
andmeta-regression in Cochrane
Reviews: a review of recent practice
Donegan S, Williams L, Dias S, Tudur-Smith C, Welton N.
PLOS ONE 2015;10(6):e0128804.
Background: If heterogeneity is detected in a meta-analysis it
may be inappropriate to draw conclusions from the pooled es-
timate. Possible causes of heterogeneity can be explored using
interaction analyses (subgroup analysis, meta-regression, strat-
iﬁcation). Interaction analyses provide information about how
a particular variable/characteristic modiﬁes a treatment effect.
There is limited research detailing how review authors explore
interactions.
Objective: To develop criteria to assess how well interaction
analyses were designed, applied, interpreted, and reported; and,
review Cochrane Reviews to establish how well interaction anal-
yses are carried out.
Design and analysis: Assessment criteria for interaction anal-
yses were compiled using recommendations in the Cochrane
Handbook for Systematic Reviews of Interventions, other method-
ological articles, and the authors’ own experience. The Cochrane
Reviews, to which the assessment criteria were applied, were
selected by choosing the most recently published review of in-
terventions (for which the protocol was accessible) from each
of the 52 Cochrane Review Groups. Information was extracted
with respect to the ﬁrst primary outcome, or the ﬁrst listed out-
come where no primary outcome was speciﬁed. Characteristics
of reviews, covariates, and planned or conducted interaction
analyses, were summarized.
Main results: The 52 Cochrane Reviews (published between May
2012 and August 2013) each included at least one covariate.
Of these, 46 (88%) reported patient-level covariates and all 52
reported study-level covariates (45 (87%) intervention-related;
19 (37%) outcome-related; 49 (94%) methodological; four (8%)
‘other’). All 52 reviews reported categorical covariates, 42 (81%)
reportedcontinuouscovariatesandsix (12%) reportedcovariates
for which the type was unclear.
The type of analysis planned and subsequently applied was dis-
crepant in 24 (46%) reviews. No review reported howorwhy each
covariatewaschosen. Twenty-two (42%) reviewsprespeciﬁedco-
variates in the protocol; no review identiﬁed post hoc covariates
as such. Eleven (21%) reviews mentioned ﬁve or more covari-
ates; ﬁve (15%) reviews had 10 or more trials for each covariate.
Only one review reported applying an interaction test for each
covariate, and one review reported whether an interaction was
detected for each covariate. No reviewdiscussed the importance,
or plausibility of the results, or the possibility of confounding for
each covariate; 13 (39%) discussed covariate distribution.
Conclusions: Interaction analyses in Cochrane Reviews could be
improved substantially. The proposed criteria could be used to
help guide the reporting and conduct of analyses.
Commentary
Prepared by Julian Higgins
Correspondence to: Julian.Higgins@bristol.ac.uk
School of Social and Community Medicine, University of Bristol,
Bristol, UK
Background: If results of studies included in a systematic review
do not agree with each other, it is useful to know why Statis-
tical analyses that investigate whether effect sizes depend on
study-level or participant-level characteristics (otherwise known
as treatment by covariate interactions) are therefore encouraged
in Cochrane Reviews. However, such analyses are fraught with
dangers and need to be undertaken with care.
What did the authors say? Donegan and colleagues undertook
a highly detailed examination of 52 Cochrane Reviews (one from
each review group in 2013), to look at how they had addressed
analyses of treatment-covariance interaction. From looking at
review protocols and initial publications of full reviews, they
found improvements tomethodology since a similar survey from
1999. However, most aspects of reporting failed to live up to the
aspirations articulated in the Cochrane Handbook for Systematic
Reviews of Interventions. For example, no review provided a
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rationale for the selection of characteristics to be investigated,
or commented on the importance of the ﬁndings, or remarked
on the possibility of confounding as an alternative explanation
for any observations. They also found that very few reviews
completely followed their prespeciﬁed plan, although – on the
bright side – they did note that most reviews had published
a plan to look at speciﬁc characteristics in the protocol, as is
recommended.
Importance of the research for practice: There is a clear impli-
cation for Cochrane Review authors: raise your game. Actually,
I’m not sure the situation is quite as bleak as it may seem. I
see statistical analyses of heterogeneity as very exploratory. Cer-
tainly it’s desirable to do all the things we’re told to do: to specify
a small number of key characteristics in advance, with a rationale
for each, and explain which speciﬁc methods will be used, and
then implement and report everything in great detail. But these
do not provide strong protection from drawing inappropriate
conclusions. Most important of all is to describe what has been
done and to interpret the results appropriately. This needs a
keen eye for the likelihood of false positive and false negative
ﬁndings, which arise primarily from having too few data and
from not entertaining alternative explanations for results. It’s
particularly disappointing that no review authors commented
on the possibility of confounding. I’m not so bothered about
review authors changing their statistical methods from protocol
to review, since I know this happens a lot through realising that
the protocol wasn’t quite right in the ﬁrst place, but I am inter-
ested in selection of appropriate methods. One issue, though
not much discussed by Donegal and colleagues, is in deﬁning
what actually constitutes an interaction analysis. I would regard
it to be one where an attempt is made to determine whether
the effect of intervention differs according to some study-level or
participant-level characteristic. For example, an analysis might
ask whether the effect is larger when treatment lasts longer, or
larger in studies within a particular healthcare setting, or using a
particular approach to implementing the intervention, or in older
patients. Such analyses – when applied to categorical character-
istics – require focus on the differences between subgroups, not
on the effects within subgroups. A particular area of confusion
is between subgroup analysis and sensitivity analysis. I don’t
think sensitivity analyses are suitable for looking at treatment by
covariate interaction, although Donegal and colleagues appear
to include this in their remit. Similarly, subgroup analyses per se
do not necessarily facilitate investigations of interaction. I would
have been interested to see an examination of the prevalence of
errors in interpretation. For example, my instinct is that a com-
mon slip-up surrounding subgroup analyses is to declare that
there’s a difference between subgroup categories on the basis of
there being a demonstrated effect within one subgroup but not
within the other. Such a ﬁnding is, of course, compatible with
the true effects being identical across the subgroups (that is, zero
treatment by covariate interaction).
Multivariate meta-analysis helps
examine the impact of outcome
reporting bias in Cochrane rheumatoid
arthritis reviews
Frosi G, Riley RD, Williamson PR, Kirkham JJ. Journal of
Clinical Epidemiology 2015;68(5):542-50.
Background: Outcome reporting bias arises when the report-
ing of outcomes is determined by statistical signiﬁcance and/or
direction of the effect size. One method to reduce outcome
reporting bias is through core outcome sets, which are an agreed
minimum set of standardized outcomes that must be measured
and reported in all trials for a particular disease/condition. In
1994, theOMERACT (OutcomeMeasures in Rheumatology) Group
ratiﬁed one of the ﬁrst core outcome sets.
Objective: To assess outcome reporting bias in Cochrane Re-
views of rheumatoid arthritis and demonstrate howmultivariate
meta-analysis may examine its impact.
Design andanalysis: Reviewspublishedby theCochraneMuscu-
loskeletal Group that evaluated pharmacological interventions
for the treatment of rheumatoid arthritis were included. Out-
come reporting bias was assessed using the Outcome Reporting
Bias in Trials (ORBIT) matrix method. The outcome matrix was
constructedusing the eightOMERACT core outcomes (tender and
swollen joints, pain, physical and patient global assessments,
function, acute phase reactants, radiological damage (studies
≥ 1 year)). Outcomes were evaluated using the 9-point ORBIT
classiﬁcation. In addition, multivariate meta-analysis was em-
ployed to investigate the impact of outcome reporting bias on
treatment effect estimates, statistical signiﬁcance, and precision
in one review.
Main results: Outcome reporting bias was assessed for 21
Cochrane Reviews. The reviews included 172 trials; 155 were
assessable (in English and obtainable). All reviews had primary
studies with missing data for at least one core outcome. Twenty-
one of the 155 assessable trials reported data fully for all core
outcomes, but the data for only 10 of these trials were ade-
quately reported in reviews. At the trial level,missing/incomplete
outcome data ranged from 36% (radiological damage) to 56%
(physician global assessment). Of the 1118 evaluable outcomes,
515 (46%) were partially or not reported and 247 (22%) were
classiﬁed under high suspicion for outcome reporting bias; 212
(19%) were clearly measured and analyzed, but the reporting of
the outcomes meant that the data could not be included in a
meta-analysis. Multivariateandunivariate results sometimeshad
important differences. The maximum change in treatment effect
estimate between the multivariate and univariate meta-analysis
approach was 176% (swollen joints).
Conclusions: Outcome reporting bias has the potential to affect
theconclusionsofmeta-analyses. Thiscouldbeavoided if trialists
reported on all measured outcomes in full. Systematic reviewers
need to address the issue of missing outcome data explicitly for
their review to be considered reliable. If missing data are un-
obtainable, multivariate meta-analysis is useful to examine the
impact of the missing data on outcomes and outcome reporting
bias on conclusions.
Commentary
Prepared by Dan Jackson
Correspondence to: dan@mrc-bsu.cam.ac.uk
MRC Biostatistics Unit, Cambridge Biomedical Campus, Cam-
bridge Institute of Public Health, Cambridge, UK
This paper investigates the role that multivariate meta-analysis
(MVMA) can play when examining the impact of outcome report-
ing bias (ORB), in the context of Cochrane rheumatoid arthritis
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reviews. They conclude that ‘‘MVMA is useful to examine the im-
pact ofmissingoutcomesandORBonconclusions’’.1 As someone
who is very enthusiastic about multivariate meta-analysis, I am
delighted to see another reason why this type of analysis might
be considered desirable.
However, in section 5.3.5 of our paper, myself and colleagues3
take the opposite view and argue that ‘‘Publication biases might
be exacerbated’’ by using a multivariate approach (although we
also make it clear that ‘‘the multivariate methods have the po-
tential to reduce bias due to partial reporting’’ in section 5.2.5).
Perhaps we were either confused or simply being deliberately
provocative. The concern here would seem to be that poorly
reported andbiased secondary outcomes, if analysed jointlywith
unbiased primary outcomes, could lead to bias in the inferences
forprimaryoutcomes. Kirkhamandcolleagues4 provideaspirited
counter to this argument.
So, is it now clear that the advantages of MVMA outweigh the
disadvantages in regard to ORB? Articles such as this one are, at
the very least, building a strong case in favour of themultivariate
approach. Before determining whether this is so, I would, how-
ever, suggest that further model-based empirical investigations,
such as the one conducted in 2005 by myself and colleagues,
are needed. Although this particular investigation found that
the ‘‘without reporting bias model for the secondary outcome’’2
resulted in similar inferences for the primary outcome in themul-
tivariatemodel, here the primary outcome data were complete. I
suspect that the casemight be different, or at least more compli-
cated and less clear, in situations where the primary outcome is
also partially reported. Further research along these lines would
be more than welcome.
For now, this paper provides more reasons to be enthusiastic
about MVMA, and so I thank the authors for that. I encourage you
to read their clear and highly accessible account of their work.
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GetReal in network meta-analysis: a
review of the methodology
Efthimiou O, Debray TP, van Valkenhoef G, Trelle S,
Panayidou K, Moons KG, et al. Research Synthesis Methods
2016 Jan 11 [Epub ahead of print]. DOI: 10.1002/jrsm.1195.
Background: Pairwise meta-analysis is an established statis-
tical tool for synthesizing evidence from multiple trials, but it
is informative only about the relative efﬁcacy of two speciﬁc
interventions. The usefulness of pairwise meta-analysis is thus
limited in real-life medical practice, where many competing in-
terventions may be available for a certain condition and studies
informing someof the pairwise comparisonsmaybe lacking. This
commonly encountered scenario has led to the development of
network meta-analysis (NMA). In the last decade, several appli-
cations, methodological developments, and empirical studies in
NMA have been published. An updated review of the methodol-
ogy is deemed timely to ensure that interested researchers use
state-of-the-artmethods for practical applications andalsowhen
conducting further methodological research.
Objective: Toreviewandsummarizecurrentlyavailablemethods
forNMA; discuss statisticalmethods for evaluating theunderlying
assumptions of the model; and provide guidance for researchers
wishing to undertake a NMA.
Design:Asearchof the literature forNMAarticleswasundertaken.
Articles were included if they contributed new methodology for
NMA; reviewed existing methodology; provided recommenda-
tions/guidance on performing NMA; discussed conceptual issues
and the assumptions; or provided an empirical assessment for
the conduct of NMA. Identiﬁed articles were tagged according to
the type of research, methodological topic, and software used.
Main content: A total of 179 articles were identiﬁed. These
articles contributed to the following topics: basic methodology
in NMA; statistical methods for evaluating inconsistency in NMA;
software options for ﬁtting a NMA model and evaluating incon-
sistency; other issues in NMA (e.g. different summary effect
measures).
Conclusions: Currently available methodology on NMA was pre-
sented. The review serves as a road map for researchers using
NMA and those conducting methodological research.
Commentary
Prepared by Brian Hutton
Correspondence to: bhutton@ohri.ca
Ottawa Hospital Research Institute, University of Ottawa School
of Epidemiology, Public Health andPreventiveMedicine, Ottawa,
Canada
In recent years, network meta-analysis (NMA) has become a vital
analytic approach in the context of systematic reviews seeking
to compare multiple healthcare interventions. This technique
enables the systematic reviewer to address research questions
involving the comparison of multiple interventions, formulating
an evidence network of trial data which serve as relevant sources
of direct and indirect evidence for such analyses. Aspects of
methodology surrounding NMA have evolved rapidly in recent
years. In this review, Efthimiou and colleagues provide readers
with a high-level overview of the beneﬁts afforded by NMA to
its users relative to traditional pairwise methods. The authors
employeda systematic search to identifymethodologic literature
related toNMA,andsubsequently sought to shed lightuponmany
of the key methodologic developments that have arisen in the
ﬁeld in recent years by providing a structured summary.
The content of this review provides readers with exposure to
both fundamental and advanced topics. Readers with limited
exposure to NMAwill ﬁnd content that will enlighten them about
considerations such as the core assumptions of transitivity and
consistency required for the performance of a valid NMA; the dif-
ferent statistical approaches to NMA performance; and also the
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array of software packages currently available to carry out these
analyses. More seasoned readers will also ﬁnd information of
interest concerning more recently emerging topics that include
the assorted modelling approaches for assessment of consis-
tency of evidence; potential implications associated with the
use of different summary effect measures; extension of models
to enable accounting for effect-modifying factors; involvement
of individual patient data; and considerations for dealing with
variable study designs; and the exploration of bias. The review
also notes a need for guidance to help standardize reporting
and enhance the reporting quality of NMAs in the peer-reviewed
literature; the PRISMA Extension Statement for network meta-
analysis has recently been published and may now help to
ﬁll this void.
The overview by Efthimiou and colleagues serves as a valuable
sourcewithmanyof thekeymethodological references related to
the practice and evaluation of network meta-analysis. Whether
new to the topic or anexperienceduser, thisworkoffers insightful
information to its readers. The continued brisk pace of method-
ological developments in this area will likely necessitate updates
in the future.
Planning future studies based on the
precision of network meta-analysis
results
Nikolakopoulou A, Mavridis D, Salanti G. Statistics in
Medicine 2015;35:978-1000
Background: When there are multiple competing interventions
for a healthcare problem, the design of new studies could be
based on the entire network of evidence as reﬂected in a network
meta-analysis (NMA). There is a practical need to answer how
many (if any) studies are needed, of which design (i.e. which
treatments to compare), and with what sample size to infer con-
clusively about the relative treatment effects of a set of target or
all competing treatments and their relative ranking.
Objective: To develop methodology to inform future studies
based on the precision of NMA results.
Main content: A framework consisting of four steps was devel-
oped for using NMA evidence for planning future studies. The
steps were: 1) evaluation of existing evidence, which involves
interpretation of the network estimateswith respect to their con-
clusiveness and the setting ofworthwhile effects for comparisons
of interest; 2) choice of future study scenarios, which involves
speciﬁcation of potential scenarios about the future designs;
3) setting a desirable level of precision for the target comparison
or treatment ranking; and, 4) calculation of the minimum sample
size for each future study scenario. Several statistical measures
to quantify the gain in precision of treatment effects and gain in
precision in treatment ranking after the network’s update were
developed. These statistical measures are used in the estimation
of sample size for future study scenarios. A published network
of interventions for the treatment of hepatocellular carcinoma is
used to illustrate the methodology.
Conclusions: The developedmethodology can be used to inform
the planning of future studies, or to prioritize updates of NMA
based on the likelihood of an important increase in precision.
The application of these methods can aid investigators, funders,
and regulators inmaking informedandevidence-baseddecisions
about planning new studies.
Commentary
Prepared by Alex Sutton
Correspondence to: ajs22@le.ac.uk
Complex Review Support Unit, Department of Health Sciences,
University of Leicester, Leicester, UK
Background: The inception of The Cochrane Collaboration was
a direct response to the need for evidence-based medicine, an
approach that is now widely accepted and practiced. But what
about the design of future trials, can we say research is as
evidence based as clinical practice? Put another way, do we
use the information available in existing studies to its full ex-
tent to inform the design of future ones? I think we do not,
but if I cannot convince you, perhaps Paul Glasziou and Iain
Chalmers can: blogs.bmj.com/bmj/2015/10/29/how-systematic-
reviews-can-reduce-waste-in-research/.
One key aspect when designing a future trial is establishing an
appropriate sample size. Traditionally sample size calculations
have been based around the analysis of the new study by itself,
but, sincemeta-analysesof randomizedcontrolled trialsareoften
placed at the top of hierarchies of evidence, a strong argument
can be made for powering the new study to inform the updated
meta-analysis (where one exists) using the information in the
existing meta-analysis to inform the calculation.
Previous papers have considered methodology for establishing
sample sizes for a pairwise meta-analysis context,1 i.e. how
large a new trial should be when comparing treatment A against
treatmentB for inclusion in a subsequent updatedmeta-analysis.
However, in this paper the authors go one stage further by con-
sidering how a new trial might impact a network meta-analysis2
to which it will subsequently be added.
What did the authors say? In order to achieve this, the authors
need to consider a further preliminary question which concerns
the treatments to be compared in the new study. Often, this will
not be easy to answer, because of evidence for one treatment
comparison in the network, for example, treatment A versus
treatment B, can indirectly inﬂuence the estimates of treatment
effects for other treatment comparisons in the network, for ex-
ample, treatmentB versus treatmentC. It shouldbe further noted
that, in some circumstances, trials withmore than two armsmay
be the most efﬁcient when considering the impact on the results
of the (updated) network meta-analysis.
In the framework presented, the impact on the precision of the
effect sizes of the treatment comparisons and the impact on the
ranking of the treatments in the network (that is which treatment
is best, second best, etc.) are both considered separately. Thus,
this paper eschews the use of simple statistical hypothesis tests,
whichoftenunderlie traditional sample sizecalculations for infer-
ence on more clinically interpretable and meaningful outcomes.
The paper is technical in places, but this is entirely necessary;
the questions they are trying to answer are multifaceted and
complex, and I would be suspicious if a simple solution were
offered! Two illustrative examples (the latter in the appendix
of the paper) are very helpful in illustrating how the approach
works inpractice, andsoftware to implement themethod ismade
available for download.
Importance of the research for practice: I ﬁrmly believe that
this alternative approach to sample size calculation - using the
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existing evidence, and considering the impact on the totality of
evidence - despite its complexities, is worthy of exploration and
this paper takes us an important step further along the road
towards doing this in a coherent way across multiple competing
treatment regimes.
Cochrane already provides high-quality meta-analyses on which
trialists can consider the impact of a new trial, and could also
help to ensure the design of future trials is more evidence-based
by making the implications for research sections of reviews as
explicit as possible (whilst laying out the rationale for such
recommendations).3 Future research to assess the added-value
of applyingmethods, such as those presented in this paper, when
writing the implications for research sections of reviews, would
be valuable. Thismay enable Cochrane Reviews to becomemore
inﬂuential in setting future research agendas. An important side
note is that thesametypeofmethodologycouldalsobeutilized to
help inform the priority schedule for updating Cochrane Reviews
as new evidence accrues.4
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Deﬁciencies in the publication and
reporting of the results of systematic
reviews presented at scientiﬁc medical
conferences
Hopewell S, Boutron I, Altman DG, Ravaud P. Journal of
Clinical Epidemiology 2015;68(12):1488-95.
Background: Inability to access full publications means that
some readerswill have only the abstract of a systematic review to
informtheir decision. In addition, research is oftenﬁrst presented
at scientiﬁcmeetings and published as an abstract in conference
proceedings or on the conference website; these abstracts may
never go on to be published in full, and if they are, there is often
a long delay before the full paper becomes available.
Objective: To evaluate the publication and quality of reporting
of abstracts of systematic reviews presented at scientiﬁcmedical
conferences.
Design and analysis: Abstracts of systematic reviews published
in the 2010 proceedings of nine international conferences of
American societies and colleges (rheumatology, diabetes, heart,
psychiatric, anaesthesiologists, clinical oncology, haematology,
thoracic, and infectious diseases) were identiﬁed. PubMed was
searched to identify corresponding full publications. Conference
abstracts and their corresponding journal abstract were com-
pared using the PRISMA checklist, and important discrepancies
highlighted.
Main results: Of 26,840 conference abstracts, 197 (< 1%) were
of systematic reviews; 103 (53%) were subsequently published in
full. The median time to publication was 14 (interquartile range
6.6 to 20.1) months. When the conference and journal abstracts
were compared, most reported the term ‘systematic review’ or
‘meta-analysis’ in the title (89% versus 88%); details of included
studies (81% versus 79%); size and direction of effect (76% versus
75%); and conclusions (79% versus 81%). Several systematic
review methods and results were poorly reported in both the
conference and journal abstract: search date (27% versus 25%);
‘Risk of bias’ assessment (18% versus 12%); result for the main
efﬁcacy outcome(s) including the number of studies (37% versus
31%) and participants (30% versus 20%); harms (17% versus
17%), strengths (17% versus 13%), and limitations (36% versus
30%) of the evidence; or funding source (1% versus 0%). Dis-
crepancies between conference and journal abstracts included
deletion of studies (13%); changes in reported efﬁcacy (11%) or
harm (10%) outcome(s); and changes in the nature or direction
of conclusions (24%).
Conclusions:Despite the importanceof systematic reviews in the
delivery of evidence-based health care, very few are presented
at scientiﬁc conferences, and only half of those presented go
on to be published in full. Serious deﬁciencies in the reporting
of abstracts of systematic reviews make it difﬁcult for readers
to assess their ﬁndings reliably. This makes them unusable
and represents a considerable waste in already limited ﬁnancial
resources.
Commentary
Prepared by Larissa Shamseerand Matthew J Page
Correspondence to: lshamseer@ohri.ca
Clinical Epidemiology Program, Ottawa Hospital Research Insti-
tute, Canada
Background: Approximately half of all studies presented as
abstracts at biomedical conferences are published in full.1 Con-
ference abstracts are peer reviewed less thoroughly than journal
articles, so their quality of reporting is generally poor. In addition,
word limits imposed on abstracts (in both conference proceed-
ings and journal articles) mean that details of the methods and
results are often incomplete. The limited space may also lead
authors to prioritize reporting of ‘positive’ or ‘signiﬁcant’ results
at the expense of ‘negative’ or null ﬁndings.2 Systematic reviews
are not immune from such reporting issues. This is problematic
because, if decision makers only have access to a systematic
review abstract with misleading or incomplete results, inappro-
priate healthcare decisions may be made. While a few have
studied selective reporting in review abstracts, the extent of non-
publication of systematic reviews is not well understood. One
study found that 20% of review protocols had no associated full
review published after eight years and those that were published
tookamedianof1.63years (range0.15to7.31years) tocomplete.3
However, this studyonlyexaminedCochraneReviews, soﬁndings
may not generalize to other systematic reviews.
What did the authors say? Hopewell and colleagues4 provide
the ﬁrst estimate of the prevalence of systematic reviews pub-
lished as conference abstracts that were subsequently published
in full, and of differences in reporting between conference and
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corresponding journal article abstracts. Findings indicate that
almost half of all systematic review abstracts presented at con-
ferences were not published up to three years after presentation;
those that were took a median of 14 months from conference
presentation to full publication.4 The study also identiﬁed a few
important discrepancies between conference and journal ab-
stracts. A few journal abstracts haddifferent numbers of included
studies and participants, had omitted or added certain efﬁcacy
and harm outcomes (e.g. omission of signiﬁcant subgroup anal-
yses or addition of signiﬁcant outcomes), and had conclusions
that differed in nature or direction (e.g. focus on a different out-
comes or subgroups) compared with corresponding conference
abstracts.
Key comments: This study is theﬁrst tohaveused thePRISMA for
Abstracts checklist5 to evaluate reporting of systematic review
abstracts. All abstracts were published prior to publication of
this guideline, so this study provides a useful baseline against
which future evaluations can be compared. The study is well
described, although authors do not speciﬁcally provide infor-
mation on how the checklist was operationalized. Readers can
assume that a point was awarded for complete reporting of all
elements for a reporting item, and no points for incomplete or
non-reporting of an item. Whether any variation in interpre-
tation of items was applied is unknown (for example, were all
items completely reported or were some mostly reported but
incomplete?).
In addition, the authors have not provided information about
the journals in which the completed systematic reviews were
published. This leaves questions unanswered regarding whether
certain journal policies impacted the reporting or content of
abstracts (for example, structured abstracts, word limits, en-
dorsement of PRISMA). The authors do not discuss whether any
of the reviews were carried out with established review organiza-
tions such as Cochrane.
Implications of this research: This study does not provide any
information speciﬁc to Cochrane Reviews. Other studies have
found that Cochrane abstracts contain less ‘spin’6 and may have
fewer reportingproblems thannon-Cochrane reviews, as recently
found in a studywe co-authored.7 Future research should include
a more comprehensive sample of systematic review conference
abstracts in order to provide readers with a more generalizable
picture of the state of reporting and non-reporting of systematic
reviews.
Future research: Research of this sort should continue so that
the research community, speciﬁcally systematic reviewers, has a
full understanding of the impact of reporting inadequacies. Au-
thors andpeer reviewers shouldbeawareof thePRISMAchecklist
for abstracts and make use of the checklist when preparing and
reviewing abstracts, for conferences and journal publications.
Methodological researchof this sort should continue andaddress
the minor limitations that we have mentioned here.
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Avoidable waste of research related to
inadequate methods in clinical trials
Yordanov Y, Dechartres A, Porcher R, Boutron I, Altman
DG, Ravaud P. BMJ 2015;350:h809.
Background: Waste occurs in all types and stages of research,
fromchoosing irrelevant questions to under-reporting trialmeth-
ods and results. A large part of waste is related to inadequate
methods; ﬂaws in design, conduct, and analysis can bias results
of trials and subsequently systematic reviews, potentially leading
to erroneous conclusions.
Objective: To assess thewaste of research related to inadequate
methods in trials included in Cochrane Reviews and to examine
to what extent this waste could be avoided.
Design and analysis: The Cochrane Database of Systematic Re-
views (CDSR) was searched between April 2012 and March 2013
for new systematic reviews of randomized controlled trials with
at least one meta-analysis and a ‘Risk of bias’ (RoB) assessment.
A random sample of 200 trials with at least one domain at a high
RoB were reassessed; for trials with conﬁrmed high RoB, related
methodological problems were identiﬁed. Possible adjustments
were proposed for each problem. Avoidable waste was deﬁned
as trials with at least one high RoB domain for which easy ad-
justments with no, or minor, cost could change all domains to
low risk. Adjustments, feasibility (easy or not) and cost were
validated by an expert panel. A simulation study was performed:
after extrapolating the reassessment of RoB to all trials, each
domain rated as being at unclear RoB was considered as missing
data and multiple imputations were used to determine whether
they were at high or low risk.
Main results: Of 1286 trials from 205 meta-analyses, 207 (16%)
were at low RoB for all domains, 523 (41%) had at least one
domain at an unclear RoB, and 556 (43%) had at least one
domain at a high RoB. Of the 556 trials with a high RoB, 200
were randomly selected and reassessed; 142 were conﬁrmed as
being at high RoB (disagreements with review authors mainly
concerned blinding of outcome assessment). Across these 142
trials, 25 types of methodological problem were identiﬁed. From
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the experts’ evaluation, adjustments were possible in 136 trials
(96%), with 71 trials (50%) requiring easy adjustments to reduce
the number of high RoB domains; 17 trials (12%) would become
low RoB for all domains. The avoidable waste represented 12%
(95% conﬁdence interval (CI) 7% to 18%) of trials with a high RoB.
After correcting for unclear RoB, avoidable waste across all 1286
trials due to inadequate methods was estimated at 42% (95% CI
36% to 49%).
Conclusions: An important burden of wasted research is related
to inadequate methods. This waste could be partly avoided by
simple and inexpensive adjustments.
Commentary
Prepared by Theresa Aves1, Lawrence Mbuagbaw1,2
Correspondence to: avest@mcmaster.ca and
mbuagblc@mcmaster.ca
1Department of Clinical Epidemiology and Biostatistics,
McMaster University, Hamilton, ON, Canada
2Biostatistics Unit, Father Sean O’Sullivan Research Centre, St
Joseph’s Healthcare-Hamilton, ON, Canada
Background: Avoidablewaste of research is a concern of interest
in the research world. It reﬂects resources expended on study-
relatedefforts that result inminimal researchvalue. Thisproblem
affects the researchers, who engage in futile efforts; the patients
who spend time participating in research, andmay be needlessly
exposed to potentially harmful interventions in studies that will
not yield meaningful results; the healthcare providers who re-
main uncertain about how touse unclear ormisleading evidence;
and policy makers who must develop policy in the absence of
credible information.1,2
Study investigators attempted to quantify the amount of waste
related to inadequate methods in trials included in Cochrane
Reviews and to determine if this waste could be avoided. This is a
well conducted methodological study, using statistical methods
including simulation to address a highly relevant issue.
What did the authors say? Authors examined trials used for
the meta-analysis of primary outcomes in Cochrane Reviews
published between April 2012 and March 2013. They selected
a random sample of 200 trials that had at least one ‘Risk of
bias’ domain established to be at high risk, then identiﬁed the
methodological problem responsible. The authors determined
25 types ofmethodological problems in 142 trialswith high risk of
bias. Of these problems, at least one adjustment could be made
in 96% (136 trials). Simple adjustments of no or minor cost were
possible in 71 of the 142 trials (50%). Avoidable waste was found
in 12% (95% conﬁdence interval (CI) 7% to 18%) of trials with at
least one domain at high risk of bias. Avoidable waste was 42%
(95% CI 36% to 49%) after adjusting for incomplete reporting.
Importance of the research for practice: Given the high pro-
portion of studies with potentially modiﬁable methodological
ﬂaws that can lead to research waste, systematic reviewers are
called upon to do two things. Firstly, they should not relent in
their efforts to appraise risk of bias in trials included in Cochrane
Reviews and secondly, they should expend every effort to con-
tact the investigators of trials to ﬁll the ‘unclear’ gap between
conduct and reporting. Users of reviews should be aware of
these challenges and focus on the least biased results. Editors
of journals should not only endorse the Standard Protocol Items:
Recommendations for Interventional Trials (SPIRIT) and CON-
SORT statements,3,4 but also ensure that optimalmethodologies
are selected and reported. Trialists are invited to invest in re-
searchmethods training, and to collaborate with biostatisticians
andmethods experts in order to reduce avoidable waste.
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Selective reporting in trials of high risk
cardiovascular devices: cross sectional
comparison between premarket
approval summaries and published
reports
Chang L, Dhruva SS, Chu J, Bero LA, Redberg RF. BMJ
2015;350:h2613.
Background: Selective reportingof favorable results for drugs in-
cludes several types of reporting bias, including failure to publish
entire studies or unfavorable outcomes, and publication of only
selected prespeciﬁed outcome analyses. The extent of selective
reporting for high risk cardiovascular devices (such as pacemak-
ers and implantable cardioverter deﬁbrillators) is unknown.
Objective: To compare the characteristics and results of clinical
trials reported in US Food and Drug Administration (FDA) doc-
uments for recently approved high-risk cardiovascular devices
with those reported in peer-reviewed publications.
Design and analysis: The FDA premarket approval database
was searched for cardiovascular devices that received premarket
approval frombeginning of January 2000 to the end of December
2010. For each summary listed in the premarket approval doc-
uments, MEDLINE was searched for corresponding publications;
where no matching publication was found and device manu-
facturers did not provide a reference, the study was considered
unpublished. A studywasclassiﬁedaspivotal, feasibility, early, or
supportive. Comparisons were made between the FDA summary
and published studies in terms of methodology, patient demo-
graphics, and results. Primary endpointswere compared in terms
of type (equivalence, non-inferiority, objective performance cri-
teria), type of controls, and number of patients analyzed. Results
were classiﬁed as identical (matched numerically and signiﬁ-
cance), similar (differed by < 5%, signiﬁcance unchanged) or
different. Generalized linear mixed-effects models were used to
estimate the relationship between the type of document and
study characteristics/primary endpoints.
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Main results: Between 1 January 2000 and 31 December 2010,
106 cardiovascular devices received FDApremarket approval; the
documents contained 177 studies. By 1 January 2013, 86 trials
(49%) had been published. Published trials were more likely to
be randomized (40% versus 29%), blinded (27% versus 7%), and
conducted in the USA (43% versus 23%). Six studies (ﬁve pivotal)
were presented as pooled data. In 22/86 (26%) studies, the num-
ber of participants enrolled differed between the FDA summary
and the corresponding publication. Demographic information
also differed: average age differed by more than one year in nine
(11%) and sex by more than 1% in 14 (16%).
Of 152 primary endpoints in the FDA documents, the correspond-
ing publications labeled three (2%) as secondary, 43 (28%) were
unlabeled, and15 (10%)werenot found; 34 (40%) studiesdiffered
from the FDA summaries in the number of primary endpoints.
Among primary results, 69 (45%) were identical, 35 (23%) similar,
17 (11%) different, and 31 (20%) could not be compared. In the
FDA summaries, 94/152 (62%) primary results favored the device,
eight (5%) favored the control, 12 (8%) favored neither, and 38
(25%) had no control or objective performance criteria. In the
published studies 65/152 (43%) favored the device, three (2%)
favored the control, 14 (9%) favored neither, and 70 (46%) could
not be compared.
Conclusions: Many clinical trials for high-risk cardiovascular
devices approved by the FDA remain unpublished. Even when
trials are published, the study population, primary endpoints,
and results can differ substantially from data submitted to the
FDA.
Commentary
Prepared by Tom Jefferson
Correspondence to: jefferson.tom@gmail.com
Centre for Evidence Based Medicine, Oxford, UK
Background. Since 2010, 14 studies have compared different
sources of data for the same trials. Typical comparisons involved
clinical study reports or other regulatory informationwith journal
publications. The results are unequivocal and shouldworry every
Cochrane author. The evidence points to varying degrees of
reporting bias in literature and discrepancies between publica-
tions and the other data sources. All trials included in the reviews
were sponsoredby thepharmaceutical industry andassessed the
effects of pharmaceuticals and biologics. These are only a pro-
portion of healthcare interventions. Non-pharmaceuticals, such
as diagnostics and prostheses, represent an equally important
part of the story, but their regulation is patchy and (at least in the
European Union (EU)) non transparent and decentralized. In the
EU there is no legal requirement for most non-pharmaceuticals
to be tested in clinical trials, even in the case of invasive devices
and the standard of reporting of the fewpublished trials is largely
understudied.
What did the authors say? Chang and colleagues took a further
step in the exploration of this obscure area.1 The authors as-
sembled premarket approval (PMA) documents for 106 high-risk
cardiovascular devices (such as deﬁbrillators) approved by the
FDA during 2000 to 2010. They reviewed the ‘summary of clinical
studies’ contained in each PMA folder and compared them with
their respective publications (when available). Publication bias
was prevalent (51% had not been published by January 2013). In
published trials the authors identiﬁed discrepancies with regu-
latory equivalents for denominators (in 26% of studies), primary
endpoints (61 of 152 had disappeared or changed labeling) and
in results (48 of 152 had changed).
The results and conclusions of Chang and colleagues’ are wholly
consistentwith theevidence frompharmaceuticalsandbiologics.
Reporting bias is likely to affect any product with a commercial
basis.
The message for Cochrane is clear: beware of publications –
reporting bias is likely to affect your review. For pharmaceuti-
cals, bias is likely to be minimized by the inclusion of clinical
study reports and approval documents obtainable from the Eu-
ropeanMedicines Agency2 andDrugs@FDA.3 The latter, however,
are essentially regulators’ reviews and not complete study re-
ports. In the case of non-pharmaceuticals, FDA PMA documents
is all we have. At least until such time as regulation of non-
pharmaceuticals and its transparency are taken seriously.
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A taxonomy of rapid reviews links
report types andmethods to speciﬁc
decision-making contexts
Hartling L, Guise JM, Kato E, Anderson J, Belinson S,
Berliner E, et al. Journal of Clinical Epidemiology
2015;68(12):1451-62.
Background:Decisionmakers require evidencewithin short time
frames, whilst maintaining transparency, unbiased assessment,
and reliability. Rapid reviews may provide timely reports, but
variation in deﬁnitions and methods of production may impact
on reliability and validity.
Objective: To describe characteristics of rapid reviews and ex-
amine the impact ofmethodological variations on their reliability
and validity.
Design and analysis: Literature discussing rapid review meth-
ods, their production, and comparisons of their results with
standard systematic reviews, were sought by searching sevenon-
line bibliographic databases and grey literature. Interviews with
English-speaking rapid review producers were also conducted.
Informationon rapidproductswere summarizedandcategorized
according to the extent of synthesis.
Main results: Thirty-six rapid products were identiﬁed from 20
public and private organizations; 19 producers participated in
60-minute telephone interviews. Experience in producing rapid
products ranged from months to 25 years, and the number of
reports from three to 400 per year. Production time for reports
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ranged from ﬁve minutes to eight months. Rapid methods be-
came more rigorous as production time increased; there were
still restrictions on databases searched, language, inclusion cri-
teria, data extracted, and duplication of effort in all products.
Rapid products were categorized as: inventories (lists evidence
available; no synthesis); rapid responses (presents best available
evidence; no formal synthesis); rapid reviews (synthesizes the
quality and ﬁndings of the evidence, qualitatively and/or quan-
titatively; most comparable to a standard systematic review); or
automated approaches (computer-generated meta-analyses in
response to user-deﬁned queries).
Oneof themaindifferencesbetweenrapidproductsandstandard
systematic reviews was the relationship with the end user. Rapid
products relied on close relationships with end users, addressing
speciﬁc decisions within preset time frames. Ongoing commu-
nication and the focused nature of the questions led to a wide
range of methods being employed.
Considerations for creating rapid products included: nature of
the decision; relationship with the end user; need for skilled
and experienced staff; capacity to mobilize skilled staff quickly;
and acceptance of modiﬁed systematic review methods. Little
evidence existed that compared rapid and standard systematic
reviews, which precludes any ﬁrm conclusions on the validity
of results and conclusions from rapid approaches. Limitations
of the production methods, particularly potential biases and
shortcomings of the conclusions, need to be clearly reported.
Conclusions: Rapid products varied considerably in their
methodology, ranging from inventories with no synthesis to au-
tomated approaches with computer-generated meta-analyses.
The similarity across rapid products was the close relationship
with end users to meet time-sensitive decisions.
Commentary
Prepared by Adrienne Stevens,1 Chantelle Garritty,1 Gerald
Gartlehner,2 Chris Kamel,3 Valerie King4
Correspondence to: methods.cochrane.org/rapidreviews/
1. Ottawa Hospital Research Institute, Canada
2. Cochrane Austria, Austria
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Rapid reviews (RRs) are gaining prominence for use in decision-
making circumstances that require a timelier compilation of the
evidence than is usually allowed by systematic reviews. Method-
ological evaluation, to date, has shown that RRs vary in how
they are developed relative to the systematic review process.
Modiﬁcations are possible at every step from limitations in scope
through to the synthesis approach, with RRs taking a few days to
several months to produce. Therefore, RRs are not a ‘one size ﬁts
all’ in terms of either process or end product, but exist along a
spectrum tailored to meet the needs of decision-makers.
As a ﬁrst of its kind in the published literature, Hartling and col-
leagues developed a taxonomy to address this spectrum. Using
a literature review and key informant interviews, they identiﬁed
and evaluated a number of relevant papers, including a sample
of 36 RRs. The taxonomy is based on the extent of synthesis
used in those sources and is summarized in Table 1 below. The
taxonomy serves as a valuable starting point but, as the authors
acknowledge, might beneﬁt from validation using a larger sam-
ple. This will help to determine whether further granularity of
characterization canbemade, andwhether other attributes need
to be considered. What readers cannot infer from the taxonomy
is the risk of bias and the reliability of ﬁndings these categories
represent, as they are not deﬁned by underlying methodological
decisions, but rather by a synthesis approach at a broader level.
Future studies with larger samples are required to inform further
issues about the certainty of research ﬁndings derived from RRs.
The authors also acknowledge that RRs are not just a ‘‘mini-
systematic review with corners cut’’,1 but that a number of
contextual factors, such as a close and iterative dialogue with
end users to ensure ﬁtness-for-purpose, inﬂuence the developed
rapid product. Through our collective experience of conducting
RRs, we would agree with this, and further note that the com-
plexity of the question(s) posed, the nature and volume of the
evidence, the decision-making context, and the user’s time frame
greatly inﬂuence the ﬁnal rapid product.
Table 1. Taxonomy of rapid products based on the
extent of evidence synthesis 1.
Category Description
Evidence
inventories
Provide a list of available evidence; no
evidence synthesis.
Rapid responses No evidence synthesis, but usually
report conclusions of existing
systematic reviews or guidelines.
Rapid reviews Perform evidence synthesis
(narrative, quantitative, or both)
and possibly strength of evidence.
Automated
approaches
Computer program queries on
databases of extracted study
elements to generate quantitative
meta-analytic synthesis.
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Use of quality checklists and need for
disease-speciﬁc guidance in economic
evaluations: a meta-review
Frederix GW, Severens JL, Ho¨vels AM. Expert Review of
Pharmacoeconomics & Outcomes Research
2015;15(4):675-85.
Background: To ensure high-quality economic evaluations, a
variety of quality checklists have been developed. Three check-
lists are commonly used and are recommended in the Cochrane
Handbook for Systematic Reviews of Interventions for critical ap-
praisal (Drummond, Consensus Health Economic Criteria (CHEC)
and Philips). Checklists have different purposes, focusing on
the reporting or conduct, or both, of modelling or trial-based
evaluations. To ensure valid appraisal of quality, checklists must
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be used for the purpose for which they are designed and used in
a comparable way between quality analyses.
Objective: To outline the heterogeneity in choice and implemen-
tation of quality checklists for economic evaluations.
Design and analysis: Web of Science was searched to identify
economic evaluations of therapies, published in English between
2006 and February 2014, that performed a quality assessment
basedon theDrummond, Phillips or CHECchecklist. Health Tech-
nologyAssessmentreviewsandCochraneReviewswereexcluded.
Informationextracted included: thenumberofmodellingstudies;
modiﬁcations to the checklist; involvementof ahealth economist
and clinician; discussion and agreement between reviewers; to-
tal number of reviewers; results of the quality assessment; any
methodological ﬂaws stated in the conclusion section; an indica-
tion for the need for standardized disease-speciﬁc methods; and
differences between economic evaluations.
Main results: Of the 42 reviews of therapies with economic
evaluations identiﬁed, 18 performed a quality assessment; 16 of
these included modelling-based studies. The Drummond check-
list was used 14 times, Philips ﬁve times, and CHEC twice; eight
used only Drummond and one used only Philips. Eight review
teams made modiﬁcations to the checklist; these changes were
not justiﬁed in two reviews. A health economist was involved in
critically appraising the economic evaluations in 83% of reviews,
and a clinician in 61%. In terms of methodological ﬂaws, vari-
ous authors concluded thatmodel-based studieswere difﬁcult to
comparedue todifferentassumptions instructureandparameter
values. Authors of three (17%) reviews concluded that given the
methodological ﬂaws or other differences, standardized disease-
speciﬁc modelling methods were needed to improve quality.
Only three (17%) author teams made no statement regarding
methodological ﬂaws or differences between included studies.
Conclusions: Heterogeneity in choice and implementation of
quality checklists for economic evaluations results in under- or
over-estimation of quality. More guidance in selecting correct
checklists is important. Current checklists seem to lack detailed
disease-speciﬁc guidance resulting in models not reﬂecting dis-
ease progression correctly. More international collaboration
should be initiated to develop and publish standardized and
open-source disease-speciﬁc reference models.
Commentary
Prepared by Luke Vale
Correspondence to: luke.vale@newcastle.ac.uk
Health Foundation Chair in Health Economics, Newcastle Univer-
sity, UK
Background: Frederix and colleagues report a review of quality
checklists used in the assessment of economic evaluations.1The
three checklists considered are commonly referred to as the
Drummond,2 CHEC3 and Phillips checklists.4 These three check-
lists were the focus because they are advocated by the Cochrane
Handbook for Systematic Reviews of Interventions (the Cochrane
Handbook) as part of the quality assessment of economic evi-
dence included in Cochrane Reviews (see chapter15 in the 2008
edition of the Cochrane Handbook).5
What did the authors say? The central argument of the paper
is that these checklists alone are insufﬁcient to judge the quality
ofmodel-based economic evaluations. Amodel-based economic
evaluation provides an explicit structure describing the disease
and care pathway for a given condition and shows how that dis-
easeandcarepathwaymight change if different interventionsare
used. Frederix and colleagues’ argument is that these checklists
do not help a reader understand if the disease and care processes
modelled are correct. They provide an example from a review of
economic evaluations of breast cancer treatments, where differ-
ences in how the disease and care process was modelled lead to
different conclusions.
Importance of the research for practice: The issue highlighted
byFrederixandcolleaguesunderpins thecurrenteconomicmeth-
ods guidance produced in 2008.5 The principle adopted is that
the goal of a review of economic evidence is not to provide a
singlemore precise estimate of costs, and cost-effectiveness, but
to understandwhy thesemay differ between outcomes. A critical
ﬁrst step for a review team is to deﬁne a clinical event pathway. A
clinical event pathway is a systematic, explicit method of repre-
senting different health and social care processes and outcomes.
It involves describing the main pathways of events that have
distinct resource implications or outcome values associatedwith
them. It serves as a framework to critique costs and beneﬁts
included, and whether the economic evaluation captured the
disease and care process appropriately. For the reviewer, failure
to do this can lead to biased conclusions because the reviewer
may not identify that an economic evaluation has failed to iden-
tify and accuratelymeasure all the costs and beneﬁts that should
be included.
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Key concepts that people need to
understand to assess claims about
treatment effects
Austvoll-Dahlgren A, Oxman AD, Chalmers I, Nsangi A,
Glenton C, Lewin S, et al. Journal of Evidence Based
Medicine 2015;8(3):112-25.
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Background: Many claims about the effects of treatments and
health policies are biased, inaccurate, or unsubstantiated. Sev-
eral resources have been developed to improve people’s ability
to assess such claims, but have not been evaluated consistently.
People need to be able to assess whether the basis for a claim
is reliable and the results relevant to them, and the need for
additional information.
Objective: To develop a list of concepts that may be important
for people to understandwhen assessing claims about treatment
effects.
Design and analysis: A list of concepts was generated from
the literature and tools for the general public, journalists, and
health professionals. Most were identiﬁed from the book, Testing
Treatments.1 The advisory group consisted of 29 researchers,
journalists and people with expertise in health literacy and com-
municating evidence-based health care. Their purpose was to
provide feedback on the concepts identiﬁed and to suggest
potentially relevant resources.
Main results: A draft list of 34 concepts was produced and as-
sessed by the advisory group. They were asked whether: any
included concepts should be omitted; concepts were described
and explained in a way that could be understood by someone
without a research background; important concepts were miss-
ing; concepts were organized in a logical way. Most members
found all the concepts were relevant, few were missing, and the
organizationwas logical. However, most thought people without
a research background would not understand the explanations
of these concepts. Nine additional concepts were suggested,
but all were considered redundant or partially covered already.
After merging some concepts, 32 were categorized into one of six
groups (detailed descriptions/explanations for each provided in
the paper):
• recognizing the need for systematic reviews of fair tests;
• judging whether a comparison of treatments was fair;
• understanding the role of chance;
• considering all relevant fair comparisons;
• understanding the results of fair comparisons;
• judging whether fair comparisons were relevant.
The new list was reassessed by the advisory group, and only
minor wording changes suggested. It was acknowledged that
some concepts would require the development or provision of
resources to help people understand and apply them.
Conclusions: The concept list provides a starting point for devel-
oping and evaluating resources to improve a person’s ability to
assess treatment effects. The concepts are considered to be uni-
versally relevant, and includeconsiderations thatcanhelppeople
assess claims found in mass media reports, advertisements and
personal communication.
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University of Southern Denmark, DK- 5230 Odense M, Denmark
Background:Many healthcare consumers are uninformed about
health issues and their daily confrontation with claims about the
effects of treatmentspresents agreat challenge. Howshould they
manage these claims? How do they know a claim is correct? Not
knowing how to deal with these claims leads tomany healthcare
consumers potentially being misled. This could lead to waste
of resources and potentially compromise consumers’ health and
wellbeing. Health literacy is a mandatory prerequisite to deal
with these claims. But, how do we increase consumer’s health
literacy?
What did the authors say? To answer this question an interna-
tionalgroupdevelopedasyllabusor inventoryof conceptsaiming
to identify what it is important to know when facing claims of
treatment effects. Based upon an iterative process involving a
number of relevant stakeholders, the group developed 32 key
concepts grouped into six different aspects, such as recognizing
the need for a fair comparison of treatments, when a compar-
ison is fair, understanding of the role of chance, different fair
comparisons, understanding the results of fair comparisons, and
whether a fair comparison is relevant or not.
Importanceof the research forpractice: Even though thegroup
madeagreateffort to formulateall theconcepts inplain language
understandable to the general public, the syllabus is merely the
ﬁrst step. The inventory of concepts should be the starting point
to develop and evaluate resources to improve people’s ability
to deal with claims about treatment effect. Prioritization of the
concepts and identiﬁcation of resources that assist their under-
standing is the next step, particularly for those in low-income
countries. For Cochrane this is an important next step in or-
der to make results from health research available to everyone.
Formulation of the Plain language summary using the inventory
concept is a possibility when promoting new Cochrane Reviews.
Thanks to the authors for an important piece of work, which of
course should be translated into as many languages as possible.
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Articles
Ourarticlesectionisanopportunitytopresentworkindevelopment,
raise awareness of work undertaken, report new developments in
Cochrane and opinion pieces. Articles are not formally peer re-
viewed; the editors review content before publication, but the
content does not necessarily reﬂect their views.
PubMed reviewmethods ﬁlter and
methods research support from
PubMed Health
Hilda Bastian
Correspondence to: hilda.bastian@nih.gov
National Center for Biotechnology Information (NCBI), US Na-
tional Library of Medicine, Bethesda MD 20894 USA
PubMed Health aims to increase the accessibility and use of
clinical effectiveness resources at PubMed, and in a dedicated
website.1 In 2015, we expanded PubMed Health to incorporate
methods research related to clinical effectiveness. This enables
methods resources by PubMedHealth partners that are currently
in the grey literature to be included both at PubMed Health and
within PubMed.2
Eligible resources are full texts or English summaries of methods
guidance, methods studies, and systematic reviews of methods
studies. There is not a methodology or subject limitation on
these, as long as the topic is relevant to clinical effectiveness
research. Although most of our partners’ methods work is in
the area of systematic reviewing, some records relate to primary
research, and research publishing and policy issues.
By April 2016, 134 full texts and 32 summaries were included.
Cochrane is a PubMed Health partner, and the Plain language
summaries and Abstracts of all the Cochrane Methodology
Review Group systematic reviews are included. Progressively
we will add further eligible resources from health technology
assessment partners like the UKNational Institute for Health and
Care Excellence (NICE) and the German Institute for Quality and
Efﬁciency in Healthcare (IQWiG). You can sign up for alerts for
newmethods resources at PubMed Health using ‘My NCBI’.2
The PubMed systematic review ﬁlter7 builds on this work, and
is a result of a collaboration between PubMed Health and the
Scientiﬁc Resource Center (SRC). The SRC is funded by the US
Agency for Healthcare Research andQuality (AHRQ) for the Effec-
tive Healthcare Program. The SRC maintains a methods library
covering all forms of publication or citation,3−5 and includes an
article alert service.6The citations are selected by SRC, based on
regular searches of PubMed, journal tables of contents, author
alerts, bibliographies, and international methodology and grey
literature web sites.6
In addition to the PubMed Health resources, the scope for the
PubMed ﬁlter covers only methods research and guidance from
the SRC library. The predominant reasons that citations are not
included in the ﬁlter are because they are solely educational or
opinion pieces, or they are conference abstracts (predominantly
Cochrane Colloquia).
A small number could not be included because they were articles
in journals or grey literature not indexed in PubMed (including
books, book chapters, and dissertations/theses), or because the
citationswere incomplete or inaccurate. Wewill be analyzing this
further and reporting on the sources and process in detail in the
future.
As of April 2016, there are over 12,000 records in the SRCmethods
library,3 and over 9000 of these are retrievable in PubMed. The
scope covers methods guidance, andmethods studies including:
• comparative evaluations of techniques;
• development, evaluation, or validation of a technique;
• analyses of the methods used by studies;
• consensus and Delphi studies and surveys of methods;
• systematic reviews of any of the above.
If you have collections of eligible studies to contribute, please get
in touch. The Cochrane Methodology Register was discontinued
in 2012,8 and its contents should already be included. However,
we will be co-ordinating with Cochrane to ensure that citations
are covered.
To use the ﬁlter, use this search string in PubMed’s search box:
sysrev methods [sb]
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You can combine it with other search terms, for example:
sysrev methods [sb] ANDmeta-analysis
See PubMed Health for further information on ways to use the
ﬁlter.7
We are working on additional ways to support methodological
work related to systematic reviewing, for example with tools
to enable research on the methods studies, and on systematic
reviews in PubMed Health (more than 40,000 latest versions of
systematic reviews published since 2003).
Acknowledgements: This work is supported by the National
Institutes of Health, National Library of Medicine. Diana Jordan
from the PubMed Health team co-ordinates the PubMed ﬁlter
project with me. We are grateful for contributions to the devel-
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References
1. PubMed Health. Bethesda (MD): National Library of
Medicine (US). Available from: www.ncbi.nlm.nih.gov/
pubmedhealth/ (accessed 20 April 2016).
2. PubMed Health. PubMed Health expands to research on
research methods. PubMed Health Blog. Bethesda (MD):
National Library of Medicine (US). Available from: www.ncbi.
nlm.nih.gov/pubmedhealth/blog/2015/06/research-methods/
(accessed 20 April 2016).
3. SRC Methods Library. CiteULike. Available from: www.
citeulike.org/user/SRCMethodsLibrary (accessed 20 April
2016).
4. SRC Methods Library. Zotero. Available from: www.zotero.
org/groups/src methods library (accessed 20 April 2016).
5. Effective Health Care Scientiﬁc Resource Center. Methods
Library Collections. Portland (OR): Scientiﬁc Resource Cen-
ter (SRC); Available from: dev.epc-src.org/methodsLibrary/
collections/index.cfm?C=1 (accessed 20 April 2016).
6. Effective Health Care Scientiﬁc Resource Center. Article
alert. Portland (OR): Scientiﬁc Resource Center (SRC). Avail-
able from: www.epc-src.org/methodsLibrary/artAlert.cfm (ac-
cessed 20 April 2016).
7. PubMed Health. Systematic review methods ﬁlter at
PubMed. Bethesda (MD): National Library of Medicine
(US). Available from: www.ncbi.nlm.nih.gov/pubmedhealth/
researchers/pubmed-systematic-review-methods-ﬁlter/ (ac-
cessed 20 April 2016).
8. Cochrane. About the Cochrane Library: Cochrane Method-
ology Register. London: Cochrane. Available from: www.
cochranelibrary.com/about/about-the-cochrane-library.html
#Cochrane Methodology Register (accessed 20 April 2016).
Overview: Keeping up to date with
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CochraneReviews shouldbe informedbyevidence-basedmeth-
ods. Methodsrelevant totheconductofsystematic reviews(SRs)
cover many topics and subjects reﬂecting the multidisciplinary
nature of SRs. Methods also involve processes used to complete
SRs. Review methods encompass everything from deciding
on the best statistical model for pooling to deciding whether
text mining approaches are as reliable as human beings for
data extraction. Review methods cover not only how reviews
are undertaken, but also how the primary research studies
reviewed were undertaken. Cochrane members need to keep
up to date with detailed knowledge of new methods in their
own disciplines and to keep abreast, more generally, with best
evidence for methods and processes in SRs beyond their own
discipline. Although keeping up to date and assimilating new
methods evidence is personal for every Cochrane member, it is
also an activity Cochrane as an organization should encourage
and, where possible, facilitate. How best to facilitate methods
updates is a continuing debate within Cochrane. This commen-
tary reﬂects brieﬂy on the past and explores some current and
future options.
Until July 2012 the Cochrane Methodology Register (CMR) was
the tool of choice for many members of Cochrane. This central
bibliography of research around systematic review methods
was compiled by the UK Cochrane Centre on behalf of the
Cochrane Methodology Review Group (http://onlinelibrary.
wiley.com/o/cochrane/cochrane clcmr articles fs.html).
Cochrane members beneﬁtted from one group taking on
the hard work of identifying and classifying relevant research
making it available in a searchable database. Since the closure
of CMR for new records there is no single, regularly updated
resource that Cochrane members can access that is focused
solely on SR methods. A bespoke methods database, that
includes full text articles, and is regularly updated, with a
well-organized index by methods topic, searchable and freely
available to members would be ideal for a large organization
with disparate methodological disciplines with many methods
interests. However, it is challenging to deﬁne the remit of such
a database, which would be an expensive resource – carrying
with it licensing and copyright complexities – when building a
database frommany different resources.
If such a single organizational database is not currently feasible,
we could explore other options. Some options are discussed
below:
1. We could produce a collaborative database facilitated by
Cochrane. It is highly likely many Cochrane members have
their own personal databases of methods papers held in
Mendeley, Paperpile, EndNote or in similar software. Also
Cochrane Review Groups’ specialized registers may con-
tain recordsofmethodspapers. Cochranecouldencourage
members and Groups to load records into a central reposi-
tory. However, such a repositorywill need the records to be
deduplicated and indexed (if this is deemed useful), which
in turn requires a relevant thesaurus and management of
any copyright and licensing issues.
2. Other organizations maintain similar databases, so in-
dividual Cochrane members could contribute to those
databases or Cochrane could collaborate to increase or
enhance coverage. For example, the SRC Methods Library
of the Agency for Healthcare Research and Quality (see
page 27) is a searchable library of over 12,000 references on
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reviews and health technology assessment methods and
processes. The challenge is to evaluate the extent of the
coverage of suchdatabases andhow far theymapon to the
requirements and interests of Cochrane members. Such a
project would also require resources.
3. Many Cochranemembers are probably using personal cur-
rent awareness services to keep up to date. These are very
varied and can takemany forms including RSS feeds, email
discussion lists, signing up to receive the contents pages
of journals, reading blogs and subscribing to newsletters
from key organizations. Saved searches can be set up on
large bibliographic databases such as MEDLINE and mem-
bers receive the results of any new publications meeting
the search criteria in an email. These are both passive
and active ways to receive new information on methods
of interest. A recent innovation via PubMed is a PubMed
Systematic Review methods ﬁlter (see page 27). This is a
tool we will likely wish to evaluate to see how far it meets
our individual and general methods needs. There are
also a range of academic websites such as ResearchGate,
Academia.edu and ORCID as well as professional network-
ing services, such as LinkedIn, that offer ways to keep up
to date with methods developments by following authors
and their outputs.
4. The Cochrane Handbooks (for systematic reviews of inter-
ventions and diagnostic test accuracy) are one excellent
form of evidence-based guidance and provide summaries
of current best evidence-based methods to those of us
lacking time to review methods developments. However,
wekeenlyawait theirupdate. CochraneHandbook chapters
would beneﬁt from transparent reporting of their update
process. Other summaries in speciﬁc disciplines may also
be valuable. The SuRe Info evidence-based summaries for
information retrieval in health technology assessment are
intended to save searchers the time needed to keep up to
date onmethods development in various searching issues.
The SuRe Info approach provides a possible template for
other methods topics.
5. Cochraneneeds to funnel its scarce resourcesbypromoting
awareness of methods developments. A useful approach
would be to evaluate current awareness resources for their
currency, overlap and added value, and provide Cochrane
members with guidance about which are most reliable for
their disciplines. This could start with the creation of an
inventory or portal with links to the different resources,
perhapsvia theCochraneMethodswebsite. If the resources
are to be evaluated, it might be helpful to canvas Cochrane
members for information about what they need to know
about a methods resource in order to decide how to use
it. For example, which methods are covered, how the
current awareness is carried out, whether it is selective or
comprehensive, how are updates supplied and how fre-
quently. There are examples of this type of approach, such
as the now retired resource, ‘Intute’ (www.webarchive.
org.uk/wayback/archive/20140614081921/http://www.jisc.
ac.uk/whatwedo/programmes/reppres/irs.aspx), or the
EFSA inventory (www.metaxis.com/EFSAInventory/). Indi-
viduals might then amend or develop their own personal
approaches to keeping up to date. They can also col-
laborate by contributing suggestions for new updating
resources to the inventory or portal to share with others.
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The Cochrane ‘Risk of bias’ tool for randomized trials is widely
used in both Cochrane Reviews and non-Cochrane reviews on
the effects of interventions. First released in 2008,1 and revised
slightly in 2011,2 the tool seeks to determine whether the ﬁnd-
ings of a randomized trial can be believed. The tool is ﬂexible
and is implemented in different ways by different review teams.
The default (and recommended) implementation is to examine
six items: sequence generation (selection bias), allocation con-
cealment (selection bias), blinding of participants and personnel
(performance bias), blinding of outcome assessment (detection
bias), incomplete outcome data (attrition bias) and selective
outcome reporting (reporting bias).2
Although it has become the dominant tool for assessing risk of
bias in randomized trials, we have identiﬁed several ways in
which it can be improved.3,4 Over the last year, we assembled
collaborators from across Cochrane and elsewhere to develop a
newversion of the tool, whichwe refer to as RoB2.0. We expect to
be announcing RoB 2.0 during the Seoul Colloquium in October
2016. Here we outline 10 key changes in RoB 2.0 compared with
the ﬁrst version of the tool.
1. The assessment targets a speciﬁc result
It is widely understood that assessments of risk of bias need to
be outcome-speciﬁc. For example, the importance of masking
(or blinding) outcome assessors may depend on how objectively
the outcome can bemeasured. We take this idea one step further
in RoB 2.0, and make it clear that the assessment is typically
speciﬁc to a particular result. For example, if two analyses are
presented, one following intention-to-treat principles and the
other not, then the risk of bias in the two resultsmay be different.
Of course, some items in the tool relate to all outcomes in the trial
(e.g. those related to randomization methods), some relate to
speciﬁc outcomes (e.g. blinded outcome assessment) and some
relate to the speciﬁc result.
2. Nomenclature
The tool will continue to involve domain-based assessments,
such that different domains of bias are assessed individually. We
have modiﬁed our terminology to explain more clearly which
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methods and procedures are being addressed in each domain.
For example, the ﬁrst domain relates to ‘Bias arising from the
randomization process’. Terms such as ‘selection bias’ and ‘per-
formance bias’ are problematic and will be dropped, because
they are either interpreted differently – or are not known – by
many people outside Cochrane.5
3. A ﬁxed set of bias domains
The revised tool will have a ﬁxed set of domains, which are
intended to cover all issues thatmight lead to a risk of bias. These
domains cannot be removed from the tool, and new domains
cannot be added. We list the domains the Table. They are broadly
the same as in the existing tool, although the existing items
on sequence generation and allocation concealment are now
grouped into a single domain about the randomization process.
As in the current tool, there is no domain for issues around fund-
ing or vested interests. Members of the Cochrane Bias Methods
Group are developing a parallel tool to assess this, to be used in
conjunction with RoB 2.0.
4. Different templates for different types of trial
To retain ﬂexibility to tailor the tool to the type of trial be-
ing assessed, we will provide different templates for different
trial designs. In the ﬁrst instance, there will be templates
for simple parallel-group trials, cluster-randomized trials, and
(two-treatment, two-period) cross-over trials. The template for
assessing a cluster-randomized trial includes additional consid-
eration of the possibility of bias in recruiting participants into
clusters once the interventions assigned to clusters are known.
The template for assessing a cross-over trial includes additional
consideration of issues such as carry-over and period effects.
5. Modiﬁcation to response options for ‘Risk of bias’ judge-
ments
Whereas in the current tool the available response options are
‘high risk’, ‘low risk’ and ‘unclear risk’, in RoB 2.0 the response
options are ‘high risk’, ‘low risk’ and ‘some concerns’. The last
option reﬂects the situation in which the rater has insufﬁcient
conﬁdence to assess the risk of bias to be low, but not enough
information to classify the risk of bias as high.
6. Introduction of ‘signalling questions’
To help reach ‘Risk of bias’ judgements, we are introducing a
series of ‘signalling questions’ within each domain. These ques-
tions are reasonably factual in nature, following the approach
used in other tools including QUADAS-26 and the new ROBINS-I
tool for non-randomized studies of interventions.7 For example,
in the ﬁrst domain about the randomization process, the opening
two questions are ‘Was the allocation sequence random?’ and
‘Was the allocation sequence concealed?’.
7. Algorithms to reach ‘Risk of bias’ judgements
Wehavedevelopedalgorithms tomap responses to the signalling
questions to judgements about risk of bias. When implemented
in software, these should facilitate the process of reaching ‘Risk
of bias’ judgements. It will be possible to over-ride the default
mappings for situations inwhich special issuesor concernsapply.
8. An overall judgement about risk of bias
Thecurrent tool doesnothavea formalprocedure for reachingan
overall judgement about risk of bias in the result. We have intro-
duced one into RoB 2.0, by implementing a rule that the overall
risk of bias for the result is the ‘worst’ risk of bias recorded across
all domains in the tool. Thus, if any domain is assessed to be at
high risk of bias, then so is the result overall. If all domains are ei-
ther assessed tobeat low riskof biasorhave someconcerns, then
theoverall result for the studyhas someconcerns. It is possible to
over-ride the rule if there are some concerns inmultiple domains,
which may lead to a judgement of high risk of bias overall.
9. Differentiation between the effect of assignment to inter-
ventionandtheeffectof startingandadhering to intervention
Perhaps the most challenging change in the new tool is that we
draw an important distinction between two intervention effects
thatmightbeof interest to the reviewauthor. Theﬁrst is theeffect
of participants being assigned to the interventions: this is the
effect that is estimated in an intention-to-treat analysis of a trial.
It is not essential that individuals are blinded or that participants
adhere to the assigned intervention for the result to be unbiased.
The second is the effect of participants starting and adhering to
the intervention. For this effect, it is essential to examine issues
suchas adherence, unintended co-interventions andwhether the
intervention was implemented successfully. We offer two differ-
ent templates for the ‘Risk of bias’ assessment, forcing the rater
to decide the effect to which ‘Risk of bias’ assessments relate.
10. Reconsideration of selective (non-)reporting
The current tool encourages a study-level judgement about
whether there has been selective reporting, in general, of the
trial results. The new tool focuses solely on the speciﬁc result
being assessed for risk of bias. If there is no result (e.g. if it
has selectively been omitted from the report) then there is no
‘Risk of bias’ assessment. Selective non-reporting is therefore
not covered by the tool, and should be assessed at the level of
the synthesis across studies. Instead, RoB 2.0 examines whether
the speciﬁc result from the trial is likely to have been selected
from multiple possible results on the basis of the ﬁndings. This
will be either because several alternative outcomemeasures are
available, orbecause several statistical analyseswereperformed.
The current tool The revision: RoB 2.0
Random sequence
generation (selection bias)
Bias arising from the
randomization process
Allocation concealment
(selection bias)
Blinding of participants and
personnel (performance
bias)
Bias due to deviations from
intended interventions
Incomplete outcome data
(attrition bias)
Bias due to missing outcome
data
Blinding of outcome
assessment (detection bias)
Bias in measurement of the
outcome
Selective reporting
(reporting bias)
Bias in selection of the
reported result
Other bias (No formal strategy for
assessing overall risk of bias)
(No formal strategy for
assessing overall risk of
bias)
Overall bias
Closing remarks
We believe the new tool will offer considerable advantages over
the existing tool. Extensive piloting has taken place already,
including a three-day event held in Bristol in February 2016 and a
subsequent round of remote piloting by individuals with varying
degrees of relevant experience. The piloting has informed de-
velopment of the tool as well as of the lengthy written guidance
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that accompanies it. Once programmed into software, we ex-
pect the tool will be easier to use than the ﬁrst version. Some
issues remain to be resolved, however, such as howmany results
should be assessed for each study, and how best to integrate the
assessment into the data extraction process. We look forward to
discussions at the 2016 Seoul Colloquiumand beyond about how
the toolmight be adopted and implemented by CochraneReview
Groups and author teams.
For further details of RoB 2.0, see www.riskofbias.info
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Cochrane systematic reviews aim to identify all available evi-
dence to answer speciﬁc questions. Hence, Cochrane requires
authors to perform a very extensive search relying on electronic
bibliographic databases, trial registries and relevant ‘grey’ liter-
ature sources. Trial registries are particularly useful to identify
unpublished studies,1complete the information available in a
published article when results are posted,2 and obtain results
for unpublished observational studies.3Searching clinical trial
registries is also crucial to detect the selective reporting of out-
comes. For example, the COMPare project (compare-trials.org)
led by Ben Goldacre, systematically checked every trial pub-
lished in the top ﬁvemedical journals and showed that of the 67
trials evaluated, only nine were perfect; 354 outcomes were not
reported and 357 new outcomes were silently added.
However, despite these extensive searches and the availability
of results of unpublished studies through trial registries, sys-
tematic reviewers have access to only a very limited amount of
existing evidence. In fact, only 61% of drug trials, 30% of non-
drug trials and 10% of observational studies are registered.4−6
Furthermore, only 13.4% of trials post their summary results
within 12 months after trial completion.7 We also lack infor-
mation about the methodological ﬂaws of the trials included
in a systematic review. For example, examination of all the
trials included in a meta-analysis of a primary outcome in the
Cochrane Reviews published in one year showed that 41% had
at least one risk of bias domain rated as being at unclear risk of
bias. Finally, Jefferson and colleagues demonstrated that the
‘devil is in the detail’, as only when examining all the informa-
tion available in the clinical study report and other regulatory
documents closely can systematic reviewers really understand
what happened during a trial and evaluate the possible ﬂaws.8
This appalling situation1,9−13 has convinced several stakehold-
ers to engage actively in an era of open science through data
sharing. The US Institute of Medicine issued a consensus report
that recommends ways to promote responsible data sharing,
including when and how to share data to maximize beneﬁts
and minimize risks.14,15 The European Medicine Agency is also
engaged in this debate16and on 14 April 2015, the World Health
Organization published a new statement on the public disclo-
sure of clinical trial results.17 The International Committee of
Medical Journal Editors recently proposed requirements to help
meet the obligations for data sharing.18
The pharmaceutical companies are part of this movement.
Some pharmaceutical companies have committed to share pa-
tient data for the studies they sponsor. A website, Clinical Study
Data Request (CSDR) (www.clinicalstudydatarequest.com),
favours centralized communication between sponsors and re-
searchers. Sponsors and funders are invited to list the studies
for which they agree to share individual patient data on the
website and to deﬁne the conditions for sharing these data.
Researchers can use this site to request access to anonymized
patient-level dataand supportingdocuments fromclinical stud-
ies to conduct further research. Their research proposals for
access are reviewed by an Independent Review Panel. The Yale
University Open Data Access (YODA) Project is also committed
to open science and data transparency and supports research
that attempts to produce concrete beneﬁts to patients, the
medical community and society as a whole. For instance, this
project has allowed for the release of two systematic reviews on
recombinant human bone morphogenetic protein-2 (rhBMP-2),
based on patient-level data from all clinical trials conducted by
Medtronic.19−21
Other initiatives aim to organize the system to help re-
searchers access all information related to a given clinical
trial. The threadedpublications initiativewas recently launched
Copyright c 2016 The Cochrane Collaboration. Chandler J, McKenzie J, Boutron I, Welch V, editors. Cochrane Methods.
Published by John Wiley & Sons, Ltd. 31 Cochrane Database of Systematic Reviews 2016,
Issue 10 (Suppl 1). dx.doi.org/10.1002/14651858.CD201601
with Crossref (blog.crossref.org/2016/05/linked-clinical-trials-
are-here ).
The project allows for linking all articles and data related to
an individual clinical trial by the trial’s registration number.
Currently, BioMed Central, PLOS and the National Institute for
Health Research are uploading data to the system, although
other publishers (including Elsevier and Wiley) will join soon.
The OpenTrials project (opentrials.net), funded by the Laura
and John Arnold foundation, is currently working to develop
a collaborative and open database for all available structured
data and documents on all clinical trials. It is designed to
host and match the registry entries; links, abstracts, or texts
of academic journal papers; portions of regulatory documents
describing individual trials; structured data on methods and
results extracted by systematic reviewers or other researchers;
clinical study reports as well as additional documents, such
as blank consent forms, blank case report forms, and proto-
cols. Such initiatives are crucial to move towards open clinical
research.
The open science revolution is an incredible advance, but also
a huge challenge for Cochrane. Strategies and methods need
to be developed to be able to manage the huge amount of
data from clinical trials. A Cochrane Methods Innovation Fund
project led by Tom Jefferson is working on guidance related
to the inclusion of clinical study reports and other regulatory
documents in Cochrane Reviews. However, the wider research
agenda remains to be clearly deﬁned.
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IntroductionandObjective: With changingdiseasepatternsand
an increasing awareness that we need to go beyond questions
of ‘what works’, the need for appropriate evaluation of complex
health interventionshasgrown. Toavoidmisleadingconclusions,
systematic reviews and health technology assessments (HTAs)
should take thecomplexityof an intervention, its implementation
in a given context, and its varying effects on different individuals
into account. New tools that bridge currentmethodological gaps
are essential to support health decision-makers.
Following major advances in the development of currently ap-
plied HTA methods, there remain limitations when assessing
complex interventions which:
1. are context-dependent, as current HTA focuses on the in-
tervention, not on the (socio-cultural, healthcare) system
within which it is used;
2. perform differently depending on the way they are im-
plemented;
3. may have different effects on different patients or popu-
lation groups;
4. furthermore, HTAusually assesses and appraises aspects
side-by-side while decision-making needs an integrated
perspective on the value of a given intervention.
The European Union (EU) funded project ‘Integrated health tech-
nology assessment for the evaluation of complex technologies’
(INTEGRATE-HTA) aimed to develop guidance on concepts and
methods that allow for patient-centred, comprehensive, and
integrated health technology assessments of complex technolo-
gies. While the focus of the project was on HTA, many of the
methods developed, and insights gained, are also directly rele-
vant to Cochrane and non-Cochrane Reviews and bring together
evidence from different types of systematic reviews for health
decision-making.
Background: Following thedeﬁnitionof theUKMedicalResearch
Council (MRC), complex interventions are characterized by the
number of interacting components within the experimental and
control interventions; the number and difﬁculty of behaviours
required by those delivering or receiving the intervention; the
number of groups or organizational levels targeted by the inter-
vention; the number and variability of outcomes; and the degree
of ﬂexibility or tailoring of the intervention permitted.1 For ex-
ample, when assessing an educational programme to prevent
the transmission of the human immunodeﬁciency virus (HIV) the
success or failure might depend on the message itself (e.g. ab-
stention or condoms, or both), the messenger (a young celebrity
or a respected religious leader), the target group (sexually active
adolescentsorelderly religiouspeople), themediumtransmitting
themessage (internet spotsor lectures), and theperceivedpreva-
lence of the disease (omnipresent threat or unlikely event). To
focus only on the content of the programmewithout considering
the other variables and interactions between themmay result in
misleading conclusions.
Methods: Different approaches were used to develop method-
ological guidance to tackle different aspects of conducting an
integrated assessment of complex health interventions. These
included building on existing concepts and methods for single
assessment aspects, that is effectiveness, ethical, socio-cultural,
economic, and legal issues. Logic models were used to concep-
tualize the intervention within its context. Logic models are a
graphic description of a system designed to identify important
elements and relationships within that system, and a means of
conceptualizing and handling complexity. Feedback from stake-
holder advisory panels in seven different European countries
ensuredpublic andpatient involvement. Thedevelopedmethod-
ological approaches were applied in a demonstration-HTA on
home-based palliative care. The applicability and relevance of
the draft guidance were reviewed by an external panel of 31 ex-
perts, representing 14 nationalities and a variety of professional
backgrounds.
Results: The main outcome of the project is a new HTA-process
that consists of ﬁve steps.
1. Deﬁnition of the intervention under assessment and the
objective of the HTA with the involvement of stakehold-
ers.
2. Development of an initial logic model that structures
participants, interventions, comparators, context, im-
plementation issues and outcomes.
3. Assessment of the evidence for the different aspects –
based on the logic model – taking variability of partici-
pants, context, implementation issues and interactions
between these into account.
4. The assessment results of step 3 are structured and
visualized by the ﬁnal logic model.
5. A structured decision-making process (not an integral
part of the HTA in a narrow sense).
The concepts andmethods underlying this process are described
in detail in six publications, comprising information on method
development and testing, as well as providing the following
step-by-step guidance on how to apply the method.
1. Guidance for assessing effectiveness, economic aspects,
ethical aspects, socio-cultural aspects and legal aspects
in complex technologies.2
2. Guidance for the assessment of treatment moderation
and patients’ preferences.3
3. Guidance for the Assessment of Context and Implemen-
tation in Health Technology Assessments (HTA) and Sys-
tematic Reviews of Complex Interventions.4
4. Guidance on the use of logicmodels in health technology
assessments of complex interventions.5
5. Guidance on choosing qualitative evidence synthesis
methods for use in health technology assessments of
complex interventions.6
6. Guidanceontheintegratedassessmentofcomplexhealth
technologies - The INTEGRATE-HTA Model.7
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All guidance publications are accessible through the project’s
website: www.integrate-hta.eu/downloads.
Conclusions: Current HTA is not adequately equipped to assess
complex interventions in a way that is meaningful for decision-
making. To achieve assessments that are patient-centred, com-
prehensive, and integrated we suggest that we:
1. make stakeholders part of the assessment – a deﬁned
perspective that brings together different viewpoints is
necessary for an integrated assessment;
2. identify and model relationships between the interven-
tion, patient characteristics, implementation issues, and
context;
3. offer an integrated assessment to decision-makers -
integration needs to start from the beginning.
Recommendations:
1. This integrated approach resonates with ongoing de-
velopments within Cochrane, such as the increasing
recognition thatweneed to take into account broader in-
ﬂuences on intervention effectiveness, whether through
crafting logic models, careful data extraction, and sub-
group analysis or through separately conducted qualita-
tive systematic reviews.
2. Similarly, involvingdistinct typesofstakeholders through
AdvisoryGroups – aswedid in our case study7 - is increas-
ingly becoming common practice in Cochrane Reviews.
3. Cochrane methodologists and authors trying to tackle
complex interventions may wish to take a closer
look at the published methodological guidance, in
particular those concerned with alternative ways of
synthesing effectiveness2 and qualitative evidence6, as-
sessing context and implementation3 and developing
logic models.5
4. The framework presented in the guidance on socio-
cultural aspects could be used to develop search strate-
gies and to consider cultural heterogeneity.2
5. Furthermore, search ﬁlters on patient preferences and
treatment moderators are suggested.3
6. Theethicsguidance2maybehelpful ifquestionsofethical
complexity are a main focus of the review.
7. Many of the INTEGRATE-HTA guidances and the step-by
step guidance would beneﬁt from reﬁnement by apply-
ing them to different types of reviews with more or less
complex health interventions.
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Introduction: Systematic reviews are a time-consuming, logis-
tically challenging and labour-intensive undertaking. These
and other challenges have led to the development of
various software tools to support the systematic review
process.
Background: A number of studies have identiﬁed and investi-
gated tools to support systematic reviews. Within healthcare, a
survey of information systems to support or automate system-
atic review tasks found a wide range of tools.1 Tools discussed
by Tsafnat and colleagues1 include Review Manager (RevMan),
federated search engines such as Quick Clinical, citation man-
agers (such as EndNote and ProCite), the Abstrackr system
to support screening of abstracts and meta-analysis tools. A
more focused cross-domain mapping study of visual data min-
ing (VDM) techniques found a number of VDM tools to support
data extraction and data synthesis2. A review of text mining
applications in systematic reviews also foundexamples ofmany
tools in use at all stages of the review process.3 In software
engineering, a broader mapping study of systematic review
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software tools was performed that identiﬁed a predominance
of visualization and text mining tools used to support study
selection, data extraction and data synthesis.4 Whilst overviews
like these are useful; in practice, it remains challenging for re-
viewers to discoverwhat tools are currently available to support
their projects. In response, we have developed an online re-
source to help researchers ﬁnd tools to support their systematic
reviews.
Systematic Review Toolbox: The Systematic Review Toolboxi
is a community-driven, searchable, web-based catalogue of
tools to support the systematic review process across multiple
domains. The resource aims to help reviewers ﬁnd appropriate
tools based on the support the tools provide for the systematic
review process. Users can perform a simple keyword search
(i.e. Quick Search) to locate tools, as well as a more detailed
search (i.e. Advanced Search), that allows users to select var-
ious criteria to ﬁnd speciﬁc types of tools and submit new
tools to the database. The resource was developed using the
programming languages PHP, SQL and JavaScript, and uses
Twitterii to manage its community.
As of April 2016, the Systematic Review Toolbox stores informa-
tion on over 100 software tools to support systematic reviews.
These include freely-available tools based on data visualiza-
tion, text mining and machine learning approaches (as well
as many others), developed to support various aspects and
stages of the systematic review process. Examples of such tools
include:
• Systematic ReviewAssistantiii (a prototype textmining tool
to support risk of bias assessments);
• WebPlotDigitizeriv (a web-based tool to automate risk of
bias assessments of randomized controlled trials); and
• RobotReviewerv (a machine learning tool to automate risk
of bias assessments).
As well as free tools, the toolbox catalogues a number of
more substantial commercial and not-for-proﬁt applications;
for example, EPPI-Reviewervi, DistillerSRvii and Covidence.viii
Although the focus of Systematic Review Toolbox is on
identifying software to support systematic reviews, the re-
source also includes links to various ‘paper-based’ tools
such as critical appraisal checklists, guidelines and reporting
standards.
Summary: There are various tools available to support sys-
tematic reviews. However, with the exception of general
purposesystems (e.g. referencemanagers,wordprocessorsand
spreadsheet packages), special-purpose software tools de-
signed to support speciﬁc aspects of the systematic review
process are not yet widely in use. To date, little is known about
the usefulness of such tools in practice, and frequently only
speculation concerning their potential is reported. To help sup-
port thematuration of tools, we encourage reviewers to employ
more special-purpose tools to support their reviews and report
back on their experiences to the systematic review and tool
development communities. York Health Economics Consor-
tium (in association with the Systematic Review Toolbox) have
organized a workshop providing an opportunity for reviewers
to learn more about software tools currently available, and to
share experiences of using tools in practice. To ﬁnd out more
information about the workshop please contact Christopher
Marshall.
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Background: Since the Cochrane Editorial Unit (CEU) screening
began, we have seen an increase in the number of reviews
using GRADE and presenting ‘Summary of ﬁndings’ (SoF) tables.1
However, we continue to see variation in the implementation
of GRADE and its integration in interpreting evidence. This may
in part be attributable to variability in the way that GRADE is
planned in review protocols.
Methods for using GRADE and preparing SoF tables should be
considered early on during the planning of review methods in
the protocol. The development of the review protocol repre-
sents an opportunity to elaborate on how GRADE will be used to
summarize and interpret the review ﬁndings.
The aim of this audit was to evaluate how GRADE and SoF tables
are included in protocols of Cochrane Reviews.
Methods: We used two cohorts of protocols published in the
Cochrane Library in August 2013 and August 2015. We devised a
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checklist comprising eight items that we considered relevant for
planningGRADEandSoF tables inprotocolsofCochraneReviews.
A full description of the methods can be found in the full audit
report, including the checklist in appendix 1.2
Results: We included 73 protocols from 28 Cochrane Review
groups in the audit. The characteristics of the two cohorts are
summarized below.
An overview of the audit ﬁndings extracted from the audit
report2 are presented in Figure 1, based on the checklist for
Characteristic 2013 2015 Total
Protocols (N) 40 33 73
N Cochrane Review Groups 25 21 28
N Protocols per group
(median, range)
1 (1 to 5) 2 (1 to 5) 2 (1 to 10)
N GRADE cited (%) 14 (35%) 30 (91%) 44 (60%)
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Figure 1. Summary of audit ﬁndings
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auditing GRADE and SoF tables in protocols in intervention
reviews.
Firstly, we observed an overall improvement with over 50%more
protocols referencing GRADE. We observed improvements be-
tween the 2013 and 2015 cohorts in the following aspects of
GRADE and SoF tables: reference to GRADEmethods, description
of GRADE quality criteria, deﬁnition ofmethods for preparing SoF
tables, and description of outcomes to be included in SoF tables.
GRADE and SoF tables were also considered under appropriate
sections in most protocols published in 2015.
However, GRADE levels of evidence, comparisons to be covered
in SoF tables and speciﬁcation of reviewers to be involved in
GRADE assessments were not well addressed in either cohort. A
full descriptionof the results canbe found in the full audit report.2
Discussion: This audit found an improvement in the planning of
key aspects of GRADE and SoF tables in protocols of Cochrane
Reviews. We believe there are also areas where greater prespec-
iﬁcation would help to optimize implementation of GRADE and
development of SoF tables.
Specifying comparisons and outcomes
Selection of outcomes for SoF tables at the protocol stage is now
more common. Prespecifying outcomes (including methods of
measurement and time-points of reporting) helps avoid bias in
the choice of outcomes,3,4 and serves as a reminder to review
teams to include results for the most relevant outcomes in SoF
tables irrespective of the amount and quality of evidence. How-
ever, somemodiﬁcations may be justiﬁed; for example, as noted
in oneprotocol ‘‘the importanceof anoutcomemayonly become
known after the protocol was written and analysis carried out’’.
This may be the case for adverse events. In these situations, au-
thors should explain and document any change in the speciﬁed
outcomes appropriately.
Thirty-six protocols included in this audit planned multiple com-
parisons, but only seven of them mentioned the comparisons to
be covered in the SoF tables. Thus, it appears most reviewers are
less aware of the relationship between comparisons addressed
in the review and SoF tables. Selective reporting of comparisons
may introduce bias, for example, if reviewers only present com-
parisons that show treatments to be effective or less harmful,
or for comparisons where there is the greatest amount of data
available. For broad review questions the full extent of rele-
vant comparisons may only become apparent after studies are
identiﬁed, and may vary depending on the analysis undertaken.
Prioritizing comparisons at the protocol stage will help focus the
review to address questions that users are likely to value most.
Specifying GRADE considerations and number of raters
We found improvements in thenumber of protocols reporting the
ﬁve considerations that can lead to downgrading the quality of
evidence (risk of bias, inconsistency, indirectness, imprecision,
publication bias). However, most protocols did not specify the
number of raters involved in the assessment of these factors; only
four protocols mentioned involvement of at least two reviewers.
Duplicate or consensual processes for ratingGRADEmerit greater
attention. Studies assessing the consistency of GRADE ratings
support the need for more than one rater.5,6With this in mind,
considerationshouldbegiven to theuseofchecklists6 inconduct-
ing GRADE assessments, as was planned in two of the included
protocols. These checklists should help improve transparency
and consistency of GRADE assessments. In particular, they may
help those with limited experience of using GRADE.7
Audit limitation
This audit has a number of limitations. We focused on stated
intentions andwe are unable to draw conclusions aboutwhether
the protocols led to better implementation of GRADE. This aspect
warrants further investigation with a separate audit. We also
identiﬁed protocols from just over half of the registered CRGs.
Thismight limit the applicability of these ﬁndings to all Cochrane
Review Groups.
Conclusion: The audit ﬁndings indicate that GRADE has become
amore routine part of protocol development. We believe that the
focus of effort should now include prioritization of comparisons
and adoption of replicablemethods in rating quality of evidence.
We would like to encourage early piloting and independent eval-
uation of GRADE and SoF tables once the analysis of data has
been undertaken but before the review is written up. This will
help better incorporation of GRADE and SoF tables into the full
review.
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I propose that we should not allow the dominant systematic re-
view (SR) paradigm to over-shadowother areas of research that
seek to conduct systematic reviews, and that complex social
interventions could inform the Cochrane approach to reviews.
Firstly, it isworth evaluatingwhether our current thinking about
‘being systematic’ aligns appropriately with the etymological
meaning of the concept. Dictionary deﬁnitions of ‘systematic’
include:
• Done or acting according to a ﬁxed plan or system; methodi-
cal. (Oxford Dictionary)
• Having, showing or involving a system, a method or a plan,
or as an expression of a certain degree of order achieved.
(Dictionary.com)
Deﬁnitions of ‘systematic’ from literature relating to system-
atic reviews include; conducting comprehensive or exhaus-
tive searches for studies;1 assuring the soundness of methods
in order to produce justiﬁable conclusions;2 and achieving
transparency of procedures to facilitate replication.3 Cochrane
deﬁnes ‘being systematic’ as a methodical approach that
uses explicitly predeﬁned, reproducible methods provided in
a protocol.4 Predeﬁningmethods in a review protocol is advan-
tageous because it assists reviewers to conceptualize complex
review procedures. It also protects against biased judgements
caused by determiningmethods in the light of review ﬁndings.5
Although, justiﬁed and reported modiﬁcations to protocols are
possible. Nevertheless, there are ‘exceptional’ review areas
where rigid adherence to predeﬁned methods is too restrictive,
speciﬁcally in:
• emerging review areas;
• areas where concepts are ill deﬁned; and
• methodologically innovative primary research areas.
For example, author teams reviewing evidence on illegal psy-
choactive substancesmayhave tochange their inclusioncriteria
while theyarestillworkingonthereview, asnewlife-threatening
drugs constantly enter the leisure circuit. This requires a high
degree of ﬂexibility by the team to adapt to fast changing
circumstances. Researchers are currently exploring progres-
sive forms of presenting scientiﬁc knowledge, including virtual
exhibitions, graphical summaries, photo novellas, ethno dra-
mas – sometimes in addition to research reports, and at other
times replacing them. More recently, primary researchers have
disseminated their ﬁndings in novel formats that challenge tra-
ditional approaches. In our current review tradition, we simply
tend to ignore these forms of relevant evidence. However, such
trends invite us to reimagine the nature of information sources
we currently consider for inclusion in our systematic reviews,
particularly in some of the qualitative evidence syntheses we
produce. It also requires us to experiment analytically and think
beyond our established toolbox of quantitative and qualitative
synthesis techniques, and review procedures.
These ‘exceptional’ review areas offer us the choice either to
avoid synthesizing evidence or to accept a certain amount of
methodological experimentation and uncertainty that might
allow us to do something useful. The question is: ‘Where dowe
want to go?’
We recently engaged in a review project exploring the im-
pact of the use of arts-based methods on empowerment pro-
cesses of vulnerable populations in community-based research
practices.6 Arts based methods can be deﬁned as ‘‘a research
method in which the arts play a primary role in any or all of the
steps of the research method. Art forms are essential to the
research process itself and central in formulating the research
question, generating data, analysing data, and presenting the
research results’’.7 During the review process it became appar-
ent thatweneededtoreassessour inclusioncriteriaoncewehad
screened and synthesized part of the review content. We recate-
gorized community-based research from geographical notions
of community to those centralized around a common cause.6
We also changed our view on what we considered practical
applications of arts-based methods by constantly negotiating
the meaning of community-based artistic projects as a partic-
ipatory research practice, and arts-based methods applied to
community-based research settings as a type of intervention.
The content of these categories shifted several times, resulting
in an iterative process of rescreening abstracts against newly
adapted deﬁnitions for inclusion criteria. This iterative process
of renegotiating the meaning of both the setting and the inter-
vention under assessment was helpful in developing a relevant
end-product. However, it meant cutting ourselves loose from
the protocol outlining our initial methodological choices that
were based on a preliminary scoping review of the literature
and the consultation of an expert.
In this particular review case, we chose to ‘experiment’ and
opt for a different review logic; iteration. Our review process
allowed this iterative inquiry, enabling multiple opportunities
for the team to revisit methodological choices following up new
leads. Furthermore, we reﬂected critically on the implications
of these choices in relation to the nature of the evidence base
available. An iterative approach to reviewing suggests:
• ‘systematic’ creates order whilst not ﬁxed;
• acceptance, for example, that in certain review projects
purposefully sampling papers featuring new and impor-
tant insights that challenge previous results may be more
beneﬁcial than exhaustive searches;8,9,10
• acceptance of substantial deviations from initial protocols
that would be reported and justiﬁed.
In other cases, people have argued that for study areas in
full development we should choose to ‘avoid’ conducting re-
views until there is consensus about core concepts and a sub-
stantial amount of evidence has been produced.11 This would
decrease the risk of drawing wrong, incomplete or skewed con-
clusions. Peter Humaidan and colleagues from the Copenhagen
Gonadotrophin-releasing Hormone Agonist (GnRHa) Triggering
Workshop Group (2011),11 raised this argument to critique the
results from several meta-analyses, including a Cochrane Re-
view that compared GnRHa versus HCG for oocyte triggering in
antagonist assisted reproductive technology (ART) cycles.12 The
lead author of the Cochrane Review concluded that there were
no clear indications for further research with GnRH agonists
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for oocyte triggering in ART in fresh autologous cycles, but, ac-
cording to Humaidan, neglected the fact that GnRHa triggering
induced a luteal phase insufﬁciency, which could not be solved
by the standard luteal phase support used in in-vitro fertiliza-
tion (IVF). In later clinical studies different means of correcting
for this insufﬁcient luteal phase were used. Ultimately, newly
developed large randomized clinical trials suggested a differ-
ent, more promising outcome of GnRH agonists. It raises the
question whether the authors (Youssef and colleagues) should
have refrained from conducting the review.
It does not seem sensible to avoid synthesizing evidence be-
cause we do not know exactly how to deal with the evidence
generated. For example, ‘not knowing’ exactly how to combine
written forms of evidence with other forms of evidence – an
issue we came across while working on the review evaluating
the impact of arts-based researchmethods13 – or, ‘not knowing’
exactly how to pool multiple layers of numerical data statisti-
cally. The ‘not knowing’ is by deﬁnition future oriented.14 We
cannot always foresee types of content or methods needed,
allowing us to progress. The systematic review process should
not necessarily predetermine an approach but allow for an
iterative development process as the ﬁeld of study develops.
Youssefandcolleagues’ ‘meta-analytical impatience’addressed
by Humaidan illustrates that, in the absence of sufﬁcient evi-
dence, we should develop our conclusions with care and avoid
‘closure’. We also learnt that in response to the conclusions
formulated, the problem of luteal phase insufﬁciency received
more attention leading to new insights.
Our ‘disciplined’ methodological behaviour of ‘being system-
atic’ has given us conﬁdence in the robustness of how reviews
are produced. However, when procedures are rigidly applied,
they may hinder us in developing and accepting analytic alter-
natives for ‘exceptional’ review areas. It is timely that we focus
on ‘living’ systematic reviews, which is the theme of this year’s
Methods Symposium at the 2016 Seoul Cochrane Colloquium.
‘Living’ systematic reviews allow review authors to update as
newresearchbecomesavailable. I suggest this is anopportunity
for exploration of new sources of information and renegotiation
ofmethodological options based on new evidence. This creates
a different set of possibilities for analysis15 for fast changing,
underdeveloped or challenging review areas. This provides an
opportunity to rethink the concept of ‘being systematic’. Itera-
tive principles have proven themselves very useful, for example,
in the big data movement where we can no longer trace the
exact origin of the data we use nor the purpose with which
these data were collected. The choice to work iteratively or use
a cyclical approach to studying evidence does not necessarily
mean that there is no plan. Simply the plan is a ‘living’ entity
rather than a ‘ﬁxed’, linear one.
We need to pull evidence intelligently from the relevant infor-
mation sources available to us when trying to meet new areas
of research. Notable developments within Cochrane include
data-mining techniques to reduce the impractical screening
workload in reviews16 and the development of new synthesis
approaches for study designs other than randomized controlled
trials.17,18
We need review authors that are willing to act upon the
challenges of working in these ‘exceptional’ review areas or
‘exceptional’ reviewcircumstancesandweneedreviewgroups
to trust them in their endeavours to develop solutions.
In all our innovative efforts, we still share the same goal, that
is, trying to create order while at the same time trying to live
up to the standard of delivering high-quality evidence. Finding
the right balance between quality and iteration is a challenge.
However, when the review community engages in reﬂexive be-
haviour and continues to share experiences, the learning curve
this creates will be beneﬁcial to all of us.
KarinHannes teaches, develops and tests primary andmeta-level
qualitative research methods. In her role as a ‘Cochranite’ she
seeks to produce qualitative evidence syntheses. Her scholarly
alter-ego resides in a social science department and seeks to
critique and progress existingmethodological toolboxes, with the
aim of enhancing their ability to study ‘wicked’ and challenging
research and review areas.
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Combining network meta-analysis with patient references to facilitate shared
decision making
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Background: Even in caseswhen comparative evidence ondrugs
exists, prescribers and patients often struggle to weigh the rela-
tive beneﬁts and harms of multiple options. One complexity of
drug therapy is the difﬁculty in making trade-offs between the
beneﬁts and harms of two or more alternatives.
Objectives: To formalize the incorporationofpatientpreferences
into treatment selection decisions, using statins as a case study.
Methods:Wecombinednetworkmeta-analysisandmulti-criteria
decision analysis. Speciﬁcally, using a systematic review of statin
trials, we calculated absolute risks of all-cause mortality, coro-
nary events, cerebrovascular events, discontinuations due to
adverse events, myalgia, transaminase elevations and creatine
kinase elevations associated with each statin. We then applied
a structured beneﬁt-risk model that allows evidence on multiple
outcomes to be combined using qualitative preference state-
ments. When combining the evidence on multiple outcomes,
we adopted simple preference statements about the relative
importance of different outcomes and considered the effect of
statins on preventingmortality to bemore important than either
coronary or cerebrovascular events, which were in turn more
important than any one of the harm outcomes.
Results: Fluvastatin has a considerable probability of both being
the best (41%) and worst (12%) statin (based on the combina-
tion of beneﬁts and harms), highlighting the uncertainty in its
evidence base. Both simvastatin and atorvastatin have a high
probability of better ranks, with a negligible probability of rank-
ingworst; simvastatin and atorvastatin have themost favourable
beneﬁt and harm proﬁles.
Conclusions: In the future, summaries of clinical evidence ob-
tainedfromnetworkmeta-analysescanbecombinedwithpatient
preferences, and considered alongside the knowledge and clin-
ical expertise of prescribers when making treatment selection
decisions.
Are predictions from test accuracy meta-analyses valid in clinical practice?
Brian HWillis, Richard D Riley
Correspondence to: b.h.willis@bham.ac.uk
Primary Care Clinical Sciences, University of Birmingham, Birmingham, UK
Background: Although meta-analysis may synthesize estimates
for a test’s accuracy, heterogeneity often blights these and it is
not always clear whether clinicians should trust these estimates
when applying them to their own practice.
Objectives: To determine whether the summary estimates of a
test’s positive and negative predictive values (PPV and NPV) are
likely to be valid in practice using a novel statistic.
Methods: Using a simple (‘leave-one-out’) cross-validation tech-
nique, wederive the distribution for a newvalidation statistic, Vn,
which measures whether the meta-analysis model’s summary
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estimate is likely to be statistically valid for new independent
studies. We apply Vn to a univariate random-effects meta-
analysis model and to a tailored meta-regression model, where
information from the setting (included as model covariates) is
used to calibrate the summary estimates of the PPV and NPV to
the clinical setting. A signiﬁcant Vn (P value< 0.05) suggests the
estimate would not be valid in a new population. Using a simu-
lation study, the type 1 error rate and power of Vn are examined
for different values of the within-study variance, between-study
variance, study sample size and number of studies included in
the meta-analysis.
Results: For 12different case examples thePPV, NPVand Vnwere
estimated. Whenusing the standardmeta-analysismodel,Vnwas
signiﬁcant (P < 0.05) for nine out of 12 PPV estimates and for
10 out of 12 NPV estimates, indicating that these estimates
were unlikely to be statistically valid in practice. In contrast,
tailored meta-regression was more likely to yield statistically
valid estimates (Table 1). The simulation studies demonstrated
that Vn performs better when the individual study sample sizes
are large (> 250) and when there is a large number of included
studies (> 25).
Conclusion: Statistical validation of a test’s PPVs andNPVs could
bepartof thesynthesisprocessofa testevaluationmeta-analysis.
Both the likely validity of the standard and tailored estimate in
a new population could be ascertained at this stage. In the ex-
amples analysed, standard meta-analysis seldom yielded a valid
estimate for the test’s performance. Importantly, this was often
remedied by taking a tailored approach to the meta-analysis,
which was more likely to yield a valid estimate.
The model predictions for the positive and negative predictive
values are tested for validity by comparing them with those ob-
served in the omitted study using the Vn statistic. The results of
standardmeta-analysis and the tailoredmeta-regressionmodels
are compared. A P value < 0.05 represents a signiﬁcant result.
Notation: Tailored MR = Tailored meta-regression; P val = P
value; k = number of studies; 1 = at a threshold of 0.5; 2 at a
threshold of 1.5
Table 1 Validation of estimates of positive and negative predictive values.
Positive Predictive value Negative Predictive value
Meta-analysis Tailored MRi Meta-analysis Tailored MRi
Test Disease k Vn P val Vn P val Vn P val Vn P val
Mammography Breast cancer 10 175.6 0.000 24.6 0.001 91.1 0.000 45.4 0.000
Centor’s criteria GABHSii 10 46.1 0.000 11.1 0.349 58.2 0.000 23.1 0.007
PAPiii test Cervical cancer 67 925.4 0.000 336.0 0.000 1279.6 0.000 404.9 0.000
PHQ-9iv Depression 10 36.4 0.000 16.1 0.096 42.2 0.000 31.5 0.000
NAATv Chlamydia (men) 12 19.3 0.062 18.9 0.048 44.4 0.000 17.5 0.072
NAATvi Chlamydia (women) 14 21.8 0.062 14.3 0.413 75.5 0.000 40.1 0.000
Platelia(ELISA)1 Invasive Aspergillosis 7 15.9 0.010 7.9 0.271 7.1 0.400 9.8 0.196
Platelia(ELISA)2 Invasive Aspergillosis 18 35.8 0.004 25.4 0.100 48.8 0.000 44.6 0.001
MRIvii Rotator cuff tear 6 10.9 0.065 2.7 0.720 4.0 0.640 3.0 0.667
USSviii Rotator cuff tear 13 30.6 0.002 20.4 0.048 43.2 0.000 21.3 0.034
Anti-CCP1ix Rheumatoid arthritis 8 25.5 0.000 17.4 0.006 83.7 0.000 11.1 0.206
Anti-CCP2ix Rheumatoid arthritis 29 71.8 0.000 51.2 0.002 331.8 0.000 61.0 0.000
i. Meta regression
ii. Group A beta haemolytic streptococcal infection
iii. Papanicolaou test
iv. Patient Health Questionnaire-9
v. Nucleic Acid Ampliﬁcation Test
vi. Nucleic Acid Ampliﬁcation Test
vii. Magnetic Resonance Imaging
viii. Ultrasound Scan
ix. Anti-Cyclic Citrullinated Peptide
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Using purposive sampling within qualitative evidence synthesis: experiences
from a Cochrane Review of parents’ views and experiences of vaccination
communication
Heather Ames
Correspondence to: HeatherMelanie.Ames@fhi.no
Norwegian Knowledge Centre for the Health Sciences, Norwegian Institute of Public Health & Health Services Research, Oslo, Norway
Background: Reviews of qualitative research, or qualitative ev-
idence synthesis (QES), are increasingly common and are now
being done by Cochrane. Identifying and including all possible
studies is a goal for reviews of intervention effectiveness, but is
not necessarily the best approach for QES. Too much data due
to a large number of studies may threaten the quality of the
analysis. Using purposive sampling of included studies is one
way of reducing the number of articles to be analysed.
Objectives: To describe an approach to purposive sampling of
studies included in a QES.
Methods: We searched electronic databases to identify studies
thatmet the following inclusioncriteria: 1) qualitativemethodsof
data collection and analysis; 2) parents or carers as participants;
and, 3) a focus on views and experiences of vaccination infor-
mation. For studies that met the inclusion criteria, we extracted
information regarding studycountry and focusandassesseddata
‘richness’ on a 1-5 scale.
Studies meeting the inclusion criteria were sampled using a
three-step purposive process:
1. we sampled any study from a low- or middle-income
country (LMIC) to help ensure geographic spread, as the
majority of studies on the topic are from high-income
settings;
2. we sampled all studies that scored 3 or more on the data
richness scale;
3. we reviewed the abstracts of the remaining studies and
sampled those that answered the review question most
closely in the most detail.
Results: Sixty studies met our inclusion criteria. We sampled
seven studies from LMIC settings; 14 studies that scored more
than 3 on the data richness scale; and ﬁve studies that answered
the review question best, leaving 26 studies for data analysis.
Conclusions: This systematic, three-step approach may prove
useful to other researchers attempting to synthesize qualitative
literature froma large number of studies. The strengthswere that
it allowed us to achieve a geographic spread of articles together
with rich data that closely answered the review question. The
weakness is that we may have overlooked articles that did not
meet our sampling criteria, but would have contributed to the
synthesis.
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Cochrane Methodology
Review Group
Mike Clarke, on behalf of the Cochrane Methodology Review
Group
Correspondence to: m.clarke@qub.ac.uk
All-IrelandHub forTrialsMethodologyResearch, Centre forPublic
Health, Queen’s University Belfast, Northern Ireland, UK
We should like to begin this report on the past year for the
Cochrane Methodology Review Group by expressing enormous
gratitude to Andy Oxman, the Group’s founding Co-ordinating
Editor, who stood down from his role in the team of editors in
2016. Andy’s insight, collaborative nature, rigour and friendship
laid the foundations for our Group, and much of the method-
ology infrastructure of Cochrane. He established our editorial
processes and led the Group with his colleagues in Oslo through
our early years. He continued to provide considerable support
when the Group’s editorial base moved to Oxford and then to
Belfast, helping to ensure thequality and relevanceof our output.
The editorial base for the Cochrane Methodology Review Group
is based in the Northern Ireland Hub for Trials Methodology
Research in Queen’s University of Belfast, Northern Ireland.
We are one of the smaller Cochrane Review Groups, and have
no dedicated funding. The Group is responsible for Cochrane
Methodology Reviews, which are among the most highly cited
Cochrane Reviews and systematically review a wide range of
issues relevant to methods for evaluating health and social care.
Mike Clarke is the Group’s Co-ordinating Editor, and also covers
the roles of Managing Editor and Information Specialist, which is
the new name for Trial Search Co-ordinators in Cochrane. How-
ever, because of our limited resources, it is important to note that
the Group is not able to conduct searches for the authors of our
reviews. Mike is supported by ﬁve Editors: Paul Glasziou, Sally
Hopewell, Asbjørn Hro´bjartsson, Philippa Middleton and Karen
Robinson.
During the last 12 months, four full Cochrane Methodology Re-
views were published for the ﬁrst time.1−4 Our complete col-
lection of protocols and full reviews was accessed more than
15,000 times in theCochrane Library during 2015, with an average
equivalent to more than one full text view of each document
every day. The most popular of all our reviews continues to be
the assessment of methods to increase response to postal and
electronic questionnaires, which was accessed nearly 2000 times
in 2015.5
In July 2015, we published a new review of 14 studies along
similar lines to that review, which compared self-administered
survey questionnaire responses collected using mobile apps
versus other methods.1 Jose´ Marcano Belisario and colleagues
produced a narrative synthesis of the evidence which suggested
that the use of apps might not affect the data, as long as using
the app rather than othermethods does not change the intended
clinical application of the survey questionnaire, its intended fre-
quency of administration, or the setting inwhich it was validated.
However, theyhighlightedmanyareasofuncertainty thatneed to
be tackled in new methodology research. Some of this research
could be embedded in future clinical trials, and the Northern Ire-
land Hub also hosts the SWAT (Study Within A Trial) programme,
which is encouraging the conduct of such research.6
These embedded studies are also of particular relevance to our
ﬁrst review of 2016, which was published on Leap Year day, 29
February.2 Nancy Preston, who has also prepared a podcast for
the review,7 led this review of strategies to help healthcare pro-
fessionals to recruit participants to research studies. The review
was able to include 11 studies that had tested ways to help
healthcare professionals to identify and approach people who
might be eligible for clinical trials and other prospective studies.
The authors conclude that there is no strong evidence for any
single strategy, but that the most promising strategies appear
to be those in which a dedicated resource, such as a clinical
recruiter or an automated alert system, is used to identify suit-
able participants, thereby reducing the demand on healthcare
professionals.
In March 2016, we published a new review from a team including
several researchers at the FrenchCochraneCentre, which investi-
gated the impact of central adjudication of outcomes compared
to onsite outcome assessment in randomized trials.3 Lee Aymar
Ndounga Diakou and others were able to draw on data from
more than 275,000 patients in 47 trials to show that, on aver-
age, there was no difference in treatment effect estimates from
onsite assessors and central adjudication committees. However,
they found that the committees might be particularly important
when onsite assessors cannot be blinded to the allocation of the
patients whose outcomes are being assessed.
Finally, the challenges of ﬁndingways to preventmisconduct and
promote integrity in theconductandpublicationof researchwere
tackled by a Cochrane Methodology Review led by Ana Marusic
and Liz Wager.4 The review highlights how improper practices
and unprofessional conduct in clinical research can lead to sig-
niﬁcant waste and harm public health. A total of 31 studies
involving nearly 10,000 participants met the inclusion criteria,
with nearly half of these being randomized trials. Overall, there
was very low quality evidence that various types of training in
research integrity had some effects on participants’ attitudes to
ethical issues, but the effects of knowledgewereminimal or short
lasting. When it came to plagiarism, they found varying effects of
training, but that programmes that included practical exercises
appeared to be the most effective.
If you are interested in contributing to the work of the Cochrane
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Methodology Review Group, as an author, referee or in some
other way, please contact Mike Clarke (m.clarke@qub.ac.uk).
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Information from the
Methods Groups
Methods Groups have an important function in Cochrane. They
play a key role in the ongoing and evolving science of systematic
reviewstoevaluatehealthcare interventions, diagnostic testsand
other related healthcare issues such as prognosis. The Groups
that are currently registered represent a breadth of methodol-
ogy, addressing, for example, bias assessment, inclusion of non-
randomized studies, qualitative research, economic evaluations,
patient reported outcomes, indirect comparisons of multiple in-
terventions and network meta-analysis, and agenda and priority
setting. There are 17 Methods Groups and their contact details
are on the inside front cover of this issue of Cochrane Methods.
Further information is provided here on their activities over the
last year. A core function of many Methods Groups is to provide
training. This often occurs as workshops presented at Cochrane
Colloquia and regional meetings. Cochrane also organizes an
annual methods training event on a speciﬁc topic. Methods
Groups also develop methods, tools and guidance; please refer
to the CochraneHandbook for Systematic Reviews of Interventions
(handbook.cochrane.org).
Adverse Effects Methods Group
Andrew Herxheimer (in memoriam), Daniela Junqueira, Su
Golder, Sunita Vohra, Yoon Loke (Co-convenors of Adverse
Effects Methods Group)
methods.cochrane.org/adverseeffects
Andrewand theyoungestConvenorof theCochraneAdverseEffects
Methods Group, Daniela Junqueira
In memoriam: With deep sadness the Cochrane Adverse Effects
Methods Group announces Andrew Herxheimer’s death. Andrew
was a founding member of The Cochrane Collaboration and the
Adverse Effects Methods Group, indeed the Group would never
have existed without him. Andrew was a pioneer in so many
ways. Hewas ahead of his timewith his passion for patients as an
important and authentic source of information. Andrew taught
us the importance of seeking the patient voice and learning from
them particularly in patient safety. Andrew was a truly amazing
man and an inspiration to many. He was always helpful, and
a multitude of Tweets and Facebook messages show how he
touched somany people’s lives. Andrew had an acute perception
of science and life, a rare talent which was genuinely shared. He
will be sorely missed. The Convenors of the Cochrane Adverse
Effects Methods Group would like to dedicate this Annual Report
to Andrew’s life and his contribution to this group. With profound
respect, we thank Andrew for his dedication and commitment to
the Adverse Effects Methods Group.
Ten days before his death, he managed to meet the group in a
teleconferencetodiscussprojectsandfutureplans. This is the last
memory we will keep from Andrew; active, kind and interested,
attending themost recent CochraneColloquium inVienna (2015).
Highlights: We are delighted to see the publication of the
PRISMA harms extension in the BMJ and encourage its use
by reviewers and Review Groups.2 Experiences of using the
PRISMA harms checklist can be posted on our discussion list
(lists.cochrane.org/mailman/listinfo/aemg) or fed back to us. We
envisage that the reporting of harms in systematic reviews will
improve as the uptake of this new tool increases.
We welcome Joey Kwong as a new co-convenor. Joey is based at
Cochrane China, the Chinese Evidence-Based Medicine Center in
Chengdu, China. She joined Cochrane China in January 2015 as
AssociateProfessor/ExecutiveAssociateDirector,andherprimary
interest is safety research of non-pharmacological interventions,
in particular those in the ﬁeld of cardiovascular medicine. Prior
to joining Cochrane China, shewasManaging Editor for Cochrane
HeartGroupandResearchAssociateProfessorat theChineseUni-
versity of Hong Kong. Our co-convenors provide representation
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Joey Kwong
from the UK, Brazil, Canada and China, and have expertise with
drug and non-drug interventions and knowledge of different
stages of the systematic review process.
The Group continues to develop the methods for producing high
quality systematic reviews and to advise Cochrane on how the
validity and precision of systematic reviews can be improved.
We now have over 150 members from 26 countries, 178 mem-
bers on our discussion list and 346 followers on Twitter. We
welcome new members (methods.cochrane.org/adverseeffects/
get-involved), new discussion list members (lists.cochrane.org/
mailman/listinfo/aemg), and new Twitter followers (twit-
ter.com/caemg1). Please ﬁnd details of our convenors on our
website.
Research and methods development: As noted above, the
PRISMA harms extension has been published2 and it is expected
that it will be used in every systematic review assessing ad-
verse events as a primary or secondary outcome. This extension
checklist contains a minimum set of four items to report harms
in reviews, with the aim of increasing transparency. A further
18 recommendations based on the original PRISMA checklist
items address special considerations for harms.2 The goals of
the PRISMA harms checklist are, not only to improve reporting,
but also to stimulate an increase in the number of reviews that
address harms, thus promoting a balanced assessment of health
interventions.
Our research into the evidence base for the most effective
search strategies and data sources for identifying harms, and
methods for assessing bias in studies of harms, is under-
way. The Methods Innovation Fund (MIF) funds this work
(methods.cochrane.org/methods-innovation-fund-2). The re-
sults of this research will eventually inform the Cochrane Hand-
book for Systematic Reviews of Interventions, online training
materials and future workshops.
Training and support activities: Su Golder, Dani Junqueira and
LilianneZorzelaall ranworkshopsat the2015ViennaColloquium:
• Adverse effects in systematic reviews: challenges for for-
mulating the question and searching for different studies
and sources of information
• Reporting adverse events in reviews and the PRISMA
harms
• Terminology challenges for data extraction and analysis
of data on adverse effects
Other presentations at the Colloquium:
Daniela Junqueira led:
• Bias in measurement of adverse outcomes in non-
randomized studies
• Inconsistent evaluation of heparin-induced thrombo-
cytopenia in Cochrane systematic reviews: are harm-
beneﬁt balance truly being appraised?
• Estimating the occurrence of non-standardized adverse
outcomes: the case of lipodystrophy
• Moving from research to practice: training students with
abilities to translate and communicate evidence
Su Golder led:
• Systematic review on social media as a data source for
information on adverse effects
Daniela Junqueira, Su Golder and Lilianne Zorzela
Other conference presentations and workshops included:
• Junqueira D - Training studentswith abilities to inﬂuence
Health Systems (12th Annual Cochrane Canada Sympo-
sium)
• Junqueira D - What the harmful effects of medicines
are, and why they matter to professionals and patients
[O que sa˜o os efeitos danosos dos medicamentos e
qual sua importaˆncia para proﬁssionais e pacientes] and
Evidence-based practice: why research is important for
clinical practice [Pra´tica baseada em evideˆncia: por queˆ
a pesquisa e´ importante para a pra´tica cl ı´ nica?]. (Belo
Horizonte, Brazil)
• GolderS -Can socialmediahelpusﬁndoutabout the side
effects of treatments?’ (NIHR Trainees’ Meeting, Leeds,
UK)
• FariaJCM,JunqueiraD,CandidoRCF,PaduaCAM,Moraes
AVSM, Frade ACM, et al. - Pharmacy education, quality
use of medicines, and scientiﬁc information in weblog
and social medias [Ensino de farma´cia, uso seguro de
medicamentos e informac¸a˜o cient ı´ ﬁca em weblog e re-
des sociais]. (I Congresso de Inovac¸a˜o e Metodologias de
Ensino, Belo Horizonte)
• Godinho, M, de Castro ML, Neto HP, Junqueira D - Ad-
verse effects of transcranial direct current stimulation
after stroke [Efeitos adversos da estimulac¸a˜o transcra-
niana de corrente cont ı´ nua apo´s o acidente vascular
cerebral]. (I Mostra de Atividades Acadeˆmicas & Encontro
de Pesquisadores e Iniciac¸a˜o Cient ı´ ﬁca, Sorocaba)
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Looking ahead: Su Golder has started her NIHR fellowship en-
titled, ‘Using unpublished data, text mining and social media
to maximize the efﬁciency and effectiveness of the retrieval of
adverse effects data’.
Daniela Junqueira has been working on a research project to
improve strategies for ‘Risk of bias’ assessment with regard to
harmful effects. There is a draft proposal for which Dani is
seeking funding, possibly integrating this with postdoc research
supervised by Sunita Vohra.
2016 Seoul Colloquium: We have proposed and submitted a
workshop for consideration at this year’s Cochrane Colloquium
in Seoul, Korea.
Training and workshops: We also intend to provide some web-
based training, as a series of short presentations on aspects such
as formulating the question, searching, quality assessment and
standards for reporting.
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4. Junqueira D. Assessment of main adverse drug reactions
in systematic reviews and clinical trials of heparins for
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Agenda and Priority Setting Methods
Group
Mona Nasser on behalf of the Agenda and Priority Setting
Methods Group (APSMG)
methods.cochrane.org/prioritysetting
Twitter: @capsmg
Highlights:
• Organizing two priority setting workshops that were well
attended at the 2015 Vienna Colloquiumand co-organizing
aworkshoponusingsystematic reviews to formulate future
research.
• A methods group meeting that involved other researchers
in this ﬁeld to encourage cross-collaboration between
Cochrane and other organizations e.g. the Campbell Col-
laboration.
• Mona Nasser presented on research priority setting at the
2015 Cochrane Methods symposium in Vienna and the ﬁrst
Cochrane symposium in Bosnia and Herzegovina.
• The survey of funders, which included evaluating their
priority setting process, was presented in Bergen (ﬁrst
evidence-based research network symposium), Edinburgh
(REWARD/EQUATOR conference), Vienna (Cochrane Collo-
quium) and London (NIHR 10-year anniversary, preconfer-
ence session on adding value).
• Conducting interviews with policy makers in the USA, Eng-
land and South Africa on setting priorities for systematic
reviews. TheUSA reportwas published in the last Cochrane
Methods Newsletter.
• Building collaborative working relations with the World
Health Organization, Evidence Based Research Network
and the Reduce Research Waste And Reward Diligence
statement (REWARD) on mutual working areas e.g. how
research priority setting is implemented.
• Further developments in using Global Burden of Disease to
inform research priority setting exercises.
• Restructuring thewebsiteof themethodsgroupandsetting
up a mailing list.
Introduction: The Group focuses on developing methodology
and advising Cochrane Groups and entities about the empirical
evidence available on methods for research priority setting, or
developing research agendas, particularly for – but not limited
to – systematic reviews. It also serves as a discussion forum
to connect people who are interested in methods for setting
research agendas or priorities inside Cochrane and elsewhere.
We also write blog posts in other websites, e.g. ‘How to reduce
waste in research? From Edinburgh to Vienna and Sarajevo’.
(monanasser.wordpress.com/category/reward-alliance).
Research and methodological developments: Currently we
do not have any dedicated funding resource. This Methods
Group is run voluntarily by academics, independent researchers
andmembers of the public to develop this area further.
Engaging with policy makers and funders: interviews were com-
pletedwith policymakers in theUSA, UK and South Africa about
their views and experience for setting priorities for systematic
reviews. As mentioned earlier, the USA interviews were pub-
lished in the last Cochrane Methods Newsletter, the rest are
being analyzed. We also work with the REWARD initiative on
how funding agencies respond to the research waste frame-
work. One area of future research interest is the process that
funding agencies use to set priorities for research. The Group
also contributed to the development of guidance on updating1
reviews which is currently in press.
Global Burden of Disease-Cochrane Project: Disease burden
should help guide research prioritization. The Global Burden of
Disease (GBD)Study (fundedby theBill andMelindaGates Foun-
dation under the direction of Christopher JL Murray at the Uni-
versity of Washington) compiles data from 1990 to the present
onmore than290diseases and injuries, 1100diseases and injury
sequelae, and 60 risk factors in more than 180 countries. The
GBD-Cochrane Project maps disease burden determined by the
GBD Study to corresponding systematic reviews and protocols
of interventions targeting the same diseases in the Cochrane
Database of Systematic Reviews (CDSR).2 This exercise helps
guide research prioritization by identifying possible therapeutic
areas that are over- andunder-represented in theCDSR. Medical
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ﬁelds examined to date include dermatology, otolaryngology,
injury,3 urology, and neglected tropical diseases.4
Training and support activities:We use systematic reviews to
inform future research (and setting priorities for research).
2015 Vienna Colloquium
• Research priority setting workshop: as well as critically ap-
praising examples of research priority setting approaches
from the Airways Group and other groups; participants de-
velopedsometips forundertakingpriority setting,method-
ological and otherwise. These are now on the Group’s
website.
• The Global Burden of Disease workshop (led by Robert
Dellavalle): was well attended and generated some inter-
esting reﬂections on how these data can be used by review
groups.
• Methods Group meeting: presentations on different meth-
ods for priority setting such as ’Gap Mapping’ were pre-
sented with subsequent reﬂection and discussion.
• Symposia:we also presented on research priority setting at
the Cochrane Methods Symposium and the ﬁrst Cochrane
symposium in Bosnia and Herzegovina.
Dissemination: We use Twitter to disseminate our work
@capsmg. We also write blog posts on other websites e.g.
‘How to reduce waste in research? From Edinburgh to Vienna
and Sarajevo’. (monanasser.wordpress.com/category/reward-
alliance).
Looking ahead: Abstracts for workshops and meetings have
been submitted for the 2016 Seoul Colloquium – the group are
particularly interested in how research priority setting is re-
ported in the literature andways of assessing the quality, trans-
parency and appropriateness of these methods. We will con-
tinue to attempt to obtain funding to develop amethods guide.
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4. Bhaumik S, Karimkhani C, Czaja CA, Williams HC, Rani M,
Nasser M, et al. Identifying gaps in research prioritization:
theglobalburdenofneglectedtropicaldiseasesasreﬂected
in the Cochrane database of systematic reviews. Journal of
Family Medicine and Primary Care 2015;4(4):507-13.
5. Moher D, Glasziou P, Chalmers I, Nasser M, Bossuyt
PM, Korevaar DA, et al. Increasing value and reducing
waste in biomedical research: who’s listening? Lancet
2016;387:1573-86.
6. Tong A, Crowe S, Chando S, Cass A, Chadban SJ, Chapman
JR, et al. Research Priorities in CKD: Report of a National
Workshop Conducted in Australia. American Journal of
Kidney Disease 2015;66(2):212-22.
7. Bhaumik S, Rana S, Karimkhani C, Welch V, Armstrong R,
Pottie K, et al. Ethics andequity in researchpriority-setting:
stakeholder engagement and the needs of disadvantaged
groups. Indian Journal of Medical Ethics 2015;12(2):110-3.
8. Petkovic J. Commentary on ethics and equity in research
priority-setting: stakeholder engagement and the needs
of disadvantaged groups. Cochrane Methods. Cochrane
Database of Systematic Reviews 2015;Suppl 1:1-72.
9. Nasser M. Commentary on engaging stakeholders to iden-
tify evidence synthesis priorities for National Health Insur-
ance Schemes: lessons learned from Uganda. Cochrane
Methods. Cochrane Database of Systematic Reviews
2015;Suppl 1:1-72.
10. Gibson M, Fox DM, King V, Zerzan J, Garrett JE, King N.
Methods and processes to select and prioritize research
topics and report design in a public health insurance
programme (Medicaid) in the USA. Cochrane Methods.
Cochrane Database of Systematic Reviews 2015;Suppl 1:1-
72.
Key members of our methods group published important
articles relevant to our work:
1. Chalmers I, Fox DM. Increasing the incidence and inﬂuence
of systematic reviews on health policy and practice. Ameri-
can Journal of Public Health 2016;106(1):11-3.
2. Kieny MP, Viergever RF, Adam T, Boerma T, Røttingen JA.
Global platform to inform investments for health R&D.
Lancet 2016;387(10024):1157.
3. Viergever RF,Hendriks TC. The10 largest public andphilan-
thropic funders of health research in the world: what they
fund and how they distribute their funds. Health Research
Policy and Systems 2016;14:12.
Applicability and Recommendations
(now Cochrane GRADEing) Methods
Group
Nancy Santesso on behalf of Holger Schu¨nemann and
Gordon Guyatt Co-convenors of Cochrane GRADEing
Methods Group
methods.cochrane.org/gradeing
Introduction: The goal of the Cochrane GRADEing group is to
develop approaches, strategies and guidance for the uptake of
information from Cochrane Reviews and their use by a wide
audience. Our projects focus on the assessment of evidence
from systematic reviews, and the presentation of summaries of
evidence, especially on ‘Summary of ﬁndings’ (SoF) tables and
Plain language summaries.
Researchandmethodologicaldevelopment:GRADEpro(grade-
pro.org) – the online version of the GRADEpro GDT software – is
freely available to Cochrane authors. Over the past year, we’ve
added a variety of features based on user testing and research:
• created SoF tables for test accuracy reviews;
• created a new format of the SoF table for intervention
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reviews that includes the ‘what happens’ column, which
conveys the results using text, and the presentation of
effects and the difference using percentages;
• created an interactive SoF table for intervention reviews
and test accuracy reviews.
TheGRADEHandbook is updatedperiodicallywith any newdevel-
opments in GRADE or SoF tables. It can be printed in its entirety
or searched and viewed online. A new section for how to GRADE
evidence from test accuracy reviews has been added. The GRADE
Handbook is available at: gradepro.org.
Guidance for writing explanations for why the evidence was
GRADEd (footnotes) was developed based on a review of pub-
lished evidence tables (see publications in the Journal of Clinical
Epidemiology below).
Guidance for rigorous assessment of risk of bias associated with
missing participant outcomedata in systematic reviewswill soon
be published. This work was based on a systematic survey of
published methodological research, iterative discussions with
experts, testing in previously published and ongoing systematic
reviews, and feedback from the GRADEWorking Group.
SoF tables for the results of a network meta-analysis are being
developed and tested, as are SoF tables for patient values and
preferences.
Aproject to incorporate randomizedandnon-randomizedstudies
in reviews of interventions and GRADE assessments was funded
bytheMethods InnovationFund. Aworkinggroupwithawiderep-
resentation of Cochrane members was created. A survey of over
120 experts fromCochrane, theGuidelines International Network
(G-I-N), and other groupswas conducted in early 2016. About half
of the 80 participants meta-analysed results from the two study
designs separately, although about 30%would pool randomized
and non-randomized studies together. Most would also present
the results from the two types of study designs separately, re-
gardless of the quality of evidence. Work continues to explore
how the twodesign types couldbe considered together, given the
new ‘Risk of bias’ tool (ROBINS-I) for non-randomized studies.
Narrative statements to communicate the results of systematic
reviews are currently being developed. This work is based on
research in how to communicate evidence in a Plain language
summary,whileconsidering themagnitudeofeffectandcertainty
of the evidence.
Training and support activities: We continue to provide full
day and 1 12 hour workshops at the Cochrane Colloquia, which
are well attended. We also provide training at the Cochrane
Standard Author Training Workshops around the world. We
continue to add newmodules about GRADE and SoF tables (ceb-
grade.mcmaster.ca). See our new video for how to create a SoF
at: www.youtube.com/watch?v=geXR9oJbLac.
We are working with the Training Group to provide feedback for
new online learning modules and to conduct webinars about
GRADE and SoF tables. We conducted and recorded a webinar
aboutcreatingtables–seethesevideosat: training.cochrane.org/
path/grade-approach-evaluating-quality-evidence-pathway/9
Key publications:
1. Akl EA, Kahale LA, Ebrahim S, Alonso-Coello P,
Schu¨nemann HJ, Guyatt GH. Three challenges described
for identifying participants with missing data in trials
reports, and potential solutions suggested to systematic
reviewers. Journal of Clinical Epidemiology 2016 Mar 2
[Epub ahead of print]. pii: S0895-4356(16)00159-1. DOI:
10.1016/j.jclinepi.2016.02.022.
2. Santesso N, Carrasco-Labra A, Langendam M,
Brignardello-Petersen R, Mustafa RA, Heus P, et al. Im-
proving GRADE evidence tables part 3: detailed guidance
for explanatory footnotes supports creating and under-
standing GRADE certainty in the evidence judgments.
Journal of Clinical Epidemiology 2016;74:28-39. DOI:
10.1016/j.jclinepi.2015.12.006.
3. Langendam M, Carrasco-Labra A, Santesso N, Mustafa
RA, Brignardello-Petersen R, Ventresca M, et al. Improv-
ing GRADE evidence tables part 2: a systematic survey
of explanatory notes shows more guidance is needed.
Journal of Clinical Epidemiology 2016;74:19-27. DOI:
10.1016/j.jclinepi.2015.12.008.
4. Carrasco-Labra A, Brignardello-Petersen R, Santesso N,
Neumann I, Mustafa RA, Mbuagbaw L, et al. Improving
GRADE evidence tables part 1: a randomized trial shows
improved understanding of content in summary of ﬁnd-
ingstableswithanewformat. JournalofClinicalEpidemi-
ology 2016;74:7-18. DOI: 10.1016/j.jclinepi.2015.12.007.
5. Mustafa RA,WierciochW, Santesso N, Cheung A, Prediger
B, Baldeh T, et al. Decision-making about healthcare
related tests and diagnostic strategies: user testing of
GRADEevidence tables. PLOSONE 2015;10(10):e0134553.
DOI: 10.1371/journal.pone.0134553.
Bias Methods Group
Doug Altman, Isabelle Boutron, Asbjørn Hro´bjartsson, David
Moher, (Co-convenors of Bias Methods Group) Camilla
Hansen (Co-ordinator)
methods.cochrane.org/bias
Twitter: @CochraneBias, @CochraneBMG
Highlights:
• The Cochrane Bias Methods Group’s secretariat relocated
fromOttawa, Canada toOdense, Denmark in January 2016.
Consequently, normal procedures have been interrupted
and the co-ordinator has changed. The Group wishes
to thank former co-ordinator Alain Mayhew for all of his
hard work up to September 2015, and to welcome Camilla
Hansen who started as co-ordinator in May 2016.
• During 2015 and 2016, the Bias Methods Group collabo-
rated with Julian Higgins and Jonathan Sterne (from the
University of Bristol) on revising both the ROBINS-I (previ-
ously ACROBAT-NRSI) tool for non-randomized trials and
the Cochrane ‘Risk of bias’ tool for randomized trials.
• The Group participated actively in trainingmembers of the
systematic review community, and organized workshops
at the 2015 Vienna Colloquium.
• Next year, the groupwill work on ﬁnishing and implement-
ing the revised version of the Cochrane ‘Risk of bias’ tool
for randomized trials.
• As of May 2016, the Twitter account had more than 700
followers. In addition, the BMGlist (the mailing list for BMG
members) has more than 180 members.
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Introduction: The Bias Methods Group (BMG) raises awareness
of theproblemofbiasand investigateswhether, and inwhichcir-
cumstances,biasesmayhaveasubstantial impactonsystematic
reviews andmeta-analyses. The BMG conducts methodological
systematic reviews, provides advice to Cochrane entities and
individuals, organizes workshops, and publicizes its ﬁndings.
The vision of the BMG is to ensure that bias in all systematic
reviews is identiﬁed, assessed, and transparently reported to
enable the production of high quality and reliable research that
allows healthcare decisions to be made on the basis of the best
available evidence.
Research andmethodological developments:During the past
year, the BMG has worked on two major projects: the ROBINS-I
tool (previously named ACROBAT-NRSI) and the Cochrane ‘Risk
of bias’ (RoB) tool for randomized trials.
A preliminary version of the ACROBAT-NRSI tool was presented
at the 2015 Vienna Colloquium in October 2015. Since then,
the tool has been adjusted in collaboration with the Cochrane
Non-Randomized Studies for InterventionsMethods Group. Fol-
lowing this work, some aspects of the tool have been revised,
and the name of the tool has been changed to ROBINS-I due to
legal issues.
As well as the ROBINS-I tool, the BMG has worked on the de-
velopment of the RoB tool 2.0. Isabelle Boutron and Asbjørn
Hro´bjartsson participated in a meeting on the issue in Bristol,
UK in the autumn of 2015. Subsequently, the group worked on
revisingdifferent aspects of theRoB tool, andexpects topresent
a product at the 2016 Seoul Colloquium in October 2016.
Training and support activities: The BMG participates actively
in training programs for Cochrane authors, editors and other
membersofthesystematicreviewcommunity. TheBMGendeav-
ours to provide training to both Cochrane and non-Cochrane
systematic reviewers via formal and informal training opportu-
nities. Materials used inworkshops and training sessions can be
easily accessed on the website.
Convenors of the BMG taught at workshops at the 2015 Vienna
Colloquium, including: ‘Using the Cochrane RCT ‘Risk of bias’
tool in systematic reviews’ and ‘Introducing a revised ‘Risk of
bias’ tool for randomized trials’. Additionally, group members
organized several other Colloquium workshops, for example,
Ian Shrier facilitated one on ‘Patient-relevant causal effects
versus intention to treat: a guide to understanding complex
analyses’.
Looking ahead:Next year, the BMGwill establish its secretariat
in Odense, and work on ﬁnishing and implementing the revised
version of the Cochrane RoB tool for randomized trials.
Key publications:
1. Baudart M, Ravaud P, Baron G, Dechartres A, Haneef R,
Boutron I. Public availability of results of observational
studies evaluating an intervention registered at ClinicalTri-
als.gov. BMCMedicine 2016;14:7.
2. Hopewell S, Boutron I, Altman DG, Ravaud P. Deﬁciencies
in the publication and reporting of the results of system-
atic reviews presented at scientiﬁc medical conferences.
Journal of Clinical Epidemiology 2015;68(12):1488-95.
3. Lazarus C, Haneef R, Ravaud P, Hopewell S, Altman DG,
Boutron I. Peer-reviewers identiﬁed spin in manuscripts
of non-randomized studies assessing therapeutic interven-
tions, but their impact on spin in abstract conclusions was
limited. Journal of Clinical Epidemiology 2016 May 7 [Epub
ahead of print]. DOI:10.1016/j.jclinepi.2016.04.012.
4. Lonjon G, Porcher R, Ergina P, FouetM, Boutron I. Potential
pitfalls of reporting and bias in observational studies with
propensity score analysis assessing a surgical procedure: a
methodological systematic review. Annals of Surgery 2016
May 26 [Epub ahead of print]. PMID: 27232253.
5. Jørgensen L, Paludan-Mu¨ller AS, Laursen DR, Savovi´c J,
Boutron I, Sterne JA, et al. Evaluation of the Cochrane
tool for assessing risk of bias in randomized clinical trials:
overviewof published comments and analysis of user prac-
tice in Cochrane and non-Cochrane reviews. Systematic
Reviews 2016;5(1):80.
6. Moher D, Altman DG: Four proposals to help im-
prove the medical research literature. PLOS Medicine
2015;12(9):e1001864.
7. Moher D, Glasziou P, Chalmers I, Nasser M, Bossuyt
PM, Korevaar DA. Increasing value and reducing waste
in biomedical research: who’s listening? Lancet
2016;387(10027):1573-86.
8. Page MJ, Shamseer L, Altman DG, Tetzlaff J, Sampson
M, Tricco AC, et al. Epidemiology and reporting charac-
teristics of systematic reviews of biomedical research: a
cross-sectional study. PLOS Medicine 2016;13(5):e1002028.
9. Yavchitz A, Ravaud P, Altman DG, Moher D, Hrobjartsson A,
Lasserson T, et al. A new classiﬁcation of spin in system-
atic reviews andmeta-analyses was developed and ranked
according to the severity. Journal of Clinical Epidemiology
2016;75:56-65.
10. Tricco AC, Antony J, Zarin W, Striﬂer L, Ghassemi M, Ivory
J, et al. A scoping review of rapid review methods. BMC
Medicine 2015;13:224.
11. ZorzelaL, LokeYK, IoannidisJP,GolderS,SantaguidaP,Alt-
man DG, et al. PRISMA harms checklist: improving harms
reporting in systematic reviews. BMJ Clinical Research
2016;353:i157.
12. Millard LAC, Flach PA, Higgins JPT. Machine learning to
assist risk-of-bias assessments in systematic reviews. In-
ternational Journal of Epidemiology 2016;45(1):266-77.
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Comparing Multiple Interventions
Methods Group
Anna Chaimani, Georgia Salanti, Tianjing Li, and
Lisa Hartling, on behalf of ComparingMultiple Interventions
Methods Group
methods.cochrane.org/cmi
Highlights:
• Groupmembers offered a one-day pre-Colloquiumwork-
shop in Vienna on indirect comparisons and network
meta-analysis based on a new Cochrane Handbook for
Systematic Reviews of Interventions chapter for network
meta-analyses.
• The Group organized a half-day post-Colloquium work-
shop in Vienna on overviews of systematic reviews.
• Group members prepared an article describing how to
writeaprotocol foracomparativeeffectiveness review in-
cluding network meta-analysis.
Introduction: The Comparing Multiple Interventions Methods
Group (CMIMG) focuses on methods for network meta-analysis
and for overviews of reviews. Network meta-analyses com-
bine results from studies that made different comparisons from
a set of treatments for the same condition, exploiting indi-
rect comparisons of treatments via common comparator treat-
ments. Overviews use explicit and systematic methods to search
for and identify multiple systematic reviews on a similar topic
for the purpose of extracting and analysing their results across
important outcomes. Overviews are published in the Cochrane
Database of Systematic Reviews.
The group’s activities focused on:
• developing methods and guidance for network meta-
analysis andoverviews of reviews in the formofCochrane
Handbook chapters;
• providing training to interested individuals;
• providingpeer reviewsupport to reviewsthat includenet-
work meta-analysis and overviews of reviews;
• serving as a forum for discussion.
The work on network meta-analysis is supported primarily by a
three-year Cochrane Methods Innovation Fund grant and one of
thegroup’sCo-Convenors (Hartling)holds funding fromtheCana-
dian Institutes of Health Research for methodological research
on overviews of reviews.
The Group currently has 106 members registered in Archie. We
have over 50 members on our newly established listserv. To join
please send an email to CMIMG@lists.cochrane.org. More than
6000 users have visited our website during the past year, and we
have over 1500 page views per month. Most users begin with our
network meta-analysis Toolkit page.
Research and methodological developments: We prepared
a new Cochrane Handbook chapter offering guidance on us-
ing network meta-analysis in Cochrane systematic reviews. Key
elements of the chapter were presented in a one-day pre-
Colloquiumworkshop in Vienna.We have also revised Chapter 22
of the Cochrane Handbook on overviews of reviews. The chapter
has been submitted to the Cochrane Handbook editors.
We have submitted two papers: the ﬁrst describes how to write a
protocol for a systematic review includingnetworkmeta-analysis
as a synthesis component, and the second describes a scoping
review of existing methodological guidance for overviews of re-
views, including identiﬁcation of inconsistencies and gaps for
future research. We offered guidance to Cochrane authors who
approached us for feedback on their protocols and reviews (for
both network meta-analyses and overviews of reviews). The
co-convenors also covered key elements of the Cochrane Hand-
book chapter on network meta-analysis at educational events
in which they participated. We published a paper describing an
evaluationof harvest plots todisplay the results ofmeta-analyses
in overviews of reviews.
Training and support activities: Apart from the one-day work-
shop for indirect comparisons and network meta-analysis and
the half-dayworkshop on overviews of systematic reviews,mem-
bers of the CMIMG also facilitated other workshops during the
Colloquium, for example on using Stata for performing net-
work meta-analysis and an introduction to overviews of reviews.
Members of the CMIMG also gave oral, rapid oral, and poster
presentations on a range of topics on networkmeta-analysis and
overviews of reviews.
For the 2016 Colloquium in Seoul, Korea, CMIMG has
planned three workshops: ‘Comparing multiple interventions
workshop 1: introduction to indirect comparison and network
meta-analysis’; ‘Comparing multiple interventions workshop 2:
estimating treatment effects and evaluating the evidence from
networkmeta-analysis’; and a half-day workshop on the ﬁrst day
of the Colloquium on overviews of reviews.
Looking ahead: Next year we hope to see publication of our
paper onwriting a protocol for a systematic review, and for all re-
mainingoutputs of ourMethods Innovation Fundproject.Wealso
hope to see publication of our paper on methods for overviews
of reviews, and the updated Chapter 22 of the Cochrane Hand-
book. We will present workshops on both overviews and network
meta-analysis at the 2016 Seoul Colloquium.
Key publications:
1. HuttonB, Salanti G, Caldwell DM,Chaimani A, SchmidCH,
Cameron C, et al. The PRISMA extension statement
for reporting of systematic reviews incorporating net-
work meta-analyses of healthcare interventions: check-
listandexplanations.Annalsof InternalMedicine2015;162
(11):777-84.
2. Higgins JPT, Welton NJ. Network meta-analysis:
a norm for comparative effectiveness? The Lancet
2015;386(9994):628-30.
3. White I. Network meta-analysis. The Stata Journal
2015;15(4):951-85
4. Chaimani A, Salanti G. Visualizing assumptions and re-
sults in network meta-analysis: the network graph pack-
age. The Stata Journal 2015;15(4):905-50.
5. Mavridis D, Giannatsi M, Cipriani A, Salanti G. A primer
on network meta-analysis with emphasis on mental
health. Evidence Based Mental Health 2015;18(2):40-6.
6. Caldwell DM, Dias S,WeltonNJ. Extending treatment net-
works in health technology assessment: how far should
we go? Value in Health 2015;18(5):673-81.
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7. Furukawa TA, Miura T, Chaimani A, Leucht S, Cipriani A,
Noma H, et al. Using the contribution matrix to evaluate
complex study limitations in a network meta-analysis:
a case study of bipolar maintenance pharmacotherapy
review. BMC Research Notes 2015;9(1):1.
8. Crick K, Wingert A, Williams K, Fernandes RM, Thomson
D, Hartling L. An evaluation of harvest plots to dis-
play results of meta-analyses in overviews of reviews: a
cross-sectional study. BMC Medical Research Methodol-
ogy 2015;15(1):91. DOI: 10.1186/s12874-015-0084-0.
Campbell and Cochrane Economics
Methods Group
Luke Vale on behalf of the C-CEMG convenors
methods.cochrane.org/economics
Highlights: Updated materials have been prepared for both
the ‘Developing brief economic commentaries’ and ‘Incorpo-
rating economics into Cochrane Intervention Review protocols’
workshops.
Researchandmethodologicaldevelopment:Decision-makers
frommany countries increasingly ask for an economic perspec-
tive when using Cochrane Reviews to inform healthcare pol-
icy. The Group seeks opportunities to collaborate with Review
Groups and author teams seeking to include an economics per-
spective within their reviews, either as formal review outcomes,
or as brief economic commentaries to continue developing and
reﬁning these approaches.
At the timeofwritingweare revising theguidanceon incorporat-
ing health economics into Cochrane Reviews substantially. New
material includes the addition of methodology for incorporat-
ing brief economic commentaries into Cochrane Intervention
Reviews as well as methods to incorporate economics into
reviews.
Training and support activities: The Group has continued to
be active in disseminating methods. Luke Vale and Erin Graybill
gave workshops on ‘Developing brief economic commentaries’
and on ‘Incorporating economics into Cochrane Intervention
Review protocols’ at the 2015 Vienna Colloquium in October
2015. Both workshops presented updated material and out-
lined approaches to identify economic evaluations, following
the withdrawal of the Health Economics Evaluation Database
and NHS Economic Evaluation Database. Both workshops were
well received (workshop materials can be obtained from the
Group’s website at: methods.cochrane.org/economics). We
anticipate that these workshops will be presented at the 2016
Colloquium in Seoul.
At the 2015 Vienna Colloquium the Group also gave a satellite
workshop to introduce attendees to the basics of health eco-
nomics. We were very grateful for the support and help of the
Vienna organizing committee.
Looking ahead: The Cochrane Handbook for Systematic Re-
views of Interventions economics chapter is in the process of a
substantial revision. This will include latest recommendations
and methods for the addition of an economics perspective to
Cochrane Reviews. We also expect to begin revisions to the on-
line training course in health economics available through the
Cochrane Training website (training.cochrane.org). We expect
to increase our capacity to develop the work of the group.
2016 Seoul Colloquium: As noted above, we hope to offer our
usual suite of workshops on both brief economic commen-
taries and incorporation of health economics into Cochrane
Intervention Reviews.
Keypublications:Ablog(bmj.com/content/350/bmj.h2463/rapid-
responses) was submitted by the group in response to a paper
by the Cochrane Injuries Group ‘The knowledge system un-
derpinning healthcare is not ﬁt for purpose and must change’
(bmj.com/content/350/bmj.h2463.full.pdf+html)
Campbell and Cochrane Equity
Methods Group
Jennifer Petkovic on behalf of the Campbell and Cochrane
Equity Methods Group
methods.cochrane.org/equity
Twitter: @CochraneEquity
Highlights:
• The PRISMA-Equity Explanation and Elaboration paper
(which accompanies the PRISMA-E 2012 reporting guide-
line) was co-published in the Journal of Clinical Epidemi-
ology, the International Journal for Equity in Health, and
the Journal of Development Effectiveness.
• Wepublishedaprotocol forasystematic reviewassessing
whetherevidencesummaries increasepolicymakers’ use
of systematic review evidence. This review has also been
registeredwith theCampbell KnowledgeTranslation and
Implementation Coordinating Group.
• Over the next two years we will continue developing an
equity extension of the CONSORT reporting guideline for
randomized controlled trials (RCTs). In 2015, we pub-
lished the protocol for this multi-phase research project.
• The Migrant Health Group started a 2 12 -year project
using the evidence-to-decision framework and equity
considerations as part of the European Centre for Dis-
easePreventionandControlRefugeesandMigrantHealth
guidelinesproject. Thisprojectaims todevelopevidence-
based recommendations for the European Union and
European Extension Countries.
• We are working with the GRADE Working Group on a
series of papers for including equity in guidelines (in-
cluding equity considerations at different stages of the
guideline development process, rating the certainty of
evidence, and evidence-to-decisions).
• Our Co-Convenor, Peter Tugwell, had his Canada Re-
search Chair in Health Equity renewed (2016-2023).
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Introduction:TheCampbellandCochraneEquityMethodsGroup
is registered with both the Campbell Collaboration and with
Cochrane. The Group aims to encourage authors of Campbell
and Cochrane Reviews to include explicit descriptions of the
effect of the interventions upon the disadvantaged and/or their
ability to reduce socioeconomic inequalities in health, and to
promote their use to the wider community.
The Migrant Health subgroup of the Methods Group focuses on
evidence-based migrant health, guidelines and migrant-equity
(methods.cochrane.org/equity/migrant-health).
The Sex/Gender Methods Group is afﬁliated as a subgroup of the
Equity Methods Group and works to promote and integrate sex
and gender analysis in primary research and systematic reviews
(methods.cochrane.org/equity/sex-and-gender-analysis).
Research andmethodological development:
• In 2015, theEquityMethodsGrouppublished thePRISMA-
Equity Explanation and Elaboration paper in the Journal
of Clinical Epidemiology, the International Journal for
Equity in Health, and the Journal of Development Effec-
tiveness. This paper accompanied the PRISMA-E 2012
Statement published in PLOS Medicine in 2012, and is
intended to improve the completeness and transparency
of reporting of equity-focused systematic reviews.
• Members of the Equity Methods Group are working with
the GRADE Working Group to develop guidance for con-
sidering equity in guidelines and recommendations. A
series of papers is in development and will provide guid-
ance for including equity in guideline development, rat-
ing the certainty of evidence, and moving from evidence
to decisions.
• A series of methodological papers on including
sex/gender considerations in systematic reviews is in
development. The Sex/Gender Methods Group is leading
this work and aims to publish the series in 2016. The
Equity Methods Group has also conducted an environ-
mental scan assessing the reporting of sex/gender in
Canadian RCTs (those funded by a Canadian organiza-
tion or with a ﬁrst or last author based in Canada). This
will be published in 2016.
• Ourmigrant health subgroup, led by Kevin Pottie, is lead-
ing the development of refugee health care guidelines for
the European Centre for Disease Control (ECDC).
Training and support activities:
• In 2015, we provided workshops on equity methods at
the2015ViennaColloquium.Weparticipated inCochrane
Standard Author Training. We presented on equitymeth-
ods in systematic reviews to the Public Health Agency
of Canada, Public Health Ontario, the GRADE Working
GroupMeeting, and theWorld Health Organization Nutri-
tion Systematic Reviews Symposium. Our PhD student,
Jennifer Petkovic, will be conducting a Campbell system-
atic review on interventions to increase policymakers’
use of systematic review evidence and evaluating our
Evidence for Equity (E4E) special collection of systematic
review summaries.
• Our postdoctoral fellow, Janet Jull, has been conduct-
ing methods studies to identify how equity is analyzed
and reported in RCTs for the development of an equity
extension to the CONSORT statement.
• Weheldayouthoutreach/discussionsessionwithaYouth
Advisory Committee (YAC) at Youth Net/Re´seau Ado. The
goal of the discussion was to engage young people in a
conversation about health research and equity. Partici-
pants at the session engaged in dialogue on:
– What is health research and health equity? A look
at evidence-based decision making and health re-
search
– Youth as health consumers and health information
seeking/decisionmaking (youth critically reviewed
health information delivered to public in themedia
– Where to look? (for reliable information)
– Tips and resources for ﬁnding reliable and accu-
rate information such as systematic reviews and
reaching out to experts of published studies.
Looking ahead: The Group is developing a reporting guideline
for equity-relevant RCTs. This project will include six phases: de-
veloping a conceptual framework, assessing empirical evidence
regarding reporting of equity in RCTs, consulting with global
experts from different disciplines and stakeholder organizations
onmethods to improve reporting of health equity in RCTs, devel-
oping draft extension items, seeking consensus on the extension
items, and disseminating the reporting guideline broadly. This
work has been funded by the Canadian Institutes for Health
Research.
Our E4E project aims to create a special collection of Cochrane
Review summaries of interventions that are effective and could
reduce health inequities. In 2015, we conducted a priority-
setting exercise with international stakeholders to identify the
most important reviews to summarize in ﬁve topic areas (depres-
sion, diabetes/obesity, HIV/AIDS, malaria, micronutrients). We
will publish the results of this exercise in 2016. We have also
published a protocol for a systematic review to assess whether
evidence summaries increase policymakers’ use of systematic
review evidence.
Key publications:
1. Welch V, Jull J, Petkovic J, Armstrong R, Boyer
Y, Cuervo LG, et al. Protocol for the development of
a CONSORT equity guideline to improve reporting of
health equity in randomized trials. Implementation Sci-
ence 2015;10:146.
2. Miramontes L, Pottie K, Jandu MB, Welch V, Miller K,
James M, et al. Including migrant populations in health
impact assessments. Bulletin of the World Health Organi-
zation 2015;93(12)888-9.
3. Welch V, Petticrew M, Petkovic J, Moher D, Wa-
ters E; PRISMA-Equity Bellagio Group. Extending the
PRISMAStatement for equity-focused systematic reviews
(PRISMA-E 2012): explanation and elaboration. Journal
of Clinical Epidemiology 2016;70:68-89. Co-published
in International Journal for Equity in Health 2015;14:92
and The Journal of Development Effectiveness 2016; DOI:
10.1080/19439342.2015.1113196.
4. McGill R, Anwar E, Orton L, Bromley H, Lloyd-Williams
F, O’Flaherty M, et al. Are interventions to promote
healthy eating equally effective for all? Systematic re-
view of socioeconomic inequalities in impact. BMCPublic
Health 2015;15:457.
5. Pottie K,Martin JP, Cornish S, Biorklund LM,Gayton I, Do-
erner F, et al. Access to healthcare for the most vul-
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nerable migrants: a humanitarian crisis. Conﬂict Health
2015;9:16.
6. Petkovic J, Welch V, Tugwell P. Do evidence summaries
increase policy-makers’ use of evidence from system-
atic reviews: a systematic review protocol. Systematic
Reviews 2015;4:122.
7. Langlois EV, Ranson MK, Ba¨rnighausen T, Bosch-
Capblanch X, Daniels K, El-Jardali F, et al. Advancing
the ﬁeld of health systems research synthesis. Systematic
Reviews 2015;4:90.
8. Bhaumik S, Rana S, Karimkhani C, Welch V, Arm-
strong R, Pottie K, et al. Ethics and equity in re-
search priority-setting: stakeholder engagement and the
needs of disadvantaged groups. Indian Journal of Medi-
cal Ethics 2015;12(2):110-3.
9. Welch V, Boyer Y, Chamberlain C. Can Cochrane Re-
views inform decisions to improve Indigenous peo-
ple’s health? [editorial].CochraneDatabaseof Systematic
Reviews 2015;(8): 10.1002/14651858.ED000103.
10. Iheozor-Ejiofor Z, Worthington HV, Walsh T, O’Malley L,
Clarkson JE, Macey R, et al. Water ﬂuoridation for the
prevention of dental caries. Cochrane Database of Sys-
tematic Reviews 2015, Issue 6. Art. No.: CD010856. DOI:
10.1002/14651858.CD010856.pub2
11. Nickerson JW, Hatcher-Roberts J, Adams O, At-
taran A, Tugwell P. Assessments of health services avail-
ability in hum anitarian emergencies: a review of as-
sessments in Haiti and Sudan using a health systems
approach. Conﬂict Health 2015;9:20.
12. KristjanssonE, FrancisDK, LiberatoS, Benkhalti JanduM,
Welch V, Batal M, et al. Food supplementation for
improving the physical and psychosocial health of
socio-economically disadvantaged children aged three
months to ﬁve years. Cochrane Database of System-
atic Reviews 2015, Issue 3. Art. No.: CD009924.
DOI: 10.1002/14651858.CD009924.pub2.
13. PetticrewM, Anderson L, Elder R, Grimshaw J, Hopkins D,
Hahn R, et al. Complex interventions and their implica-
tions for systematic reviews: A pragmatic approach. In-
ternational Journal of Nursing Studies 2015;52(7):1211-6.
Individual Participant Data
Meta-analysis Methods Group
Larysa Rydzewska, Jayne Tierney, Lesley Stewart, Maroeska
Rovers and Mike Clarke (Co-convenors of IPD MA Methods
Group)
methods.cochrane.org/ipdma
Highlights:
• 2015 Vienna Colloquium
• Individual participant data (IPD)-relatedpresentations and
workshop
• Special sessions on moving beyond the published article
• Series of ‘state of the art’ papers relating to IPD – all now
fully published
• Newwebsite address
Introduction: Systematic reviews based on aggregate data can
often be constrained by the availability and quality of such
data. However, meta-analyses based on IPD involve the cen-
tral collection and reanalysis of data from all relevant studies,
and can bring about substantial beneﬁts to the quality of the
data and analyses, translating to more detailed and reliable
results. The IPD Meta-analysis Methods Group now has more
than100members conducting IPDmeta-analyses inprevention,
diagnosis, treatment, rehabilitation and prognosis in a range of
healthcare areas, including cancer, epilepsy, stroke, perinatal
care, renal disease, arthritis andmalaria, as well as undertaking
IPD-related methodological research.
• State of the art’ papers relating to IPD
We previously reported that members of the Group have
collaborated to develop a ‘state of the art’ series of
papers on the impact, understanding and use of system-
atic reviews and meta-analyses based on IPD, as well
as a stand-alone extension to PRISMA. This collection of
open-access papers are now all fully published1−5 and
further details are available on our website, and on
the Cochrane Methods website (methods.cochrane.org/
news/individual-participant-data-meta-analysis-
everything-you-always-wanted-know).
• 2015 Vienna Colloquium
Members of theGroup facilitatedaworkshop16 aimedat in-
troducingtheuseof IPDinmeta-analysisofprognosticstud-
ies. There were also eight oral presentations17−24 focussed
on methodological research and developments relating to
IPD. Abstracts from both the workshop and the presen-
tations are available on the Cochrane website (abstracts.
cochrane.org/search/site/?f[0]=im ﬁeld year%3A26).
We also contributed to a special session that described new
opportunities for accessing IPD that are emerging in response
to transparency and data sharing initiatives, and discussed how
this may enable a greater proportion of systematic reviews to
utilize IPD to circumvent reporting bias.
Please visit our website for further information about the ac-
tivities of the Group, together with resources and guidance for
those planning or undertaking IPD reviews, and information
about IPD reviews and IPD-related methodological research
published by Groupmembers.
Research and methodological development: Members of the
Group have also published a number of papers on a variety of
topics, including restricted mean survival time,6−8 multivariate
meta-analysis of IPD,9 the development and implementation of
prediction models10,11 and reviews of current methods being
used in both standard and network IPD meta-analyses.12−14 A
study protocol has also been published which aims to inves-
tigate the impact of ﬁnancial incentives when requesting IPD
from trialists.15
Training and support: In addition to running workshops at
Cochrane Colloquia, the IPD Methods Group can also provide
specialist advice on IPD Reviews and peer review IPD elements
of Cochrane Reviews. We encourage Cochrane authors need-
ing advice, or wishing to join the Group, to contact us via our
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website, which also lists details of IPD-related training courses
provided by members of the Group.
Workshops and presentations at the 2015 Vienna Colloquium
• Debray T, et al. Individual Participant Data (IPD) meta-
analysis of prognostic studies. [Workshop session 5; W85]
• Stewart L, et al. The PRISMA-IPD Statement: preferred
reporting items for a systematic review and meta-analysis
of individual participant data. [Rapid Oral session 4; RO
4.1]
• Tudur Smith C, et al. A framework for deciding if individual
participant data are likely to be worthwhile. [Rapid Oral
session 6; RO 6.1]
• Debray T, et al. Imputation of systematically missing pre-
dictors in an individual participant data meta-analysis: a
generalized approach using MICE. [Rapid Oral session 6;
RO 6.2]
• Scott N, et al. The advantages of individual participant
data (IPD) in smaller-scale systematic reviews. [Rapid Oral
session 6; RO 6.3]
• Rogozinska E, et al. Complex interventions and compos-
ite outcomes in Individual Participant Data (IPD) meta-
analysis: double challenge in i-WIP IPD. [Rapid Oral session
6; RO 6.6]
• Nolan S, et al. The changing world of data sharing and
data transparency: what does this mean for individual
participant data reviews [Oral session 9; O 9.2]
• Frosi G, et al. Multivariate meta-analysis of multiple cor-
related outcomes with individual participant data: how
much do we gain? [Oral session 9; O 9.3]
• Debray T, et al. Individual Participant Data (IPD) meta-
analysis of diagnostic and prognostic modeling studies: a
practical introduction to their rationale and conduct. [Oral
session 12; O 12.2]
Looking ahead: In the present era of increased clinical data
sharing, there are numerous initiatives and platforms develop-
ing to facilitate data access, and therefore greater opportunities
for theuseof IPD. In response, theGroupareplanning topublish
further papers on the use of IPD in systematic reviews, and will
address the subject of data transparency from the viewpoint of
the IPD meta-analyst at one of the plenary sessions during the
2016 Seoul Colloquium.
Key publications
1. Vale CL, Rydzewska L, Rovers MM, Emberson JR, Gueyfﬁer
F, Stewart LA; Cochrane IPDMeta-analysis Methods Group.
Uptake of systematic reviews and meta-analyses based
on individual participant data in clinical practice guide-
lines: descriptive study. BMJ 2015;350:h1088. DOI:
10.1136/bmj.h1088.
2. Tierney JF, Pignon JP, Gueyffyier F, Clarke M, Askie L, Vale
CL; Cochrane IPD Meta-analysis Methods Group. How indi-
vidual participant datameta-analyses have inﬂuenced trial
design, conduct and analysis. Journal of Clinical Epidemiol-
ogy 2015;68(11):1325-35.
3. Tierney JF, Vale CL, Riley R, Smith CT, Stewart L,
Clarke M, et al. Individual participant data (IPD)
meta-analyses of randomised controlled trial: guid-
ance on their use. PLOS Medicine 2015;12(7):e1001855.
DOI:10.1371/journal.pmed.1001855.
4. Debray TP, Riley R, Rovers MM, Reitsma JB, Moons KG; on
behalf of the Cochrane IPD Meta-analysis Methods Group.
Individual Participant Data (IPD)meta-analysis of diagnos-
tic andprognosticmodeling studies: guidance on their use.
PLOS Medicine 2015;12(10):e1001886.
5. Stewart LA, Clarke M, Rovers M, Riley R, Simmonds M,
Stewart G, et al. Preferred Reporting Items for a Systematic
Review and Meta-analysis of Individual Participant Data:
the PRISMA-IPD statement. JAMA 2015;313(16):1657-65.
6. Wei Y, Royston P, Tierney JF, Parmar MK. Meta-analysis
of time-to-event outcomes from randomized trials using
restricted mean survival time: application to individual
participant data. Statistics in Medicine 2015;34:2881-98.
7. Lueza B, Rotolo F, Bonastre J, Pognon JP, Michiels S. Bias
and precision of methods for estimating the difference in
restricted mean survival time from an individual patient
data meta-analysis. BMC Medical Research Methodology
2016;16:36.
8. Lueza B, Maugen A, Pignon JP, Rivero-Arias O, Bonastre J;
MAR-LC Collaborative Group. Difference in restrictedmean
survival time for cost-effectiveness analysis using individ-
ual patient datameta-analysis: evidence fromacase study.
PLOS ONE 2016;11(3):e0150032.
9. RileyR, PriceMJ, JacksonD,WardleM,Gueyfﬁer,Wang J, et
al. Multivariate meta-analysis using individual participant
data. Research Synthesis Methods 2015;6(2):157-74.
10. Wynants L, Bouwmeester W, Moons KG, Moerbeek M, Tim-
mermanD, VanHuffel S, et al. A simulation study of sample
size demonstrated the importance of the number of events
pervariable todeveloppredictionmodels inclustereddata.
Journal of Clinical Epidemiology 2015 Dec;68(12):1406-14.
11. Snell KIE, Hua H, Debray TP, Ensor J, Look MP, Moons KG,
et al. Multivariate meta-analysis of individual participant
data helped externally validate the performance and im-
plementation of a prediction model. Journal of Clinical
Epidemiology 2015;69:40-50.
12. EfthimiouO,DebrayTP, vanVankenhoefG, TrelleS,Panayi-
dou K, Moons KG, et al; on behalf of the GetReal Methods
Review Group. GetReal in network meta-analysis: a review
of the methodology. Research Synthesis Methods 2016 Jan
11 [Epub ahead of print]. DOI: 10.1002/jrsm.1195.
13. Debray TPA, Moons KG, van Vankelhoef G, Efthimiou O,
Hummel N, Groenwold RH, et al; on behalf of the GetReal
Methods Review Group. Get real in individual participant
data (IPD) meta-analysis: a review of the methodology.
Research Synthesis Methods 2015;6: 239-309.
14. Veroniki AA, Straus SE, Soobiah C, Elliott MJ, Tricco AC. A
scoping review of indirect comparison methods and appli-
cationsusing individualpatientdata.BMCMedicalResearch
Methodology 2016;16(1):47.
15. Veroniki AA, Straus SE, Ashoor H, Stewart LA, Clarke M,
Tricco AC. Contacting authors to retrieve individual patient
data: study protocol for a randomized controlled trial.
Trials 2016;17(1):138.
16. Jolani S, Debray TP, Kofﬁjberg H, van Buuren S, Moons
KG. Imputation of systematically missing predictors in an
individual participant data meta-analysis: a generalized
approach using MICE. Statistics in Medicine 2015;34(11):
1841-63.
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Information Retrieval Methods Group
Julie Glanville, Carol Lefebvre, Jessie McGowan, Alison
Weightman (Co-Convenors of IR Methods Group) and
Bernadette Coles (Co-ordinator)
methods.cochrane.org/irmg
Highlights: The Peer Review of Electronic Search Strategies
(PRESS) checklist has been updated and republished - see below.
Introduction: The Information Retrieval Methods Group (IRMG)
was formed in 2004. Its remit is to provide advice to Cochrane
on information retrieval policy and practice; provide training and
support; conduct empirical research (including systematic re-
views) into information retrievalmethods; helpmonitor the qual-
ity of searching techniques employed in systematic reviews and
to serve as a forum for discussion. The Group currently has over
350 members on its discussion list. Please contact Bernadette
Coles, IRMG Co-ordinator, to join (Colesbm@cardiff.ac.uk), or
sign up via our email discussion list.
Research andmethodological developments:
Clinical Study Reports (CSRs): Tom Jefferson of the Acute Respi-
ratory Infections Group, is leading a project entitled: ‘Interim
guidance on the inclusion of clinical study reports and other
regulatory documents in Cochrane Reviews’, with input from
the IRMG and a number of other Methods Groups. The aim of
the project is to develop guidance on how to decide whether
to incorporate clinical study reports and other regulatory doc-
uments into Cochrane Reviews. The team will draw on their
experience with neuraminidase inhibitors, the ﬁrst Cochrane
Review to be based entirely on regulatory documents, and
similar experiences of others. For further information on this
and other Methods Innovation Fund-funded projects, please see
methods.cochrane.org/methods-innovation-fund-2.
Cochrane Handbook for Systematic Reviews of Interventions
(Cochrane Handbook): Agreement has been reached to adopt
a ‘publish when ready’ model not only for the major revision of
the Cochrane Handbook (due for publication in 2017) but also for
the ‘minor update’, which has been in process for some time. We
hope, therefore, that the ‘minor update’ to Chapter 6: Searching
for studies (incorporating MECIR standards), will be published by
the end of 2016.
Embase: Good progress continues to be made on the project to
add Embase records to CENTRAL, led by Anna Noel-Storr (IRMG
member and Information Specialist with the Cochrane Dementia
and Cognitive Improvement Group). For further details, see:
www.cochranelibrary.com/help/central-creation-details.html.
Peer Review of Electronic Search Strategies (PRESS: The PRESS
Checklist was updated as a guideline by a team led by
Jessie McGowan, Carol Lefebvre and Margaret Sampson (see
publications).
Training and support activities: The IRMG ran three workshops
at the 2015 Vienna Colloquium.
• Bernadette Coles, Julie Glanville and Carol Lefebvre:
Searching for studies for inclusion in Cochrane Reviews:
an introduction.
• Gordon Dooley, Julie Glanville and Carol Lefebvre:
Searching trials registers and trials results registers.
• Julie Glanville and Rene Spijker: Searching for diagnostic
test accuracy studies.
Looking ahead
• The Cochrane Rapid Reviews Methods Group: The newly
establishedCochraneRapidReviewsMethodsGroupwas
supported by the IRMG Co-Convenors. Given the addi-
tional complexities around identifying studies for rapid
reviews, IRMG very much welcomes this development
and looks forward to working closely with this Group.
• MECIR and Search Strategies Audit: IRMG still plans to
conduct a survey, in line with its remit to help monitor
the quality of searching techniques employed in sys-
tematic reviews, to examine search strategy quality and
compliance with MECIR standards, but has been unable
to obtain funding to date. This survey is likely to be based
on a similar funding application submitted to Cochrane
in March 2010.
• Search methods in Public Health: Collaborative work by
members of the IRMG (Alison Weightman, Claire Stans-
ﬁeld and Paul Levay) is ongoing to expand a recent
analysis of public health systematic reviews to develop
guidance on information sources, with a view to jour-
nal submission in late 2016. This work builds on a
poster presentation at the 2015 Evidence Based Library
and Information Practice (EBLIP) conference in Brisbane:
Systematic reviews of public health interventions to sup-
port practice and policy: Where should you look?
Key publications:
1. McGowan J, Sampson M, Salzwedel D, Cogo E, Foerster
V, Lefebvre C. PRESS: Peer Review of Electronic Search
Strategies 2015 Guideline Statement. Journal of Clinical
Epidemiology 2016;75:40-6. PMID: 27005575.
2. McGowan J, Sampson M, Salzwedel D, Cogo E, Foerster
V, Lefebvre C. PRESS – Peer Review Electronic Search
Strategies: 2015 Guideline Explanation and Elaboration
(PRESS E&E). Ottawa: CADTH; 2016 Jan.
Presentations:
1. Glanville J. Is it appropriate to limit searches to prospec-
tive trials registries? Research evidence. Paper presented
at the Cochrane Methods Symposium, Vienna October
2015.
2. GlanvilleJ,DooleyG,Noel-StorrA,FoxleeR. Improvingac-
cess to reportsofRCTs fromEmbase: innovativemethods
to enhance the Cochrane Central Register of Controlled
Trials (CENTRAL). Paper presented at the MLA/CHLA
MOSAIC conference, Toronto Canada, May 2016.
3. Weightman AL, on behalf of the IRMG. Searching and
screening efﬁciency: emerging techniques for systematic
review. Search Solutions conference [The Information
Retrieval Specialist Group of The Chartered Institute for
IT] London, November 2015.
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Non-Randomised Studies for
Interventions Methods Group
Barney Reeves on behalf of the Non-randomised Studies for
Interventions Methods Group
methods.cochrane.org/nrsi
Highlights:
• UK Medical Research Council award to Julian Higgins
for further methodological development and validation
of ROBINS-I
• ROBINS-I article submitted to BMJ
• WorkshopsonROBINS-I at the 2015ViennaColloquiumand
the Cochrane 2016 UK & Ireland Symposium
• Checklistof studydesign featuresextendedto includemore
features
Introduction: The remit of the Non-Randomised Studies Meth-
odsGroup (NRSMG) is toadvise theSteeringGroup tosetapolicy
and formulate guidance about the inclusion of non-randomized
studies (NRS) of the effectiveness of healthcare interventions
in Cochrane Reviews (CR). Membership of the Group is open to
anyone who wishes to contribute actively. However, prospec-
tive members should note that the Group’s focus is primarily
methodological, rather than focused on particular healthcare
interventions. To play an active part in the Group, we anticipate
that members need to have a good training in epidemiology or
statistics.
Research andmethodological development
This year, the NRSMG has progressed issues raised by the
ROBINS-I (aka ACROBAT-NRSI).1 We are pleased to congratulate
Julian Higgins on the award of a grant from the UK Medical
Research Council (MRC) in October 2015 to develop ROBINS-I
further. Speciﬁc objectives of the proposed research are:
• to consider the face validity of ROBINS-I, by reviewing liter-
ature relevant to its theoretical and empirical basis and by
investigating how well the tool identiﬁes instances when
the results of non-randomized studies and corresponding
randomized trials are discrepant;
• to develop signalling questions tailored for a wider variety
of study designs, including time series studies, before-
after studies and natural experiments, and analyses such
as those based on instrumental variables and regression
discontinuities;
• to examine empirically the relationship between assess-
ments made using the tool and effect estimates in various
types of non-randomized study; and
• to facilitate implementation of ROBINS -I by producing an
interactive, online version inwhich structure, guidanceand
informative examples are integrated.
NRSMGmembers, colleagues from the Bias Methods Group and
others, participated in the development of version 2 of the
‘Risk of bias’ tool for randomized controlled trials; the revised
tool is structured with signalling questions in the same way as
ROBINS-I, including special signalling questions for cross-over
trials and cluster-randomized trials.
In addition to the further work on ROBINS-I, NRSMG mem-
bers (Barney Reeves, George Wells and HughWaddington) have
recently submitted a manuscript describing an extension to
the study design checklist originally published in the Cochrane
Handbook for Systematic Reviews of Interventions. This checklist
is intended to help authors understand what researchers actu-
ally did in primary studies, avoiding reliance on study design
labels, as these are not consistently used by researchers or
consistently indexed in literature databases. The extension is
designed to embracedifferences in terminologybetweenhealth
service and health system research communities, and includes
new features to reconcile differences in perception about the
intrinsic strength of some designs and analyses (time series,
before-after studies and natural experiments, and instrumental
variableand regressiondiscontinuity analyses) to infer causality
between intervention and outcome.
Work on the revised version of A Measurement Tool to As-
sess Systematic Reviews (AMSTAR; Bev Shea and colleagues),
which is designed to assess systematics reviews that include
either/both non-randomized studies or randomized controlled
trials, is complete and the revised version is being piloted.
Training and support activities: We have continued to run
workshops about ROBINS-I, including two at the 2015 Vienna
Colloquium and two at the Cochrane UK & Ireland Symposium
in March 2016. These workshops were well received, but are
almost certainly insufﬁcient to equip an author to use ROBINS-I
in earnest. We hope better online support and other formal
training will result from research conducted by Julian’s MRC
grant. Moreover, the fourth objective of this grant should –
ﬁnally! – also honour the commitment from the Paris workshop
to develop on-line training tools for ROBINS-I.
Looking ahead: All of the discussions over the last year have
highlighted the need for guidance for review authors about
when to include non-randomized studies in a review. Therefore,
our attention is now focused on writing a paper about the draft
algorithm to help review authors to make this decision.
Key publications
1. Sterne JAC, Hernan MA, Reeves BC, Savovic J, Berkman
ND, Viswanathan M, et al; on behalf of the development
group for ACROBAT-NRSI. ROBINS-I: a tool for assessing
risk of bias in non-randomized studies of interventions.
Submitted, BMJ.
2. Reeves BC, Deeks JJ, Higgins JPT, Wells GA. Chapter
13: Including non-randomized studies. In: Higgins JPT,
Green S, editor(s), Cochrane Handbook for Systematic
Reviews of Interventions Version 5.1.0 (updated March
2011). The Cochrane Collaboration,2011. Available from
www.cochrane-handbook.org.
3. Higgins JPT, Ramsay C, Reeves BC, Shea B, Valentine J,
Tugwell P, et al. Issues relating to study design and risk of
bias when including non-randomized studies in systematic
reviews on the effects of interventions. Research Synthesis
Methods 2013;4:12-25.
4. Reeves BC, Wells GA, Waddington H. Classifying studies to
evaluate the effects of health care or health system inter-
ventions based on design features: a taxonomy without
labels. Submitted, Journal of Clinical Epidemiology.
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Patient Reported Outcomes Methods
Group
Donald Patrick, Gordon Guyatt (Co-Convenors of PRO
Methods Group), Tatiana Gauchon (Co-ordinator)
methods.cochrane.org/pro
Highlights:
• The patient-reported outcome (PRO) reviews have been
updated and put on the PRO Methods Group (PROMG)
website (methods.cochrane.org/pro/documents).
• We are conducting a study of Minimally Important Differ-
ences (MIDs) inPROs fundedby theCanadian Institutesof
HealthResearch tosummarizeandappraise theavailable
methods toestimateanchor-basedMIDs (Zhang2015, be-
low). We will document all anchor-based MIDs reported
for adults and pediatric populations and will develop a
rating instrument to assess the credibility of the reported
MIDs. With the information collected, we will create an
inventory of available anchor-based MIDs, including the
context in which theywere assessed (condition/disease),
and the conﬁdence that users can place in a particular
MID.
• The PROMG met with the musculoskeletal and pain-
related review groups at the 2015 Vienna Colloquium to
foster collaboration on future editions of the PRO meth-
ods handbook (follow-up in Busse andBeaton references
below).
• The Cochrane Handbook for Systematic Reviews for In-
terventions chapter on PRO methods was revised for
the current edition and is being revised with multiple
author input from Viennameeting, with author contribu-
tions from the musculoskeletal and pain-related review
groups.
• We conductedworkshops at the 2015 Vienna Colloquium
Methods that focused on interpretation of PRO results in
systematic reviews and cross-cultural adaptation of PRO
instruments in Cochrane Reviews.
• The PROMG will give a half-day workshop at the 2016
Seoul Colloquium on ‘Making results of patient-reported
outcomes interpretable and cross cultural adaptation of
PROmeasuresandtheirevaluation inCochraneReviews’.
Introduction: The focus of the Group is on patient-important
outcomes in treatment trials. The goal is to see that PROs are in-
cluded in all Cochrane Reviewswhere appropriate. A second goal
is to assist reviewers preparing Cochrane Reviews to evaluate the
methods and outcomes of PROs used in clinical trials included in
systematic reviews andmeta-analyses.
Research andmethodological development
This year the PROMG is embarking on a study of the MIDs associ-
ated with PROs used in Cochrane Reviews.
Publications have included:
• a consensus statement on reporting pain outcomes in
systematic reviews;
• the ﬁrst empirical exploration of whether MIDs should
be assessed and reported in relative or absolute terms
(results suggest generally as absolute);
• documentation of the limited quality of life outcome
reporting in clinical trials on pain;
• documentation of the planning and reporting of out-
comes in clinical trials on cancer;
• ﬁndings suggesting the necessity for different interpreta-
tions of heterogeneity in continuous rather than binary
outcomes;
• importance of content validity in assessing pain out-
comes, and conﬁrmation that clinicians interpret PRO
results more easily when reported as binary outcomes;
• documentation of the need for evidence-based choice of
outcomemeasures for ‘Summary of ﬁndings’ tables.
As described above we are working on a project to summa-
rize all published MIDs for PROs used in clinical trials including
assessmentof theiracceptabilityandﬁtwithestablishedmethod-
ological criteria. Wewill searchMEDLINE, Embase, PsycINFO, and
CINAHL (1989 to present) to identify studies addressing methods
to estimate anchor-based MIDs of PRO instruments or reporting
empirical ascertainmentofanchor-basedMIDs. Pairsof reviewers
will screen citations identiﬁed, and extract relevant data. We will
summarize the availablemethods and develop a new instrument
to address the credibility of empirically ascertainedMIDs. Wewill
evaluate the credibility of all studies reporting on anchor-based
MIDs estimates using our new credibility tool, and assess inter-
rater reliability. Our synthesis will improve the interpretation
of results of clinical trials using PROs; inform clinical practice
guidelines, trading off desirable and undesirable outcomes; and
facilitate sample size calculations for clinical trials using PROs as
primary outcomes.
Key publications
1. Alba AC, Alexander PE, Chang J, MacIssac J, DeFry S,
Guyatt G. High statistical heterogeneity is more frequent
in meta-analysis of continuous than binary outcomes.
Journal of Clinical Epidemiology 2016;70:129-35.
2. Beaton DE, Terwee CB, Singh JA, Hawker GA, Patrick DL,
Burke LB, et al. A call for evidence-based decision mak-
ing when selecting outcome measurement instruments
for summary of ﬁndings tables in systematic reviews:
results from an OMERACT Working Group. Journal of
Rheumatology 2015 Sep 15 [Epub ahead of print]. pii:
jrheum.141446.
3. Busse JW, Bartlett SJ, Dougados M, Johnston BC, Guyatt
GH, Kirwan JR, et al. Optimal strategies for reporting
pain in clinical trials and systematic reviews: recom-
mendations from an OMERACT 12 workshop. Journal of
Rheumatology 2015;42(10):1962-70.
4. Johnston BC, Alonso-Coello P, Friedrich JO, Mustafa RA,
Tikkinen KAO, Neumann I, et al. Do clinicians under-
stand the size of treatment effects? A randomized survey
across 8 countries. Canadian Medical Association Journal
2016;188(1):25-32.
5. Johnston BC, Ebrahim S, Carrasco-Labra A, Furukawa
TA, Patrick DL, Crawford MW, et al. Minimally impor-
tant difference estimates and methods: a protocol. BMJ
Open 2015;5(10):e007953. DOI: 10.1136/bmjopen-2015-
007953.
6. Mulla SM, Maqbool A, Sivananthan L, Lopes LC, Schan-
delmaier S, Kamaleldin M, et al. Reporting of IMMPACT-
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recommended core outcome domains among trials as-
sessing opioids for chronic non-cancer pain. Pain
2015;156(9):1615-9.
7. Schandelmaier S, Conen K, Von Elm E, You JJ, Blumle A,
Tomonaga Y, et al. Planning and reporting of quality-
of-life outcomes in cancer trials. Annals of Oncology
2015;26(9):1966-73.
8. Zhang Y, Zhang S, Thabane L, Furukawa TA, Johnston
BC, Guyatt GH. Although not consistently superior, the
absolute approach to framing the minimally important
difference has advantages over the relative approach.
Journal of Clinical Epidemiology 2015;68(8):888-94.
Prognosis Methods Group
Rachel Ogilvie, MA (PMG Co-Coordinator) on behalf of the
PMG Convenors
methods.cochrane.org/prognosis
Highlights:
• The Prognosis Methods Group (PMG) continues to make
progress on three original exemplar reviews and has ap-
proved ﬁve additional exemplars.
• Coordination of the PMG has moved to Halifax, Nova Sco-
tia at Dalhousie University, which hosts the Nova Scotia
Site of Cochrane Canada under Jill Hayden. The new co-
coordinators of the PMG are Rachel Ogilvie and Andrea
Smith (CochranePMG@dal.ca).
• In Fall [autumn] 2015 the PMG launched the PMG mem-
ber survey to determine capacity and interest among our
membership. Results of this survey will enable us to
target members who are interested in being involved in
the activities of the group (Active Members), and those
who are interested in staying informed of developments in
prognostic reviews (Associate Members).
Introduction: The Group registered with Cochrane in 2008,
with the role to develop the best methodological standards for
conducting systematic reviews of prognosis studies. We cur-
rently have an international membership of approximately 170
researchers
PMG Convenors:
• Doug Altman (UK)
• Jill Hayden (Canada)
• Karel Moons (The Netherlands)
• Richard Riley (UK)
• Katrina Williams (Australia)
• Susan Woolfenden (Australia)
Research andmethodological development
There are three established exemplar reviewswhichwill bepub-
lished in the Cochrane Library. Each addresses an important
type of prognosis research: 1) overall prognosis; 2) prognostic
factors; and 3) prognosticmodels. Recently, ﬁve new exemplars
were approved, three of which use the newly established PMG
exemplar approval protocol. Two of the ﬁve newly approved
exemplars are also described below.
Established Exemplar Reviews
Overall Prognosis Exemplar Review: This is an update of an
existing review focusing on the topic of overall prognosis of
autism spectrumdisorder (ASD), investigating the proportion of
individuals with ASDwho are still diagnosed with an ASD one or
more years later. The review is registeredwith the Cochrane De-
velopmental, Psychosocial and Learning Problems Group and
the protocol is being ﬁnalized for submission.
Prognostic Factor Exemplar Review: The protocol for this re-
view, titled ‘Individual recovery expectations and prognosis of
outcomes in non-speciﬁc low back pain’, is registered with
the Cochrane Back and Neck Review Group, and was pub-
lished in Issue 9, 2014 of the Cochrane Database of Systematic
Reviews. This review was funded by the Canadian Institutes
of Health Research. Preliminary results were presented as a
poster, ‘Methodological insights from a prognostic factor ex-
emplar review: individual recovery expectations and prognosis
of outcomes in non-speciﬁc low back pain’, at the 2015 Vi-
enna Colloquium, and identiﬁed key methodological issues in
the conduct of prognostic factor reviews. Final results will be
forthcoming later this year.
Prognostic Model Exemplar Review: The title, ‘Prediction mod-
els for the risk of postoperative nausea and vomiting’ was
published with the Anaesthesia Review Group in 2014.
Newly Approved Exemplar Reviews (2 of 5)
Prognostic Model Exemplar Review 2: This newly approved
exemplar review protocol, ‘Prognostic models for chronic lym-
phocytic leukaemia: an exemplar systematic review and meta-
analysis’ was registered with the Haematological Malignancies
Group in 2015, and published in January 2016.
Prognostic Factor Exemplar Review 2: The protocol for this
exemplar review, ‘Interim PET scan results for prognosis of
Hodgkin lymphoma’ is currentlyunderdevelopment for submis-
sion in 2016.The review is registered with the Haematological
Malignancies Group.
Quality In Prognosis Studies (QUIPS): TheQUIPS tool can be used
to assess risk of bias in prognostic factor studies. We receive
regular queries about application of the tool; the 2006 and
2013 publications of this tool have been cited 752 times (Google
Scholar, March 2016).
The following are important tools for these reviews:
Critical Appraisal and Data Extraction for Systematic Reviews
of Prediction Modelling Studies (CHARMS): The CHARMS guid-
ance aims to guide systematic reviewers of studies developing,
validating, and/or updating diagnostic or prognostic predic-
tion models. CHARMS provides a template and checklist for
designing the review question and protocol, and for data ex-
traction from and critical appraisal of the primary studies. It
was published in 2014. The uptake of the tool is ever-growing in
systematic reviews of prediction models.
Transparent Reporting of amultivariable predictionmodel for In-
dividualPrognosisOr Diagnosis (TRIPOD): TheTRIPODstatement
is an evidence-based reporting guideline for studies developing,
validating, and/or updating or extending diagnostic or prognos-
tic prediction models, developed by an international group of
experts comprising statisticians, methodologists, clinicians and
medical journal editors.
Prediction study risk of bias assessment tool (PROBAST): The
PROBAST initiative is currently developing a formal ‘Risk of bias’
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tool for primary studies reporting on the development, valida-
tion, and/or updating of a diagnostic or prognostic prediction
model. It is under development by an international group of
experts comprising statisticians, methodologists, clinicians and
medical journal editors. A new version of the PROBAST tool is
under development and will be available towards the end of
2016.
Search strategy: A validated search strategy for the retrieval
of primary studies for systematic reviews of prognostic studies
was published in 2012.
The Group offers very successful and sought after educational
sessions on primary prognostic studies as well as on systematic
reviews of prognostic studies each year at Utrecht University.
Prognosis Research Strategy (PROGRESS)
This recommends registration and sharing of protocols of prog-
nostic studies. Keele University also offer valuable educational
sessions. Please contact Group for further information or visit
our website.
GRADE: In 2015 theGRADEWorkingGrouppublished recommen-
dations for prognostic evidence that provides an approach to
determine conﬁdence in estimates of overall prognosis in broad
populations.
Training and support activities: Six methodological work-
shops were held at the 2015 Vienna Colloquium and elsewhere.
• Systematic reviews of prognostic studies 1: design, proto-
col, and data extraction using the CHARMS checklist
• Systematic reviews of prognostic studies 2: assessing risk
of bias in studies of prognostic factors using the QUIPS tool
• Systematic reviews of prognostic studies 3: assessing risk
of bias in studies of prediction models using the PROBAST
tool
• Systematic reviews of prognostic studies 4: quantitative
synthesis andmeta-analytical approaches
• Systematic reviews of prognostic studies 5: using GRADE in
systematic reviews of studies on overall prognosis
• Individual Participant Data (IPD)meta-analysis of prognos-
tic studies
• PROGRESS training course – this three-day course covers
systematic reviews of prognosis studies. It has been held
at Keele University from 2013 to 2016
• Statistical methods for evidence synthesis of individual par-
ticipant data – a two-dayworkshop held at Keele in Decem-
ber 2015 and May 2016.
• The Group runs two face-to-face week-long courses on
primary prognostic studies, and systematic reviews and
meta-analysis of prognostic studies at Utrecht University
every year. By the end of 2016 these two courses will also
beoffered inanonline format (www.msc-epidemiology.nl).
The course leaders of both the Keele and Utrecht Universities
include members of the Cochrane Prognosis Methods Group.
Looking ahead: The PMG Convenors and Coordinators ﬁeld
regular requests for guidance or direct support, or both, from
Cochrane Review authors. This year we are focusing efforts on
building capacity within the PMG; one approach we will pilot is
the new Cochrane Task Exchange, which should enable appro-
priate and willing experts to be matched with those authors in
need of support. We are encouraging our Active Members to
build expert proﬁles in Task Exchange and authors to post their
prognostic review support requests to Task Exchange. While
this process will take time to implement, we anticipate that by
Fall 2016 it should be functioning as intended. We will continue
to help with reviews and coordinate direct contact between
authors andmethodologists where appropriate.
The Discretionary Fund activities will continue as the exemplar
reviews move along, with preliminary objectives met by end of
2016. NewMethods InnovationFundactivities (2016 to2018)will
include testing of prognostic reviewmethods and development
of training materials.
Workshops are being planned for the 2016 Seoul Colloquium in
South Korea.
Key publications:
1. Groenwold RH, Moons KG, Pajouheshnia R, Altman DG,
Collins GS, Debray TP, et al. Explicit inclusion of treat-
ment in prognostic modelling was recommended in ob-
servational and randomised settings. Journal of Clinical
Epidemiology 2016 April 1 [Epub ahead of print]. pii: S0895-
4356(16)30030-0. DOI: 10.1016.
2. KattanMW,HessKR,AminMB,LuY,MoonsKG,Gershenwald
JE, et al. American Joint Committee on cancer acceptance
criteria for inclusion of risk models for individualized prog-
nosis in the practice of precision medicine. CA: A Cancer
Journal forClinicians2016January19 [Epubaheadofprint].
DOI: 10.3322/caac.21339.
3. Kleinrouweler CE, Cheong-See FM, Collins GS, Kwee A,
Thangaratinam S, Khan KS, et al. Prognostic models in
obstetrics: available, but far from applicable. American
Journal of Obstetrics and Gynecology 2016;214(1):79-90.
4. Collins GS, Reitsma JB, Altman DG, Moons KGM. Trans-
parent Reporting of a multivariable prediction model for
Individual Prognosis Or Diagnosis (TRIPOD): the TRIPOD
statement. Annals of Internal Medicine 2015;162:55-63.
5. Moons KGM, Altman DG, Reitsma JB, Ioannidis JPA,
Macaskill P, Steyerberg EW, et al. Transparent Reporting
of a multivariable prediction model for Individual Progno-
sis Or Diagnosis (TRIPOD): Explanation and Elaboration.
Annals of Internal Medicine 2015;162:W1-W73.
6. CroftP, AltmanDG,DeeksJJ,DunnKM,HayAD,Hemingway
H, et al. The science of clinical practice: disease diagno-
sis or patient prognosis? Evidence about ‘‘what is likely
to happen’’ should shape clinical practice. BMC Medicine
2015;13:20.
7. Iorio A, Spencer FA, Falavigna M, Alba C, Lang E, Burnand
B, et al. Use of GRADE for assessment of evidence about
prognosis: rating conﬁdence in estimates of event rates in
broad categories of patients. BMJ 2015;350:h870.
8. Debray TP, Riley RD, Rovers MM, Reitsma JB, Moons KG;
Cochrane IPD Meta-analysis Methods Group. Individual
participant data (IPD) meta-analyses of diagnostic and
prognostic modeling studies: guidance on their use. PLOS
Medicine 2015;12(10):e1001886.
9. DebrayTP,MoonsKG, vanValkenhoefG, EfthimiouO,Hum-
melN,GroenwoldRH,etal. Get real in individualparticipant
data (IPD) meta-analysis: a review of themethodology. Re-
search Synthesis Methods 2015;6(4):293-309.
10. Moons KG, Altman DG, Reitsma JB, Collins GS. new guide-
line for the reporting of studies developing, validating, or
updating a multivariable clinical prediction model: the
TRIPOD statement. Advanced Anatomy and Pathology
2015;22(5):303-5.
11. Snell KI, Hua H, Debray TP, Ensor J, Look MP, Moons KG,
et al. Multivariate meta-analysis of individual participant
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data helped externally validate the performance and im-
plementation of a prediction model. Journal of Clinical
Epidemiology 2016;69:40-50.
12. Wynants L, Bouwmeester W, Moons KG, Moerbeek M, Tim-
mermanD, VanHuffel S, et al. A simulation study of sample
size demonstrated the importance of the number of events
pervariable todeveloppredictionmodels inclustereddata.
Journal of Clinical Epidemiology 2015; 68(12):1406-14.
Prospective Meta-Analysis Group
Davina Ghersi, Jesse Berlin and Lisa Askie (Co-convenors of
PMA Methods Group)
methods.cochrane.org/pma
Introduction: The Prospective Meta-Analysis Group is open to
anyone who is conducting, has conducted, or is interested in
conducting a prospective meta-analysis (PMA), regardless of the
area of health care investigated. A PMA is a meta-analysis in
which studies (usually randomized controlled trials) are identi-
ﬁed, evaluated and determined to be eligible before the results
of any of the studies become known. PMA can help to overcome
someof the recognizedproblemsof retrospectivemeta-analyses.
The PMA Methods Group now has 79 members. We were pleased
to launch our new website in 2015 in line with the Cochrane re-
branding. Throughout theyear, the co-convenorsmetevery three
months by teleconference to discuss methodological enquiries,
research projects, website updates and relevant Cochrane mat-
ters, e.g. the revisedCochranedatasharingpolicyandmonitoring
forms.
Training and support activities: The convenors provide advice
to requests from members and also others wanting to prepare
a prospective meta-analysis protocol, including the editors of
Cochrane Review Groups and the authors of these reviews. Ad-
vice is givenby email or telephone, or throughparticipation in the
advisory committees of several PMAs (for example, ongoingPMAs
of neonatal oxygen levels, and interventions for the prevention
of childhood obesity).
Frequently, the co-convenors also provide advice on prospective
meta-analysis as part of their regular jobs and via presentations
to internal and external organizations. Co-convenor Jesse Berlin,
as part of his role at Johnson & Johnson, has been participating
in developing company policies around transparency and data
sharing. He is also a member of the Council for International Or-
ganizations of Medical Sciences (CIOMS) Working Group X, which
is producing a guideline on meta-analysis of safety data in drug
development to be published in the near future.
Looking ahead: The Group is looking to expand its remit to
incorporate prospective trial registration.
Key publications:
1. Askie LM, Offringa M. Systematic reviews and meta-
analysis. Seminars in Fetal and Neonatal Medicone
2015;20(6):403-9.
2. Tierney JF, Pignon J-P, Gueffyier F, ClarkeM, Askie L, Vale
CL, et al. How individual participant data meta-analyses
have inﬂuenced trial design, conduct, and analysis. Jour-
nal of Clinical Epidemiology 2015;68(11):1325-35.
3. Stewart LA, Clarke M, Rovers M, Riley RD, Simmonds M,
Stewart G, et al for the PRISMA-IPD Development Group.
Preferred Reporting Items for a Systematic Review and
Meta-analysis of Individual ParticipantData: thePRISMA-
IPD statement. JAMA 2015;313(16):1657-65.
Qualitative and Implementation
Methods Group
Andrew Booth (Convenor on Call) and Jane Noyes (Lead
Convenor) on behalf of the Qualitative and
Implementation Methods Group
methods.cochrane.org/qi
Twitter: @cochranequal
Highlights of 2015 to 2016
• Cochrane Qualitative and Implementation Methods Group
(CQIMG) convenors worked collectively on updated guid-
ance to be published as series of journal articles in 2016.
• CQIMG Twitter account (@cochranequal) posted its 1001st
Tweet (18months from September 2014 to April 2016) with
the large majority within the 2015 to 2016 reporting year.
• CQIMG convenors made a major contribution to inter-
national qualitative evidence synthesis-related projects
(Methodological InvestigationofCochraneReviewsofCom-
plex Interventions (MICCI); Conﬁdence in the Evidence
from Reviews of Qualitative research (CERQual); Checklist
for Implementation (Ch-IMP); EmERGE; Integrated health
technology assessment for the evaluation of complex tech-
nologies (INTEGRATE-HTA).
• A recent audit revealed 18 relevant qualitative synthesis
titles (six reviews and 12 protocols) registered across 11
CochraneReviewGroupswith three groups recordingmore
thanone title: EPOC (ﬁve), Consumers andCommunication
(three) and Public Health (two).
• CQIMGStudyandMethodologyRegister transferred toEnd-
note platform (8106 records).
• CQIMG feed alerted to 141 relevantmethodological articles
(www.citeulike.org/group/17235).
• CQIMG membership survey sought to harness wider quali-
tative synthesis expertize.
• CochraneMethods Innovation Fund (MIF) funding awarded
to develop the Cochrane qualitative Methodological Limi-
tations Tool (CAMELOT) for use with CERQual.
• New ﬂexible RevMan template released for non-standard
Cochrane Reviews.
Introduction: Against a rapidly shifting landscape of method-
ological development, our ten convenors advanced method-
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ological innovation while expanding CQIMG coverage to reﬂect
itswider implementationbriefandpartnershipworkoncomplex
interventions. TheCQIMGhasbeneﬁtedfromaperiodofstability
in convenor membership with speciﬁc roles relating to the au-
thorship of guidance, publicity and current awareness. The two
successful annual workshops in Belgium/Netherlands and the
UK continue to enjoy extensive input by the convenors, proﬁling
CQIMG methods. Three CQIMG workshops at the 2015 Vienna
Colloquiumdemonstrated the group’s commitment to capacity
building. Other priorities tackled through working groups in-
cluded: membership, and qualitative synthesis requirements of
the RevMan ﬂexible template.
Research and methodological developments: In addition to
funded and unfunded work undertaken to support the de-
velopment of the Group’s own methodological guidance, the
CQIMG has played a major part in international qualitative syn-
thesis. January 2016 saw the appearance of further papers
related to the Cochrane MIF project on ‘Methodological Investi-
gation of Cochrane Reviews of Complex Interventions’ (MICCI)
an important cross-Methods Group initiative led by Professor
Jane Noyes. Six CQIMG convenors are represented on the
eMERGe project (Evaluating mHealth technology in HIV to im-
prove Empowerment and healthcare utilisation: Research and
innovation to Generate Evidence for personalized care) or Ad-
visory group on reporting standards for Meta-ethnography (An-
drew Booth, Kate Flemming, Ruth Garside, Karin Hannes, Jane
Noyes and James Thomas) and three on the GRADE-CERQual
core group (Booth, Garside, Noyes). Three co-convenors were
instrumental to the development of the Ch-IMP checklist for
implementation (Cargo, Hannes, Thomas) while Booth, Noyes
and Flemming worked with European colleagues on the Euro-
pean Union-funded INTEGRATE-HTA project to produce a guide
for selecting appropriate methods of evidence synthesis, which
will support the forthcoming updated CQIMG Supplementary
Guidance.
Training and support activities: CQIMG convenors delivered
threeworkshops at the 2015 Vienna Colloquiumandworkshops
elsewhere entitled:
2015 Vienna Colloquium CQIMG Workshop Ruth Garside demon-
strates that hands are as graphic as a forest plot!
• Development of a checklist to assess implementation (Ch-
IMP) in systematic reviews: the case of provider-based
programs targeting children and youth
• Assessing implementation in complex interventions: tips,
strategies and examples
• Synthesis of qualitative research ﬁndings: what are they,
where are they, and what to do with them?
• The Evidence Synthesis of QUalitative Research in Eu-
rope (ESQUIRE) 2015 three-day workshop (University
of Shefﬁeld, August 2015) and the three-day ‘System-
atic reviews of quantitative and/or qualitative evidence’
workshop (University of Leuven, March 2016) were
both well-attended and stimulated wide methodological
debate.
• Karin Hannes delivered Cochrane-based materials at the
SystematicReviewsinSocialSciencesSymposiuminGhent,
Belgium in March 2016 and at Stellenbosch University,
South Africa in February 2016.
• Jane Noyes contributed to a two-day workshop in Wash-
ington to support the Agency for Healthcare Research and
Quality (AHRQ) in developing new guidance on undertak-
ing complex intervention reviews, and presented at the
Complex Intervention Special Session at the 2015 Vienna
Colloquium.
• Kate Flemming and Ruth Garside (CQIMG Convenors) were
invited to Bangladesh by the James P Grant School of Pub-
lic Health, Brac University, Dhaka to deliver a short course
entitled ‘Introduction to systematic reviews and synthesis
of quantitative and qualitative evidence’ in April 2015. The
trip was funded by a grant from USAID. Forty participants
ranging from research assistants to senior Bangladeshi
public health academics took part in the course, whichwas
extremely well received.
Looking ahead: Key to the CQIMG strategy are publication
and dissemination of the updated guidance to reﬂect a wider
range of synthesis types, the increasing complexity of review
questions, and newmethodological directions prompted by the
implementation agenda. The Group intends to incorporate the
updated guidance in regular external and Colloquium work-
shops and to offer further support through videos and slide
presentations.
Key publications:
1. Alderdice F, McNeill J, Lasserson T, Beller E, Carroll M,
Hundley V, et al. Do Cochrane summaries help student
midwives understand the ﬁndings of Cochrane systematic
reviews: the BRIEF randomised trial. Systematic Reviews
2016;5:40. DOI: 10.1186/s13643-016-0214-8.
2. Benoot C, Hannes K, Bilsen J. The use of purposeful sam-
pling in aqualitative evidence synthesis: aworked example
on sexual adjustment to a cancer trajectory. BMC Medical
Research Methodology 2016;16:21. DOI: 10.1186/s12874-
016-0114-6.
3. Booth A. Searching for qualitative research for inclusion
in systematic reviews: a structuredmethodological review.
Systematic Reviews 2016;5(1):74. DOI: 10.1186/s13643-016-
0249-x.
4. Booth, A, Noyes J, Flemming K, Gerhardus A, Wahlster P,
Van Der Wilt GJ, et al. Guidance on choosing qualitative
evidence synthesis methods for use in health technology
assessments of complex interventions. Available from:
www.integrate-hta.eu/downloads/.
5. Carroll C, Booth A. Quality assessment of qualitative evi-
dence for systematic reviewand synthesis: Is itmeaningful,
and if so, how should it be performed? Research Synthesis
Methods 2015;6(2):149-54.
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6. Cargo M, Stankov I, Thomas J, Saini M, Rogers P, Mayo-
Wilson E, et al. Development, inter-rater reliability and
feasibility of a checklist to assess implementation (Ch-IMP)
in systematic reviews: the case of provider-based preven-
tion and treatment programs targeting children and youth.
BMCMedical Research Methodology 2015;15(1):1.
7. France EF, Ring N, Noyes J, Maxwell M, Jepson R, Duncan
E, et al. Protocol-developing meta-ethnography reporting
guidelines (eMERGe). BMC Medical Research Methodology
2015;15(1):103.
8. Frost J, Garside R, Cooper C, Britten N. Meta-study as
diagnostic: toward content over form in qualitative synthe-
sis. Qualitative Health Research 2016;26:307-19.
9. Kneale D, Thomas J, Harris K. Developing and optimising
the use of logic models in systematic reviews: exploring
practice and good practice in the use of programme theory
in reviews. PLOS ONE 2015;10(11):e0142187.
10. Lewin S, Glenton C, Munthe-Kaas H, Carlsen B, Colvin
CJ, Gu¨lmezoglu M, et al. Using qualitative evidence in
decision making for health and social interventions: an
approach to assess conﬁdence in ﬁndings from qualita-
tive evidence syntheses (GRADE-CERQual). PLOS Medicine
2015;12(10):e1001895.
11. Noyes J, Hendry M, Booth A, Chandler J, Lewin S, Glenton
C, et al. Current use and Cochrane guidance on selection of
social theories for systematic reviews of complex interven-
tions. Journal of Clinical Epidemiology 2016;75:78-92. DOI:
10.1016/j.jclinepi.2015.12.009.
12. Noyes J, Hendry M, Lewin S, Glenton C, Chandler J, Rashid-
ian A. Qualitative ”trial-sibling” studies and ”unrelated”
qualitative studies contributed to complex intervention
reviews. Journal of Clinical Epidemiology 2016;74:133-43.
13. Sutcliffe K, Thomas J, Stokes G, Hinds K, Bangpan M. Inter-
vention Component Analysis (ICA): a pragmatic approach
for identifying the critical features of complex interven-
tions. Systematic Reviews 2015;4:140.
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Rapid Reviews Methods Group
Chantelle Garritty, Gerald Gartlehner, Chris Kamel, Valerie King,
Adrienne Stevens (Co-convenors of RR Methods Group)
methods.cochrane.org/rapidreviews
Highlights: The Cochrane Rapid ReviewsMethods Group (RRMG)
was ofﬁcially approved as a Cochrane Methods Group in October
2015.
Introduction: A rapid review (RR) is describedas amember of the
knowledge syntheses family1 that uses abbreviated systematic
review methods, and is completed within a shorter time frame,
ranging froma fewweeks tousually nomore than sixmonths. The
role of theRRMG is to guide theproductionof rapid reviews, given
they are increasingly employed as a research synthesis tool to
support timely, evidence-informed decision-making. Presently,
the group consists of ﬁve co-convenors: from Canada, the USA
andAustria. Althoughnot funded formally, the group is sustained
through institutional in-kind support provided by the Ottawa
Hospital Research Institute (OHRI), Cochrane Austria, the Center
for Evidence-based Policy at Oregon Health & Science University
(OHSU), and the Canadian Agency for Drugs and Technologies
in Health (CADTH). Virtual co-administration is provided by the
Ottawa Methods Centre based at OHRI, and Cochrane Austria.
When our groupwas launched, ourmembershipwas alreadywell
developed, with more than 250 individuals from 30 countries,
and this continues to grow.
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Research and methodological developments: Active work is
ongoing in a number of methodological areas and includes the
following projects.
• An international survey to assess how much uncertainty
decision-makers are willing to accept when using rapid
reviews (Barbara Nussbaumer, Gerald Gartlehner).
• A suite of methodological studies exploring:
– conduct characteristics of recent rapid reviews in-
cluding examining level of synthesis undertaken,
quality of conduct, and interpretation methods
(Chantelle Garritty);
– relation of completeness of reporting of rapid re-
views to publication status: protocol for a compar-
ative, cross-sectional methodological study (Adri-
enne Stevens);
– formatting and structural attributes of rapid review
reports: a cross-sectional methodological study
(Chantelle Garritty);
– protocol development for a non-inferiority study
assessing the impact of abbreviated literature
searches on conclusions of reviews (Gerald
Gartlehner, Barbara Nussbaumer).
Training and support activities: This past year, the core con-
venorship of the group participated in several training initiatives
and presentations speciﬁc to rapid reviews. The RRMG was in-
volvedwith the following sessionsat the2015ViennaColloquium:
• Garritty C, Griebler U, Heise T, King V, Lhachimi S, Mutsch
M, Polisena J, Stevens A. Rapid review workshop: timely
evidence synthesis for decision makers.
• Garritty C, Guise JM, Hartling L, King V, Mavergames C,
Pestridege C, Rada G, Stevens A, Tricco A, Umscheid
C (alphabetical order). Rapid reviews: terminology,
methodology, and potential utility for Cochrane (special
session).
• Stevens A, Garritty C. Rapid review on the effectiveness
of personal protective equipment for healthcare workers
caring for patients with ﬁlovirus disease.
• King V, Garritty C, Polisena J, Stevens A. Rapid reviews:
appropriateness and applicability (poster presentation).
The RRMGwas involved in the following sessions at Evidence Live
2015 (Oxford, UK):
• Garritty C, King V, Polisena J. Rapid reviews: a practical
knowledge synthesis tool for decision makers (work-
shop).
• Polisena J, Garritty C, Kamel C, Stevens A, Abou-setta A,
King V. Rapid review programs to support health care
and policy decision making: a descriptive analysis of
processes andmethods.
• King V, Polisena J, Garritty C. Applications and appro-
priateness of rapid reviews. Rapid review programs to
support health care and policy decision making: a de-
scriptive analysis of processes andmethods.
Other workshops included:
• Garritty C, Stevens A, Hamel C. Introduction to rapid
reviews course (two-day workshop). University of Mani-
toba Centre for Healthcare Innovations. 24-26 Feb 2016,
Winnipeg, MB, Canada.
• GarrittyC, StevensA. PuttingEvidence intoPractice (PEP)
workshop – rapid review course (three-day workshop).
UniversityofAlberta. 21-23Nov2015, Edmonton, Alberta,
Canada.
• Kamel C. Quick and snappy: a decade of rapid response
evidence. CADTH Symposium. 14 April 2015, Saskatoon
(SK), Canada.
Looking ahead: Again this coming year, the RRMG will hold
introductory training on rapid review methodology offered as a
pre-Colloquium workshop at the 2016 Seoul Colloquium. We will
also run another workshop at the Colloquium entitled, ‘Rapid
review programs and methods: description and discussion of
the experiences from among Convenors of the Cochrane Rapid
Reviews Methods Group.’ At Evidence Live 2016 in Oxford, we
will give a talk designed to acquaint an audience interested in
evidence and policy implementation with the RRMG: ‘The new
Cochrane Rapid Reviews Methods Group: development, goals
and linkages.’ As a new entity, we aim to engage further with
our membership through social media in the coming year. With
regard to rapid review methodology, plans are underway to ex-
plore a consensus deﬁnition of ‘rapid review’, and to conduct
a survey of international research funding agencies in order to
determine their perspectives on the utility of rapid reviews. We
also plan to explore efﬁcient ways to identify rapid reviews from
the published literature through search ﬁlter design.
Key publications:
Because rapid reviews are an emerging ﬁeld, we have identiﬁed
a list of key papers published this past year; several of which
involve members of the RRMG.
1. Hartling L, Guise JM, Hempel S, Featherstone R,
Mitchell MD, Motu’apuaka ML, et al. EPC Methods:
AHRQ End User Perspectives of Rapid Reviews. Re-
search White Paper. (Prepared by the Scientiﬁc Re-
source Center under Contract No. 290-2012-00004-
C.) AHRQ Publication No.16-EHC014-EF. Rockville, MD:
Agency for Healthcare Research and Quality; April 2016.
www.ncbi.nlm.nih.gov/books/NBK362006/.
2. Hite J, GluckME. Rapid evidence reviews for health policy
and practice. AcademyHealth.www.academyhealth.
org/ﬁles/publications/AH Rapid%20Evidence%20
Reviews%20Brief.pdf (accessed March 2016).
3. Kelly SE, Moher D, Clifford TJ. Quality of conduct and
reporting in rapid reviews: an exploration of compliance
with PRISMA and AMSTAR guidelines. Systematic Reviews
2016;5:79.
4. Tricco AC, Zarin W, Antony J, Hutton B, Moher D, Sherifali
D, et al. An international survey and modiﬁed Del-
phi approach revealed numerous rapid review methods.
Journal of Clinical Epidemiology 2016;70;61-7.
5. Canadian Agency for Drugs and Technologies in Health
(CADTH). Rapid review summit: then, now and in the fu-
ture. 2015 February 3-4; Vancouver (BC). CADTH Summit
Series. www.cadth.ca/cadth-summit-series.
6. Featherstone RM, Dryden DM, Foisy M, Guise JM, Mitchell
MD, Paynter RA, et al. Advancing knowledge of rapid
reviews: an analysis of results, conclusions and recom-
mendations from published review articles examining
rapid reviews. Systematic Reviews 2015;4:50.
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7. Haby M, Chapman E, Reveiz L, Barreto J, Clark R.
Methodologies for rapid response for evidence in-
formed decision making in health policy and practice:
an overview of systematic reviews and primary stud-
ies (Protocol). 2015. www.crd.york.ac.uk/PROSPERO/
display record.asp?ID=CRD42015015998.
8. Hartling L, Guise JM, Kato E, Anderson J, Berliner E, Dry-
den DM, et al. Taxonomy of rapid reviews links report
types andmethods to speciﬁc decision-making contexts.
Journal of Clinical Epidemiology 2015;68(12);1451-62.
9. Hartling L, Guise JM, Kato E, Anderson J, Arsonson N,
Belinson S, et al. EPC Methods: An Exploration of
Methods and Context for the Production of Rapid Re-
views [Internet]. Rockville (MD): Agency for Healthcare
Research and Quality (US); 2015 Feb. Available from:
www.ncbi.nlm.nih.gov/books/NBK274092/
10. Hayden JA, Killian L, Zygmunt A, Babineau J, Martin-
Misener R, Jensen JL, et al. Methods of a multi-faceted
rapid knowledge synthesis project to inform the imple-
mentation of a new health service model: Collaborative
Emergency Centres. Systematic Reviews 2015;4:7.
11. Hersi M, Stevens A, Quach P, Hamel C, Thavorn K, Garritty
C, et al. Effectiveness of personal protective equipment
for healthcare workers caring for patients with ﬁlovirus
disease: a rapid review. PLOS ONE 2015 October 9; DOI:
10.1371/journal.pone.014029.
12. Jayakumar KL, Lavenberg JA, Mitchell MD, Doshi JA, Leas
B, Goldmann DR, et al. Evidence synthesis activities of a
hospital evidence-based practice center and impact on
hospital decision making. Journal of Hospital Medicine
2016;11(3):185-92.
13. Kelly SE. Deconstructing rapid reviews: an exploration
of knowledge, traits and attitudes. [MSc thesis] Ottawa:
School of Epidemiology, Public Health and Preventive
Medicine, FacultyofMedicine,UniversityofOttawa, 2015.
www.ruor.uottawa.ca/bitstream/10393/33021/3/Kelly
Shannon 2015 Thesis.pdf
14. Moher D, Stewart L, Shekelle P. All in the family: sys-
tematic reviews, rapid reviews, scoping reviews, re-
alist reviews, and more. Systematic Reviews 2015;
4:183.
15. Polisena J, Garritty C, Umscheid CA, Kamel C, Samra K,
Smith J, et al. Rapid Review Summit: an overview
and initiation of a research agenda. Systematic Reviews
2015;4:111.
16. Polisena J, Garritty C, Kamel C, Stevens A, Abou-Setta AM.
Rapid review programs to support health care and policy
decision making: a descriptive analysis of processes and
methods. Systematic Reviews 2015;4:26.
17. Schunemann HJ, Moja L. Reviews: rapid! rapid! rapid!
. . .and systematic. Systematic Reviews 2015;4:4.
18. Tricco AC, Antony J, Zarin W, Striﬂer L, Ghassemi M, Ivory
J, et al. A scoping review of rapid review methods. BMC
Medicine 2015;13:224.
19. Tsertsvadze A, Chen YF, Moher D, Sutcliffe P, McCarthy N.
How to conduct systematic reviews more expeditiously?
Systematic Reviews?2015;4:160.
20. Varker T, Forbes D, Dell L, Weston A, Merlin T, Hod-
son S, et al. Rapid evidence assessment: increas-
ing the transparency of an emerging methodology.
Journal of Evaluation in Clinical Practice 2015;21(6):
1199-204.
21. Wilson MG, Lavis JN, Gauvin FP. Developing a rapid-
response program for health system decision-makers in
Canada: ﬁndings from an issue brief and stakeholder
dialogue. Systematic Reviews 2015;4:25.
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1. Moher D, Stewart L, Shekelle P. All in the family: sys-
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Screening and Diagnostic Test Methods
Group
Yemisi Takwoingi, Mariska Leeﬂang, Petra Macaskill, Paul
Good, Clare Davenport and Jon Deeks, with contributions
fromMatthewMcInnes and Penny Whiting.
methods.cochrane.org/sdt
Highlights:
• Development of Plain language summaries for Cochrane
Diagnostic Test Accuracy (DTA) Reviews
• Initiation of development of PRISMA-DTA
• Launch of BioMedCentral (BMC) Diagnostic andPrognostic
Research journal
• PublicationofStandards forReportingDiagnosticAccuracy
(STARD) 2015
• One-day pre-Colloquiumworkshop in Vienna (2015)
• Publication of more online training materials for DTA re-
views
Introduction: Members of our methods group provide sub-
stantial support for the DTA Editorial process through their
roles as editors and also as reviewers. As of April 2016, 58
Cochrane DTA reviews have been published in the Cochrane
Library, compared with 44 in April 2015, 19 in April 2014 and 12
in April 2013. A total of 96 protocols has also been published
(source: www.thecochranelibrary.com). We now have over a
1000 contributors to Cochrane DTA reviews from across the
globe (Norway to New Zealand, Colombia to the Philippines).
Thirty-ﬁvedifferentCochraneReviewGroups (CRGs)areproduc-
ing Cochrane DTA reviews, and some are cited in World Health
Organization (WHO) guidance.
• Membersofourgrouparepublishingonlinetrainingmateri-
als for authors planning to produce a Cochrane DTA review
to ensure that training resources are available around the
world. Seventeen modules are now available online (see
methods.cochrane.org/sdt/dta-review-author-training for
links and a complete list) and more planned modules
should be published in the months to come. Chapters
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of the Cochrane Handbook for Diagnostic Test Accuracy
Reviews are available at srdta.cochrane.org.
• Diagnostic and prognostic medical research now has a
dedicated journal. The new BMC Diagnostic and Prog-
nostic Research journal will provide a platform for dis-
seminating empirical primary studies, systematic reviews
(including meta-analyses) as well as articles on method-
ology, protocols and commentaries addressing diagnostic
and prognostic studies. For additional information, see
diagnprognres.biomedcentral.com/.
• Incomplete reporting is a major source of research waste.
To improve the quality of reporting of diagnostic accuracy
studies, the STARD statement was developed, and pub-
lished originally in 2003. STARD 2015, an updated list of 30
essential items that should be included in every report of a
diagnostic accuracy study was published towards the end
of 2015 (see references below).
Research andmethodological developments:
• In 2015, Penny Whiting, Clare Davenport and Mariska
Leeﬂang were awarded a Methods Innovation Fund grant
to develop a template and guidance for Plain language
summaries (PLS) for Cochrane DTA reviews. Guidance for
PLS for Cochrane Intervention Reviews is now developed,
however, there are challenges for writing PLS that are spe-
ciﬁctoDTAreviews,duetothe lackof familiaritywithreview
methods, the two-dimensional nature of the outcome (per-
formance of a test in individuals with the target condition
and performance in individuals without the condition) and
communicating the downstream consequences of a test
result (linking test results to potential patient outcomes).
The project is following a four-stage approach: qualitative
focusgroups, one-on-oneuser testing, aweb-basedsurvey,
and producing a template and guidance for PLS for DTA
reviews based on the ﬁndings from the ﬁrst three stages.
The focus groupshavebeencompletedanddatahavebeen
used to produce a ﬁrst draft of a DTA review PLS template.
Further reﬁnement through user testing and a web-based
survey is underway. The template and guidance should be
available for launch at the 2016 Seoul Colloquium.
• Patrick Bossuyt, Matthew McInnes and David Moher have
assembled a research team involving members of the
Screening and Diagnostic Test Methods Group (SDTMG), to
develop, disseminateand implementaguideline for report-
ing systematic reviews and meta-analyses of DTA studies.
This project will be carried out under theworking title ‘Pre-
ferred Reporting Items for Systematic reviews and Meta-
AnalysisofDiagnosticTestAccuracy (PRISMA-DTA)’.Thean-
ticipated date of completion is late 2017. For further infor-
mation see: www.equator-network.org/library/reporting-
guidelines-under-development/#52.
• In July 2016, the Test Evaluation Research Group in
Birmingham is hosting the 4th Methods for Evaluating
Medical Tests and Biomarkers (MEMTAB) Symposium at
the University of Birmingham. The two-day event, held
every two to three years, attracts researchers actively
involved in the development, evaluation or regulation of
biomarkers, diagnostic modalities or other medical tests.
Whilst the symposium is not exclusively for Cochrane con-
tributors, the vast majority are authors of Cochrane DTA
reviews.
Training and support activities:
• In October 2015 we provided a pre-Colloquium training
event in Vienna. The one-day workshop combined our se-
ries of workshops usually run throughout the Colloquium
into a one-day programme, and was delivered through
a mixture of interactive presentations, discussions and
small group exercises. Participants were introduced to
the process of question formulation for a DTA review;
the methodology for quality assessment; the principles of
meta-analysis and recommended statistical methods; po-
tential sources of heterogeneity andmethods for assessing
heterogeneity; comparisons of test accuracy; and present-
ing and interpreting results. The workshop was facilitated
by eight of ourmembers andwasattendedby31delegates.
The feedback we received was very positive.
• The DTA editorial process continues to be amajor commit-
ment with all members covering both the Editorial Team
and our Methods Group. Our training of DTA editors nom-
inated by Cochrane Review Groups (CRGs) is still ongoing,
and those already trained continue to participate in one of
the two DTA Editorial Teammeetings that take place each
month. The DTA editors from CRGs typically manage DTA
reviews from their own review groups. Co-ordination of the
DTA editorial process is still managed by members of the
Birmingham team.
We are always keen to hear from anyone interested in volun-
teering as a peer reviewer. All DTA protocols and full reviews
are scrutinized by three external peer reviewers during the DTA
editorial process; a generalmethodologist, a statistician and an
informationsearchspecialist. Anyone interested involunteering
please contact Paul Good (a.p.good@bham.ac.uk).
Looking ahead: A pre-Colloquium workshop on methods for
developing Cochrane DTA reviews will take place in Seoul on
23 October 2016. This will be similar to the ones held at the
2015 Vienna Colloquium and the 2014 Hyderabad Colloquium.
In addition, workshops on PLS and advanced methods for
meta-analysis have been submitted.
Key publications
1. Bossuyt PM, Reitsma JB, Bruns DE, Gatsonis CA, Glasziou
PP, Irwig L, et al; for the STARD Group. STARD 2015:
an updated list of essential items for reporting diagnostic
accuracy studies.
(a) Radiology 2015;277(3):826-32. DOI: 10.1148/ra-
diol.2015151516.
(b) BMJ 2015;351:h5527. DOI: 10.1136/bmj.h5527.
(c) Clinical Chemistry 2015;61(12):1446-52. DOI:
0.1373/clinchem.2015.246280.
2. Takwoingi Y, Guo B, Riley R, Deeks J. Performance of
methods formeta-analysis of diagnostic test accuracywith
few studies or sparse data. Statistical Methods in Medical
Research 2015 Jun 26 [Epub ahead of print].
3. Menten J, Lesaffre E. A general framework for comparative
Bayesian meta-analysis of diagnostic studies. BMCMedical
Research Methodology 2015;15:70.
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Statistical Methods Group
Joanne McKenzie, Joseph Beyene, Georgia Salanti, and Catrin
Tudur-Smith (Convenors of the Statistical Methods Group), Kerry
Dwan (Research Associate), Adriani Nikolakopoulou (Coordinator)
methods.cochrane.org/statistics
Twitter: @CochraneStats
Highlights:
• Organizing and delivering the 2016 Cochrane Methods
Training Event ‘Statistical methods training for statisti-
cians supporting CRGs’. Thirty statisticians, primarily
from the UK and Europe, attended the two-day training
event in Birmingham (17-18 March). Topics included ‘Es-
timating and interpreting heterogeneity and summary
effects’, ‘Explaining heterogeneity’, ‘Dealing with small
studies’, ‘Challengeswithcontinuousoutcomes’, ‘Missing
data’, ‘Meta-analysisof individualparticipantdata’, anda
session on the common statistical issues in Cochrane Re-
views. Slides of the presentations will be made available
on the Statistical Methods Group (SMG) website.
• The SMG scientiﬁc meeting at the 2015 Vienna Collo-
quium addressed the topic of how to deal with small,
potentially biased, studies in meta-analysis. This topic
had been raised on the SMG mailing list, and resulted
in an interesting discussion. Two presentations at the
SMGmeeting outlined a range of approaches to dealwith
small study effects. Wolfgang Viechtbauer (Maastricht
University) presented on the idea of using an alterna-
tive weighting scheme for the random-effectsmodel that
de-emphasizes the weight given to small studies. Anne
Rutjes (University of Bern) compared a range of ap-
proaches (including exclusion of small trials) applied to
meta-analyses of osteoarthritis trials. These presenta-
tions were followed by discussion, with the consensus
that small studies should not be excluded from meta-
analyses; however, their impact should be examined
carefully.
Introduction: The SMG provides a forum in which statistical
issues related to Cochrane can be discussed. It provides policy
advice on statistical issues, organizes training activities, and an
annual scientiﬁc meeting at the Cochrane Colloquium. The SMG
currently has 275 members from 33 countries, primarily based
in the UK (36%), Europe (24%), USA (11%), Australia (8%) and
Canada (8%). If you have a strong interest in meta-analysis and
wish to become amember of the SMG list, please contact Adriani
Nikolakopoulou (nikolakopoulou.adriani@gmail.com).
Research andmethodological developments:Mark Simmonds
(Centre for Reviews and Dissemination, University of York, UK) is
leading a Methods Innovation Fund project on behalf of the SMG
to investigate ‘Statistical methods for updating meta-analyses’.
This will allow the SMG to provide advice on whether adjustment
of results is necessary when undertaking updates in Cochrane
Reviews, and if so, what the recommended statistical methods
are.
Thus far a literature review has identiﬁed four key statistical
methods for updatingmeta-analyses, alongwith a range of infor-
mal methods and guidance. These methods have been applied
to extracted data from over 70 Cochrane Reviews updated since
2014. Preliminary results suggest that updating a meta-analysis
using conventional methods carries a substantial risk of giving
an inappropriately statistically signiﬁcant result, either because
of a false positive ﬁnding (Type I error), or because the data are
insufﬁcient to be genuinely conclusive. The identiﬁed statistical
methods for updating can prevent these errors. A simulation
study is underway to compare the statistical approaches to
updating meta-analyses formally.
Training and support activities: Five core workshops on intro-
ductory meta-analysis topics were offered at the 2015 Vienna
Colloquium. Four workshops will be presented at the 2016 Seoul
Colloquium in Korea (basic ideas ofmeta-analysis; meta-analysis
of binary and continuous outcomes; dealing with heterogeneity;
and time-to-event data). In addition to the workshops presented
at Colloquia, SMG members present workshops on statistical
issues in systematic reviews at regional Cochrane events and
non-Cochrane events.
Lookingahead: This year’s SMGscientiﬁcmeetingwill takeplace
at the 2016 Seoul Colloquium on Monday 24 October from 1.00-
1.50 pm. We plan to have a presentation on statistical methods
for updating meta-analyses, and the new ‘Risk of bias’ tools for
randomized trials and non-randomized studies.
Key publications: The SMG website includes a list of pub-
lications to which its members have contributed (available
at: methods.cochrane.org/statistics/publications). Members
can submit their publications at any time through a form
on the website (methods.cochrane.org/statistics/suggestions-
further-cochrane-methods-statistics-group-publications), or al-
ternatively, email them to Kerry Dwan (kdwan@cochrane.org).
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Participants attending the Cochrane Methods Training Event ‘Statistical methods training for statisticians supporting CRGs’, held in
Birmingham, UK, 17-18 March 2016
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Future Meetings
Cochrane Colloquium 2017
Global Evidence Summit 2017
Capetown, South Africa
12-16 September 2017
www.globalevidencesummit.org
Twitter: @GESummit and #GESummit17
Cochrane is joining with four other leading organizations – the
Guidelines International Network, The Campbell Collaboration,
the International Society for Evidence-based Health Care, and
the Joanna Briggs Institute - to hold the ﬁrst ‘Global Evidence
Summit’ (GES).
The theme of the GES, ‘Using Evidence. Improving Lives’, will
highlight and promote evidence-informed approaches to health
policyanddevelopment, forthemostcost-effective interventions.
The summitwill focus on the opportunities and challenges facing
low- and middle-income countries – a reason why the GES is to
be hosted in Cape Town, South Africa. The event is expected
to attract up to 2000 delegates and will bring together many
parts of the evidence community to promote evidence-informed
decision-making worldwide.
More detail on dates, registration, and the scientiﬁc programme
will be announced in the coming months.
Research Integrity Meeting 2017
Amsterdam, The Netherlands
28-31 May 2017
www.wcri2017.org
The 5thWorld Conference onResearch Integritywill be organized
around the interlinked themes of transparency and accountabil-
ity, building on the premise that the honesty and reliability of
research are best served by openly sharing all aspects of research
and by taking personal responsibility for it. The conference
program will explore the challenges of promoting transparency
and accountability and the consequences of the failure to do so,
with the overall goal of developing an evidence-based agenda
for addressing the various lapses of integrity that seem to have
become an endemic problem in research today.
Fourth global symposium on health
systems research 2016
Resilient and Responsive Health Systems For a Changing
World
Vancouver, Canada
14-18 November 2016
www.csih.org/en/events/fourth-global-symposium-on-health-
systems-research/
The Global Symposium on Health Systems Research is hosted
every two years by Health Systems Global to bring together its
memberswith the full range of players involved in health systems
and policy research. There is currently no other international
gathering that serves the needs of this community.
The Symposium aims to:
• share new state-of-the-art evidence;
• review the progress and challenges towards implemen-
tation of the global agenda of priority research;
• identify and discuss the approaches to strengthen the
scientiﬁc rigour of health systems research including
concepts, frameworks, measures andmethods; and
• facilitate greater research collaboration and learning
communities across disciplines, sectors, initiatives and
countries.
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International Peer Review Congress
2017
Chicago, Illinois, USA
10-12 September 2017
www.peerreviewcongress.org/index.html
This congress aims to encourage research into the quality and
credibility of peer review and scientiﬁc publication, to establish
the evidence base on which scientists can improve the conduct,
reporting, and dissemination of scientiﬁc research.
5th International Society for
Evidence-Based Healthcare Annual
Conference
Best Evidence & Healthcare Decisions: Connecting the dots
7-9 December 2016
Kish Island, Iran
www.isehc2016.com/en/
The 2016 International Society for Evidence-Based Healthcare
Congress (ISEHC-2016) is an annual conferences, and one of the
largest gatherings of clinicians, researchers and policy makers
in the ﬁeld of evidence-based health care (EBHC) and policy
making. The organizing committee is endeavouring to bring
together top experts and academics from around the world to
exchange ideas about the constantly evolving ﬁeld of EBHC, and
to discover novel opportunities to connect the dots between
research evidence and health policy.
UK Cochrane Symposium
14-15 March 2017
Keble College, Oxford, UK
Canadian Cochrane Symposium
11-12th May 2017
Location to be announced
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Availability of Cochrane Methods
Additional copies of Cochrane Methods may be obtained free of
charge from Louisa Dunn (ldunn@cochrane.org)
Cochrane Methods is also available electronically via the
Cochrane Library website
www.cochranelibrary.com/cochrane-database-of-systematic-
reviews/cochrane-methods.html
More Information
The Cochrane Library
The Cochrane Library (www.cochranelibrary.com) contains the
Cochrane Database of Systematic Reviews (CDSR), which includes
Cochrane Reviews and Protocols as well as editorials and sup-
plements, and ﬁve other databases: the Database of Abstracts
of Reviews of Effects (DARE) (up to March 2015), the Cochrane
Central Register of Controlled Trials (CENTRAL), the Cochrane
Methodology Register (CMR) (up to July 2012), the Health Tech-
nology Assessment (HTA) Database and the NHS Economic Eval-
uation Database (EED) (up to March 2015). This includes access
to previous issues of this supplement.
Cochrane on the web
A wide range of information about Cochrane is available from
www.cochrane.org, this includes Cochrane’s mission, our part-
ners and summaries of all the Cochrane Reviews in the current
issue of the Cochrane Library. Information on methods activity
and the Methods Groups is available at methods.cochrane.org.
International Cochrane Newsletters
Cochrane produces ‘Cochrane Community’, a monthly newslet-
ter put together by Cochrane’s Communications & External
Affairs Department that provides up-to-date information on
projects and initiatives, news from the Steering Group and
the Central Executive team as well as from Centres, Review
Groups, Fields, and Methods groups. The Cochrane Commu-
nity newsletter provides an excellent way of keeping informed
about Cochrane activities and policies. This newsletter is used
to announce and discuss matters relevant to Cochrane as a
whole. Please visit: community.cochrane.org/news/newsletters/
cochrane-community
CochraneConnect isCochrane’sofﬁcial externalnewsletter. Each
month it highlights the latest Cochrane Reviews, impact, events,
and news. To subscribe please go to community.cochrane.org/
news/newsletters/cochrane-connect
Cochrane Centre Internet Sites
There are 14 Cochrane Centres round the world; to speak to
someone about Cochrane please contact your local Centre.
Australasian Cochrane Centre
acc.cochrane.org
Brazilian Cochrane Centre
centrocochranedobrasil.org
Canadian Cochrane Centre
ccnc.cochrane.org
Chinese Cochrane Center
ebm.org.cn
Dutch Cochrane Centre
cochrane.nl
French Cochrane Centre
fr.cochrane.org
German Cochrane Centre
cochrane.de
Iberoamerican Cochrane Centre
cochrane.es
Italian Cochrane Centre
cochrane.it
Nordic Cochrane Centre
cochrane.dk
South African Cochrane Centre
southafrica.cochrane.org
South Asian Centre
cochrane-sacn.org
UK Cochrane Centre
uk.cochrane.org
US Cochrane Center
cochrane.us
